

PUBLICATIONS

Prof. Dr. med. Dr.h.c. Michael Oellerich
FAACC, FAMM, FFPPath (RCPI), FRCPath

Distinguished Research Professor
of Clinical Chemistry

Department of Clinical Pharmacology
George-August-University Göttingen
Germany

Table of Content

P U B L I C A T I O N S.....	1
Prof. Dr. med. Dr.h.c. Michael Oellerich	1
ORIGINAL ARTICLES	4
Clinical chemistry - analytical methods	4
Hypoglycemic substances	10
Liver function, liver transplantation	12
Lipoproteins, plasminogen, oxidant stress, liver and small bowel injury, inflammation, prenatal programming.....	17
Therapeutic drug monitoring (pharmacokinetics, pharmacogenetics, pharmacodynamics)	20
Proteomics.....	35
Molecular diagnostics	38
BOOK CHAPTERS.....	43
REVIEWS.....	52
MULTICENTRE STUDIES.....	61
BOOKS EDITED	63
EDITORIALS, LETTERS TO THE EDITOR, QUESTIONS AND ANSWERS.....	65
GUEST EDITOR	69
GENE BANK ENTRIES	70
PROTEOME ENTRIES	71
COMMITTEE RECOMMENDATIONS	74
NEWSLETTER	75
ABSTRACTS	76

Dissertation:

"Über die Freisetzung von Magnesium- und Calcium-Ionen aus einer Mikrosomenfraktion der Meerschweinchenleber unter Einwirkung von Phenyläthylbiguanid".

Ludolf-Krehl-Klinik Heidelberg
(Direktor: Prof.Dr.G.Schettler)
Ruprecht-Karl-Universität, Heidelberg 1970

Habilitation:

"Untersuchungen über die blutglucosesenkende Wirkung der 2-(Phenyläthylhydrazano)- und 2-(2-Cyclohexyläthylhydrazono)-propionsäure".

Institut für Klinische Chemie
(Direktor: Prof.Dr.Dr.J.Büttner)
Medizinische Hochschule Hannover, Hannover 1978

ORIGINAL ARTICLES

Clinical chemistry - analytical methods

1. Haeckel R, Haindl H, Hultsch E, Mariss P, **Oellerich M**. Comparison of 8 different colorimetric, radiochemical and immunological procedures for the determination of iron binding capacity. *Z Klin Chem Klin Biochem* 1973; 11:529-534.
2. **Oellerich M**, Külpmann WR, Haeckel R. Drug screening by enzyme immunoassay (EMIT) and thin-layer chromatography (Drug Skreen). *J Clin Chem Clin Biochem* 1977; 15:275-283.
3. **Oellerich M**, Külpmann WR, Haeckel R, Heyer R. Determination of phenobarbital and phenytoin in serum by a mechanized immunoassay (EMIT) in comparison with a gas-liquid chromatographic method. *J Clin Chem Clin Biochem* 1977; 15:353-358.
4. **Oellerich M**, Haindl H, Haeckel R. Die Bestimmung von Digoxin im Serum mit Enzymimmunotests. *Internist* 1978; 19:188-190.
5. **Oellerich M**, Sybrecht GW, Haeckel R. Monitoring of serum theophylline concentrations by a fully mechanized enzyme immunoassay (EMIT). *J Clin Chem Clin Biochem* 1979; 17:299-302.
6. **Oellerich M**, Haindl H, Haeckel R. Evaluation of enzyme immunoassays for determination of thyroxine (EMIT, ENZYMUN) and of thyroxine binding index. *J Clin Chem Clin Biochem* 1979; 17:483-488.
7. Borner K, Colombo JP, Bachman C, Haeckel R, **Oellerich M**, Westerink D, Fischer M, Wimmer P, Vogt W, Tausch A, Knedel M, Minder W, Blum J, Portenhauser R. Die Bestimmung von Thyroxin im Serum mit einem heterogenen Enzymimmunoassay: Ergebnisse einer gemeinsamen Erprobung. *J Clin Chem Clin Biochem* 1979; 17:471-481.

8. **Oellerich M**, Engelhardt P, Schaadt M, Diehl V. Determination of methotrexate in serum by a rapid, fully mechanized enzyme immunoassay (EMIT). *J Clin Chem Clin Biochem* 1980; 18:169-174.
9. Haeckel R, **Oellerich M**. Evaluation of the 30°C-version of the ACA (Automatic Clinical Analyzer). *Dt Ges f Klin Chem e V - Mitteilungen* 1980; 11:74-95.
10. **Oellerich M**, Haindl H. Determination of triiodothyronine in serum by enzyme- and radioimmunoassay - a comparative study. *J Clin Chem Clin Biochem* 1981; 19:447-451.
11. Braun S, Vogt W, Borner K, Delcourt R, Eber O, Ederveen AB, Haas H, Kagedal B, Kaltwasser F, Löund H, **Oellerich M**, Haidl H, Wagner H. Bestimmung von Trijodthyronin im Serum mit einem heterogenen Enzymimmunoassay: Ergebnisse einer gemeinsamen Erprobung. *J Clin Chem Clin Biochem* 1981; 19:911-918.
12. Külpmann WR, **Oellerich M**. Monitoring of therapeutic serum concentrations of antiepileptic drugs by a newly developed gas chromatographic procedure and enzyme immunoassay (EMIT): a comparative study. *J Clin Chem Clin Biochem* 1981; 19:249-258.
13. **Oellerich M**, Külpmann WR, Beneking M, Sybrecht GW, Staib AH, Schuster R. Determination of theophylline in serum by non-isotopic immunoassays (EMIT, SLFIA, NIIA) and HPLC - a comparative study. *Fresenius Z Anal Chem* 1982; 311:355-356.
14. **Oellerich M**, Haeckel R, Haindl H. Evaluation of EMIT adapted to the Cobas Bio centrifugal analyzer. *J Clin Chem Clin Biochem* 1982; 20:756-772.
15. **Oellerich M**, Hannemann P, Külpmann WR, Beneking M, Sybrecht GW. Die Bestimmung von Theophyllin im Serum mit radioaktivitätsfreien Immunotests und Hochdruck-Flüssigkeits-Chromatographie. *Internist* 1982; 23:641-646.
16. **Oellerich M**, Seiler D, Nagel D, Weidemann G, Weiss L, Hoffmann GE, Temme H, Henkel E, Colombo JP, Peheim E, Hagemann P, Bayer PM, Gibitz JH, Malqvist E, Dati F, Habenstein K. Teststreifen für den schnellen Nachweis der α -Amylase im Urin. Eine kooperative Studie. *Dtsch med. Wschr* 1983; 108:1308-1311 (engl. u. japan. Übersetzung 1983).

17. Schumann G, Isberner I, **Oellerich M**. Highly specific HPLC method for the determination of theophylline in serum. *Fresenius Z Anal Chem* 1984; 317:677.
18. Külpmann WR, Gey S, Beneking M, Kohl B, **Oellerich M**. Determination of total and free phenytoin in serum by non-isotopic immunoassays and gas chromatography. *J Clin Chem Clin Biochem* 1984; 22:773-779.
19. Kessler A Ch, Rudorff KH, **Oellerich M**, Horn K, Mattersberger J, Hesch RD. Medizinische und klinische Evaluation einer neuen enzymimmunologischen Meßmethode zur Bestimmung des Thyroxin bindenden Globulins (TBG) und des T₄/TBG-Quotienten: Eine multizentrische Studie. *J Clin Chem Clin Biochem* 1985; 23:117-127.
20. Niemann A, **Oellerich M**, Schumann G, Sybrecht GW. Determination of theophylline in saliva, using fluorescence polarization immunoassay (FPIA). *J Clin Chem Clin Biochem* 1985; 23:725-732.
21. Schumann G, **Oellerich M**, Wonigeit K, Wrenger M. Ciclosporin: HPLC routine method with column switching. *Fresenius Z Anal Chem* 1986; 324:328-329.
22. Wrenger M, **Oellerich M**, Raude E, Riedmann M. HPLC methods for therapeutic drug monitoring involving direct serum injection, column switching and simple mobile phase adjustments. *Fresenius Z Anal Chem* 1986; 324:350-351.
23. Raude E, **Oellerich M**, Wrenger M. Methotrexate: specific HPLC routine method involving column switching. *Fresenius Z Anal Chem* 1988; 330:384-385.
24. Martz W, **Oellerich M**. Flucytosine: determination in serum by HPLC and dosage individualization. *Fresenius J Anal Chem* 1990; 337:122.
25. Martz W, **Oellerich M**, Schumann G. Determination of methotrexate in serum: the aca MTHO immunoassay and HPLC compared. *J Clin Chem Clin Biochem* 1990; 28:951-953.
26. Wieland E, Diedrich F, Schettler V, Schuff-Werner P, **Oellerich M**. Lipid hydroperoxide determination in serum by HPLC and iodometry. *Fresenius J Anal Chem* 1992; 343:62-63.

27. Wieland E, Schettler V, Diedrich F, Schuff-Werner P, **Oellerich M**. Determination of lipid hydroperoxides in serum. Iodometry and high performance liquid chromatography compared. *Eur J Clin Chem Clin Biochem* 1992; 30:363-369.
28. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, **Oellerich M**, Schauer A. Determination of a fragment of the *c-erbB-2* translational product p185 in serum of breast cancer patients. *J Cancer Res Clin Oncol* 1993; 119:249-252.
29. Petersen D, Demertzis S, Freund M, Schumann G, **Oellerich M**. Individualization of 5-Fluorocytosine Therapy. *Chemotherapy* 1994; 40:149-156.
30. Zielmann S, Mielck F, Roth AT, Lüdtker R, Sydow M, **Oellerich M**. Die Bestimmung von Gesamteiweiß eignet sich nicht zur Diagnose der therapie-bedürftigen Hypoalbuminämie bei Intensivpatienten. *Anaesthesist* 1995; 44:700-704.
31. Heller C, Hinzmann R, Hofmann M, Kaufhold S, Henkel E, **Oellerich M**. Lipid interference in the determination of the concentration of haemoglobin in plasma using the ACA SX analyzer. *Eur J Clin Chem Clin Biochem* 1996; 34:811-816.
32. Scholer A, Boecker J, Engelmayer U, Feldmann K, Hannak D, Kattermann R, **Oellerich M**, Raith H, Schlebusch H, Wieland H, Willems D, Jarausch J, Domke I. Comparability of a new turbidimetric digoxin test with other immunochemical tests and with HPLC - a multicenter evaluation. *Clin Chem* 1997; 43:92-99.
33. Andreeva M, Niedmann PD, Schütz E, Wieland E, Armstrong VW, **Oellerich M**. Determination of MEGX by HPLC with fluorescence detection. *Clin Chem* 1997; 43:1081-1083.
34. Andreeva M, Niedmann PD, Binder L, Armstrong VW, Meden H, Binder M, **Oellerich M**. A simple and reliable reverse-phase high-performance liquid chromatographic procedure for determination of paclitaxel (taxol) in human serum. *Ther Drug Monit* 1997; 19: 327-332.
35. Schütz E, Shipkova M, Niedmann PD, Wieland E, Armstrong VW, **Oellerich M**. Determination of monoethylglycinexylidide by fluorescence polarization immunoassay in highly icteric serum samples: modified precipitation procedure and HPLC compared. *Clin Chem* 1998; 44:1269-1274.

36. Shipkova M, Niedmann PD, Armstrong VW, Schütz E, Wieland E, Shaw LM, **Oellerich M**. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. *Clin Chem* 1998; 44:1481-1488.
37. Schütz E, Svinarov D, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, **Oellerich M**. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. *Clin Chem* 1998; 44:2158-2164.
38. Meyer T, Binder L, Graeber T, Luthé H, Kreuzer H, **Oellerich M**, Buchwald AB. Superiority of combined CK-MB and Troponin I measurements for the early risk stratification of unselected patients presenting with acute chest pain. *Cardiology* 1999; 90:286-294.
39. Streit F, Niedmann PD, Shipkova M, Armstrong VW, **Oellerich M**. Rapid and sensitive liquid chromatography-tandem mass spectrometric method for determination of monoethylglycinexylidide. *Clin Chem* 2001; 47: 1853-1856.
40. von Ahsen N, Ehrlich B, Scott CS, Riggert J, **Oellerich M**. Cryoglobulins interfere with platelet counts by optical and impedance methods but not with the CD61 immunoplatelet count. *Clin Chem* 2001; 47: 1858-1860.
41. Streit F, Armstrong VW, **Oellerich M**. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. *Clin Chem* 2002; 48: 955-958.
42. Streit F, Shipkova M, Armstrong VW, **Oellerich M**. Validation of a rapid and sensitive liquid chromatography tandem mass spectrometry method for free and total mycophenolic acid. *Clin Chem* 2004; 50:152-159.
43. Shipkova M, Niedmann PD, Armstrong VW, **Oellerich M**, Wieland E. Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. *Clin Chem* 2004; 50: 438-441.
44. Brandhorst G, Engelmayer J, Götze S, **Oellerich M**, von Ahsen N. Pre-analytical effects of different lithium heparin plasma separation tubes in the routine clinical chemistry laboratory. *Clin Chem Lab Med* 2011; 49: 1473-1477.

45. Petrova DT, Cocisiu GA, Eberle C, Rhode KH, Brandhorst G, Walson PD, **Oellerich M**. Can the Roche hemolysis index be used for automated determination of cell-free haemoglobin? A comparison to photometric assays. *Clin Biochem* 2013; 46: 1298-1301.

Hypoglycemic substances

46. **Oellerich M**, Haeckel R. Inhibition of gluconeogenesis and of cell respiration by 1-(2-pyrimidinyl)-4-imino-1,4-dihydropyridinium chloride in perfused guinea pig liver. *Biochem Pharmacol* 1975; 24:1085-1088.
47. Haeckel R, **Oellerich M**. Inhibition of gluconeogenesis by sodium nitroprusside in the perfused guinea pig liver. *Arzneim-Forsch (Drug Res)* 1976; 26:2052-2054.
48. Haeckel R, **Oellerich M**. The influence of hydrazine, phenelzine and nialamide on gluconeogenesis and cell respiration in the perfused guinea pig liver. *Eur J Clin Invest* 1977; 7:393-400.
49. Haeckel R, **Oellerich M**. Hydrazonopropionic acids, a new class of non-hormonal hypoglycaemic compounds. *Biochem Soc Transactions* 1979; 7:749-752.
50. Haeckel R, **Oellerich M**. Hydrazonopropionic acids, a new class of hypoglycemic substances. 1. Hypoglycemic effect of 2-(phenylethylhydrazono)- and 2-(2-cyclohexylethylhydrazono)-propionic acid. *Horm Metab Res* 1979; 11:606-611.
51. **Oellerich M**, Haeckel R. Hydrazonopropionic acids, a new class of hypoglycemic substances. 2. Influence of 2-(phenylethylhydrazono)- and 2-(2-cyclohexylethylhydrazono)-propionic acid on redox systems, acid base status and monoamino oxidase activity. *Horm Metab Res* 1980; 12:182-189.
52. Haeckel R, Terlutter H, Schumann G, **Oellerich M**. Hydrazonopropionic acids, a new class of hypoglycemic substances. 3. Inhibition of jejunal glucose uptake in the rat and guinea pig. *Horm Metabol Res* 1984; 16:423-427.
53. **Oellerich M**, Haeckel R, Wirries KH, Schumann G, Beneking M. Hydrazonopropionic acids, a new class of hypoglycemic substances. 4. Hypoglycemic effects of 2-(3-methylcinnamylhydrazono)-propionate in the rat and guinea pig. *Horm Metabol Res* 1984; 16:619-625.
54. Haeckel R, **Oellerich M**, Schumann G, Beneking M. Hydrazonopropionic acids, a new class of hypoglycemic substances. 6. Inhibition of hepatic gluconeogenesis by 2-(3-methylcinnamyl-hydrazono)-propionate in the rat and guinea pig. *Horm Metabol Res* 1985; 17:115-122.

55. Beneking M, **Oellerich M**, Haeckel R, Binder L. Inhibition of mitochondrial carnitine acylcarnitine translocase-mediated uptake of carnitine 2-(3-methyl-cinnamyl-hydrazono)-propionate. Hydrazonopropionic acids, a new class of hypoglycaemic substances, VI. *J Clin Chem Clin Biochem* 1987; 25:467-471.
56. Haeckel R, Fink PC, **Oellerich M**. Influence of 2-(3-methyl-cinnamyl-hydrazono)-propionate on glucose and palmitate oxidation in human mononuclear leukocytes. Hydrazonopropionic acids, a new class of hypoglycaemic substances, VII. *J Clin Chem Clin Biochem* 1987; 25:561-566.
57. Binder L, **Oellerich M**, Haeckel R, Beneking M. Effects of 2-(3-methyl-cinnamyl-hydrazono)-propionate on fatty acid and glucose oxidation in the isolated rat diaphragm using ^{14}C -labelled substrates. Hydrazonopropionic acids, a new class of hypoglycaemic substances, VIII. *J Clin Chem Clin Biochem* 1988; 26:815-819.
58. Beneking M, **Oellerich M**, Binder L, Choitz GF, Haeckel R. Inhibition of mitochondrial carnitine acylcarnitine translocase by hypoglycaemia-inducing substances. *J Clin Chem Clin Biochem* 1990; 28:323-327.
59. Haeckel R, Colic D, Binder L, **Oellerich M**. Stimulation of glucose metabolism in human blood cells by inhibitors of carnitine-dependent fatty acid transport. *J Clin Chem Clin Biochem* 1990; 28:329-333.

Liver function, liver transplantation

60. **Oellerich M**, Raude E, Burdelski M, Schulz M, Schmidt FW, Ringe B, Lamesch P, Pichlmayr R, Raith H, Scheruhn M, Wrenger M, Wittekind Ch. Monoethylglycinexylidide formation kinetics: A novel approach to assessment of liver function. *J Clin Chem Clin Biochem* 1987; 25:845-853.
61. Burdelski M, **Oellerich M**, Lamesch P, Raude E, Ringe B, Neuhaus P, Bortfeld S, Kämmerling C, Raith H, Scheruhn M, Westphal C, Worm M, Pichlmayr R. Evaluation of quantitative liver function test in liver donors. *Transplant Proc* 1987; 19:3838-3839.
62. Burdelski M, **Oellerich M**, Raude E, Lamesch P, Ringe B, Raith H, Scheruhn M, Westphal C, Worm M, Bortfeld S, Schulz M, Wittekind C, Hoyer PF, Pichlmayr R. A novel approach to assessment of liver function in donors. *Transplant Proc* 1988; 20, Suppl. 1:591-593.
63. 63. Lamesch P, Ringe B, Neuhaus P, Burdelski M, **Oellerich M**, Pichlmayr R. Qualitative assessment of liver function after hypovolemic, hypoxemic, and ischemic shock in a transplantation model. *Transplant Proc* 1988; 20:994-995.
64. Burdelski M, **Oellerich M**, Bornscheuer A, Luebbe N, Ringe B, Lamesch P, Raude E, Raith H, Scheruhn M, Gubernatis G, Pichlmayr R. Donor rating in human liver transplantation: correlation of oxygen consumption after revascularization with MEGX formation in donors. *Transplant Proc* 1989; 21:2392-2393.
65. Gubernatis G, Bornscheuer A, Taki Y, Farle M, Lübbe N, Yamaoka Y, Beneking M, Burdelski M, **Oellerich M**. Total oxygen consumption, ketone body ratio and a special score are early indicators of irreversible liver allograft dysfunction. *Transplant Proc* 1989; 21:2279-2281.
66. **Oellerich M**, Burdelski M, Ringe B, Lamesch P, Gubernatis G, Bunzendahl H, Pichlmayr R, Herrmann H. Lignocaine metabolite formation as a measure of pre-transplant liver function. *Lancet* 1989; i:640-642.
67. **Oellerich M**, Burdelski M, Lautz HU, Schulz M, Schmidt FW, Herrmann H. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. *Ther Drug Monit* 1990; 12:219-226.

68. Taki Y, Gubernatis G, Yamaoka Y, **Oellerich M**, Yamamoto Y, Ringe B, Okamoto R, Bunzendahl H, Beneking M, Burdelski M, Bornscheuer A, Pichlmayr R. Significance of arterial ketone body ratio measurement in human transplantation. *Transplantation* 1990; 49:535-539.
69. Yamaoka Y, Taki Y, Gubernatis G, Nakatani T, Okamoto R, Yamamoto Y, Ishikawa Y, Ringe B, Bunzendahl H, **Oellerich M**, Kobayashi K, Ozawa K, Pichlmayr R. Evaluation of the liver graft before procurement. Significance of arterial ketone body ratio in brain-dead patients. *Transplant Int* 1990; 3:78-81.
70. Lamesch P, Ringe B, **Oellerich M**, Burdelski M, Beyrau R, Gubernatis G, Pichlmayr R. Assessment of liver function in the early postoperative period after liver transplantation with ICG, MEGX, and GAL tests. *Transplant Proc* 1990; 22:1539-1541.
71. **Oellerich M**, Burdelski M, Lautz HU, Rodeck B, Duewel J, Schulz M, Schmidt FW, Brodehl J, Pichlmayr R. Assessment of pre-transplant prognosis in patients with cirrhosis. *Transplantation* 1991; 51:801-806.
72. **Oellerich M**, Burdelski M, Ringe B, Wittekind Ch, Lamesch P, Lautz HU, Gubernatis G, Beyrau R, Pichlmayr R. Functional state of the donor liver and early outcome of transplantation. *Transplant Proc* 1991; 23:1575-1578.
73. Lautz HU, **Oellerich M**, Burdelski M, Bürger M, Engelmayer U, Pirlich M, Knoke A, Schmidt FW. Assessment of short-term prognosis in transplant candidates with postnecrotic or biliary cirrhosis. *Transplant Proc* 1991; 23:1572-1574.
74. Ozaki N, Ringe B, Bunzendahl H, Taki Y, Gubernatis G, **Oellerich M**, Kuse ER, Kinchi T, Yamachi K, Takada Y, Yamaguchi T, Ozawa K, Pichlmayr R. Ketone body ratio as an indicator of early graft survival in clinical liver transplantation. *Clin Transplantation* 1991; 5:48-54.
75. **Oellerich M**, Burdelski M, Lautz HU, Binder L, Pichlmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. *Hepatology* 1991; 14:1029-1034.
76. Ozaki N, Gubernatis G, Ringe B, **Oellerich M**, Washida M, Yamaoka Y, Ozawa K, Pichlmayr R. Arterial blood ketone body ratio as an indicator for viability of donor livers. *Transplant Proc* 1991; 23:2487-2489.

77. Goeschen K, **Oellerich M**, Wedeking H, Elling D. Überprüfung der Leberfunktion in der Schwangerschaft mit Hilfe des MEGX-Tests unter besonderer Berücksichtigung der SIH und des HELLP-Syndrom. *Gyn Comp* 1991; 2:65.
78. Lehmann U, **Oellerich M**, Pape D, Sturm JA, Regel G. Leberfunktionsdiagnostik bei polytraumatisierten Patienten mittels MEGX-Test. In: *Chirurgisches Forum 1992 f. experim. u. klinische Forschung*. Gall, Berger, Ungeheuer (Hrsg.), Springer-Verlag Berlin 1992: 437-440.
79. Burdelski M, **Oellerich M**, Düwel J, Raith H, Scheruhn M, Ringe B, Rodeck B, Latta A, Pichlmayr R, Brodehl J. Pre- and post-transplant assessment of liver function in pediatric liver transplantation. *Eur J Pediatr* 1992; 151 [Suppl.1]: 39-43.
80. Yamaoka Y, Washida M, Manaka D, Gubernatis G, Ringe B, Ozaki N, Yamaguchi T, Takada Y, **Oellerich M**, Ozawa K, Pichlmayr R. Arterial ketone body ratio as a predictor of donor liver viability in human liver transplantation. *Transplantation* 1993; 55: 92-95.
81. **Oellerich M**, Hartmann H, Ringe B, Burdelski M, Lautz HU, Pichlmayr R. Assessment of prognosis in transplant candidates by use of the Pugh-MEGX score. *Transplant Proc* 1993; 25:1116-1119.
82. Ozaki N, Ringe B, Gubernatis G, Takada Y, Yamaguchi T, Yamaoka Y, **Oellerich M**, Ozawa K, Pichlmayr R. Changes in energy substrates in relation to arterial ketone body ratio after human orthotopic liver transplantation. *Surgery* 1993; 113: 403-409.
83. **Oellerich M**, Schütz E, Polzien F, Ringe B, Armstrong VW, Hartmann H, Burdelski M. Influence of gender on the monoethylglycineylidide test in normal subjects and liver donors. *Ther Drug Monit* 1994; 16:225-231.
84. Christians U, Kohlhaw K, Esselmann H, Sürig T, Luy M, Kaltefleiter M, Beyrau R, Linck A, Ringe B, **Oellerich M**, Sewing KFR. The Yin and Yang of lidocaine and cyclosporine metabolism in liver graft recipients. *Transplant Proc* 1994; 26:2827-2828.
85. Armstrong VW, Kaltefleiter M, Luy-Kaltefleiter M, Schütz E, Wieland E, Loss M, Winkler M, Ringe B, **Oellerich M**. Metabolic liver function and lipoprotein metabolism

- after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. *Transplant Proc* 1995; 27:1201-1203.
86. Lehmann U, Armstrong VW, Schütz E, Regel G, Pape D, **Oellerich M**. Monoethylglycinexylidide as an early predictor of posttraumatic multiple organ failure. *Ther Drug Monit* 1995; 17:125-132.
 87. Armstrong VW, Schütz E, Kaltefleiter M, Luy M, Helmhold M, Wieland E, Ringe B, **Oellerich M**. Relationship of apolipoproteins AI, B and lipoprotein Lp(a) to hepatic function of liver recipients during the early post-transplant period. *Eur J Clin Invest* 1995; 25:485-493.
 88. Schütz E, Luy-Kaltefleiter M, Kaltefleiter M, Burdelski M, Ringe B, Armstrong VW, **Oellerich M**. The value of serial determination of MEGX and hyaluronic acid after orthotopic liver transplantation. *Eur J Clin Invest* 1996; 26:907-916.
 89. Burdelski M, Schütz E, Nolte-Buchholtz S, Armstrong VW, **Oellerich M**. Prognostic value of the monoethylglycinexylidide test in pediatric liver transplant candidates. *Ther Drug Monit* 1996; 18:378-382.
 90. Autschbach R, Falk V, Lange H, **Oellerich M**, Walther T, Mohr FW, Dalichau H. Assessment of metabolic liver function and hepatic blood flow during cardiopulmonary bypass. *Thorac. cardiovasc.Surgeon* 1996; 44:76-80.
 91. El Desoky ES, Ahmed AM, Nafeh MA, Ahmed HA, Schütz E, Armstrong VW, **Oellerich M**. Assessment of liver function by the MEGX test in patients with schistosomiasis and cirrhosis. *Clin Biochem* 1999; 32:207-212.
 92. Igonin AA, Armstrong VW, Shipkova M, Kukes VG, **Oellerich M**. The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia. *Clin Chem Lab Med* 2000; 38:1125-1128.
 93. Hein OV, Öhring R, Schilling A, **Oellerich M**, Armstrong VW, Kox WJ, Spies C. N-acetylcysteine decreases lactate signal intensities in liver tissue and improves liver function in septic shock patients, as shown by magnetic resonance spectroscopy: extended case report. *Critical Care* 2004; 8:R66-R71.

94. Braun JP, Schroeder T, Buehner S, Dohmen P, Moshirzadeh M, Grosse J, Streit F, Schlaefke A, Armstrong VW, **Oellerich M**, Lochs H, Konertz W, Kox WJ, Spies C. Splanchnic oxygen transport, hepatic function and gastrointestinal barrier after normothermic cardiopulmonary bypass. *Acta Anaesthesiol Scand* 2004; 48: 697-703.
95. Dresing K, Armstrong VW, Leip CL, Streit F, Burchardi H, Stürmer KM, **Oellerich M**. Real-time assessment of hepatic function is related to clinical outcome in critically ill patients after polytrauma. *Clin Biochem* 2007; 40: 1194-1200.
96. Lorf T, Schnitzbauer AA, Schaefers SKH, Scherer MN, Schlitt HJ, **Oellerich M**, Becker H, Obed A. Prognostic value of the monoethylglycinexylidide (MEGX)-test prior to liver resection. *Hepatogastroenterol* 2008; 55: 539-43.
97. Neumann S, Frenz M, Streit F, **Oellerich M**. Formation of monoethylglycinexylidide (MEGX) in clinically healthy dogs. *Can J Vet Res* 2011; 75: 317-20.
98. Nörthen A, Asendorf T, Walson PD, **Oellerich M**. Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation. *Clin Biochem* 2018; 52: 20-25.

Lipoproteins, plasminogen, oxidant stress, liver and small bowel injury, inflammation, prenatal programming

99. Wieland E, Brandes A, Armstrong VW, **Oellerich M**. Oxidative modification of low density lipoproteins by human polymorphonuclear leukocytes. *Eur J Clin Chem Clin Biochem* 1993; 31:725-731.
100. Wieland E, Schütz E, Armstrong VW, Ringe B, **Oellerich M**. QSA 10 (Idebenone) or probucol supplementation of organ preservation solutions prevents oxygen radical-mediated injury of hepatic microsomes. *Transplant Proc* 1995; 27:738-740.
101. Wieland E, Schütz E, Armstrong VW, Küthe F, Heller C, **Oellerich M**. Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solutions. *Transplantation* 1995; 60:444-451.
102. von Ahsen N, Helmhold M, Eisenhauer T, Armstrong VW, **Oellerich M**. Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose. *Eur J Clin Invest* 1996; 26:668-675.
103. Schütz E, Wieland E, Heine L, Hensel A, Schmiedl A, Armstrong VW, Richter J, Schuff-Werner P, Günther E, **Oellerich M**. Acceleration of hepatocellular energy by idebenone during early reperfusion after cold preservation ameliorates heat shock protein70 gene expression in a pig liver model. *Transplantation* 1997; 64:901-907.
104. Schütz E, Wieland E, Hensel A, Niedmann PD, Dreiss A, Armstrong VW, Schuff-Werner P, **Oellerich M**. Suppression of leukocyte-enhanced cold ischemia/reperfusion injury of liver endothelium with the benzoquinone antioxidant idebenone. *Clin. Biochem.* 1997; 30:619-624.
105. Osmers RGW, Schütz E, Diedrich F, Wehry B, Krauß T, **Oellerich M**, Kuhn W. Increased serum levels of hyaluronic acid in pregnancies complicated by preeclampsia or hemolysis, elevated liver enzymes, and low platelets syndrome. *Am J Obstet Gynecol* 1998; 178:341-345.
106. Braun F, Schütz E, Laabs S, Hanack U, Sattler B, Lorf T, Wieland E, **Oellerich M**, Ringe B. Development of a porcine small bowel ex vivo perfusion model. *Transplant Proc* 1998; 30:2613-5.

13.01.25

Lipoproteins, plasminogen, oxidant stress, liver and small bowel injury, inflammation, prenatal programming

107. Binder C, Schulz M, Hiddemann W, **Oellerich M**. Caspase-activation and induction of inducible nitric oxide-synthase during TNF- α -triggered apoptosis. *Anticancer Research* 1999; 19: 1715-1720.
108. Binder C, Schulz M, Hiddemann W, **Oellerich M**. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor- α -induced apoptosis in MCF-7 and other epithelial tumor cells. *Laboratory Investigation* 1999; 79:1703-1712.
109. Wieland E, **Oellerich M**, Braun F, Schütz E. c-fos and c-jun mRNA expression in a pig liver model of ischemia/reperfusion: effect of extended cold storage and the antioxidant idebenone. *Clin Biochem* 2000; 33: 285-290.
110. Schettler V, Kuhn W, Kleinoeder T, Armstrong VW, **Oellerich M**, Müller GA, Wieland E. No acute impact of haemodialysis treatment on free radical scavenging enzyme gene expression in white blood cells. *J Intern Med* 2003; 253: 201-207.
111. Igonin AA, Armstrong VW, Shipkova M, Lazareva NB, Kukes VG, **Oellerich M**. Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. *Clin Biochem* 2004; 37: 204-209.
112. Zerr I, Bodemer M, Kaboth U, Kretzschmar H, **Oellerich M**, Armstrong VW. Plasminogen activities and concentrations in patients with sporadic Creutzfeldt-Jacob disease. *Neuroscience Letters* 2004; 371: 163-166.
113. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. Marmoset glutathione peroxidases: cDNA sequences, molecular evolution, and gene expression. *J Med Primatol* 2006; 35: 155-164.
114. Heller T, Geide A, Bonitz U, Wegner U, Gröne HJ, Armstrong VW, **Oellerich M**. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. *Transplantation* 2008; 85: 739-747.
115. Atanasova S, Wieland E, Schlumbohm C, Korecka M, Shaw L, von Ahsen N, Fuchs E, **Oellerich M**, Armstrong V. Prenatal dexamethasone exposure in the common marmoset monkey enhances gene expression of antioxidant enzymes in the aorta of adult offspring. *Stress* 2009; 12: 215-224.

116. Bramlage CP, Schlumbohm C, Pryce CR, Mirza S, Schnell C, Amann K, Armstrong VW, Eitner F, Zapf A, Feldon J, **Oellerich M**, Fuchs E, Müller GA, Strutz F. Prenatal dexamethasone exposure does not alter blood pressure and nephron number in the young adult marmoset monkey. *Hypertension* 2009; 54: 1115-1122.
117. Nyirenda NJ, Carter R, Tang JI, de Vries A, Schlumbohm C, Hillier SG, Streit F, **Oellerich M**, Armstrong VW, Fuchs E, Seckl JR. Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1. *Diabetes* 2009; 58: 2873-9.
118. Brandhorst G, Weigand S, Eberle C, Raddatz D, Karaus M, **Oellerich M**, Walson PD. CD4+ Immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity. *Clin Chim Acta* 2013; 421: 31-33.
119. Wagner NM, Brandhorst G, Czepluch F, Lankeit M, Eberle C, Herzberg S, Faustin V, Riggert J, **Oellerich M**, Hasenfuss G, Konstantinides S, Schäfer K. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. *Obesity* 2013; 21: 461-468.

**Therapeutic drug monitoring (pharmacokinetics, pharmacogenetics,
pharmacodynamics)**

120. Kley HK, **Oellerich M**, Wiegelmann W, Herrmann J, Rudorff KH, Nieschlag E, Krüskemper HL. The effect of methadone on hypophyseal and peripheral glandular hormones during withdrawal. *Horm Metab Res* 1977; 9:484-488.
121. Külpmann WR, **Oellerich M**, Blume U, Schmidt E, Bartels M. Vergleichende in vitro Untersuchungen zur Hämoperfusion mit verschiedenen Adsorbentien. *Klin Wochenschr* 1978; 56:1171-1178.
122. Wettengel R, **Oellerich M**, Schnitker J. Vergleichende Untersuchung der Theophyllin-Serum-Konzentration und der bronchospasmolytischen Wirkung von Cholintheophyllinat (Euspirax[®]) und Theophyllin-Äthylendiamin (Euphyllin retard[®]) bei Patienten mit obstruktiver Atemwegserkrankung. *Prax Pneumol* 1979; 33:1125-1131.
123. Wemhöner S, **Oellerich M**, Sybrecht G. Optimierung der Therapie mit Theophyllin-Präparaten bei obstruktiven Ventilationsstörungen. 1. Bioverfügbarkeit und Pharmakokinetik verschiedener Theophyllin-Präparate. *Prax Pneumol* 1981; 35:36-41.
- Optimisation of theophylline therapy in obstructive respiratory disorders: bioavailability and pharmacokinetics of various theophylline preparations. *Brit J Clin Pract* 1981; Supplement 10:28-34.
124. Wemhöner S, **Oellerich M**, Sybrecht G. Optimierung der Therapie mit Theophyllin-Präparaten bei obstruktiven Ventilationsstörungen. 2. Anwendung von Theophyllin-retard-Präparaten in der Dauertherapie bei Nichtrauchern mit und ohne Herzinsuffizienz. *Prax Pneumol* 1981; 35:42-46.
- Optimisation of theophylline therapy in obstructive respiratory disorders: theophylline-retard preparations for the long term treatment of non-smokers with or without cardiac insufficiency. *Brit J Clin Pract* 1981; Supplement 10:35-39.
125. Ranke C, Schmidt G, **Oellerich M**, Sybrecht GW. Optimierung der Therapie mit Theophyllin-Präparaten bei obstruktiven Ventilationsstörungen. 3. Vorhersage der Theophyllin-Clearance mit einer einfachen pharmakokinetischen Methode und

Vergleich der Bioverfügbarkeit verschiedener Theophyllin-retard-Präparate. Prax Klin Pneumol 1983; 37:99-108.

126. Schmidt G, Ranke C, Creutzig H, **Oellerich M**, Sybrecht GW. Optimierung der Therapie mit Theophyllin-Präparaten bei obstruktiven Ventilationsstörungen. 4. Einfluß von Theophyllin auf mukoziliäre Clearance und den maximalen inspiratorischen Mundokklusionsdruck. Prax Klin Pneumol 1983; 37:154-160. Therapiewoche 33:979-987.

Influence of theophylline on mucociliary clearance and maximum inspiratory mouth occlusion pressure. Brit J Clin Pract 1983; Suppl 23:15-21.

127. **Oellerich M**, Ranke C, Schmidt G, Sybrecht GW. Optimierte Dosierung von Theophyllin durch Abschätzung der Clearance mit einer einfachen pharmakokinetischen Methode. Therapiewoche 1983; 33:1131-1137.

Optimised theophylline dosage by estimation of clearance using a simple pharmacokinetic method. Brit J Clin Pract 1983; Suppl 23:37-41.

128. **Oellerich M**, Müller-Vahl H. The EMIT^R Free LevelTM ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin. Clin Pharmacokinetics 1984; 9, Suppl. 1:61-70.

129. Wilkens JH, Neuenkirchen H, Sybrecht GW, **Oellerich M**. Individualizing theophylline dosage: evaluation of a single point maintenance dose prediction method. Eur J Clin Pharmacol 1984; 26:491-498.

130. Schmäscke J, **Oellerich M**, Schumann G, Sybrecht GW. Pharmakokinetik von Theophyllin, Proxiphyllin und Diprophyllin in einem Kombinationspräparat bei gesunden Probanden. Prax Klin Pneumol 1985; 39:19-27.

131. Neuenkirchen H, Wilkens JH, **Oellerich M**, Sybrecht GW. Nocturnal asthma: Effect of a once per evening dose of sustained release theophylline. Eur J Respir Dis 1985; 66:196-204.

132. Kluge TBR, **Oellerich M**, Schumann G, Sybrecht GW. Enprofylline: Pharmacokinetics and acute effect on bronchial reactivity in normal subjects compared to theophylline and placebo. Eur J Clin Pharmacol 1986; 30:21-25.

133. Böttger HCh, **Oellerich M**, Sybrecht GW. Use of aminoglycosides in critically ill patients: Individualisation of dosage using Bayesian statistics and pharmacokinetic principles. *Ther Drug Monit* 1988; 10:280-286.
134. Heins M, Kurtin L, **Oellerich M**, Maes R, Sybrecht GW. Nocturnal asthma: Slow release terbutaline versus slow release theophylline therapy. *Eur Respir J* 1988; 1:306-310.
135. Stein U, **Oellerich M**, Sybrecht GW, Schneider B. Evaluation of a novel Bayesian method for individualizing theophylline dosage. *J Clin Chem Clin Biochem* 1988; 26:405-414.
136. Raude E, **Oellerich M**, Weinel P, Freund M, Schrappe M, Riehm H, Poliwoda H. High-dose methotrexate: Pharmacokinetics in children and young adults. *Int J Clin Pharmacol Ther Toxicol* 1988; 26:364-370.
137. Oldhafer KJ, Schumann G, Wonigeit K, **Oellerich M**, Ringe B, Pichlmayr R. Cyclosporine A monitoring by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC) after liver transplantation: Influence of route of administration and of liver function on the RIA: HPLC ratio. *Transplant Proc* 1988; 20, Suppl 3:361-365.
138. Schnabel D, von Treufels S, **Oellerich M**, Böttger HCh, Sybrecht GW. Untersuchungen zur Dosistitration mit Euphyllong nach vorausgegangener Serumkonzentrationsbestimmung im steady state. *Pneumologie* 1990; 44:287-288.
139. Martz W, **Oellerich M**, Schnabel D, Sybrecht GW. Individualization of theophylline dosage: A Bayesian method evaluated in patients with once-daily dosing. *Ther Drug Monit* 1991; 13:420-424.
140. Winkler M, Schumann G, Petersen D, **Oellerich M**, Wonigeit K. Monoclonal fluorescence polarization immunoassay evaluated for monitoring cyclosporine in whole blood after kidney, heart, and liver transplantation. *Clin Chem* 1992; 38:123-126.
141. Schütz E, Gummert J, Mohr FW, Armstrong VW, **Oellerich M**. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. *Transplant Proc* 1995; 27:1298-1300.

142. Gummert J, Schütz E, **Oellerich M**, Mohr FW, Dalichau H. Monitoring of TPMT in heart transplant recipients under immunosuppression with azathioprine. *Artif Organs* 1995; 19:918-920.
143. Schütz E, Gummert J, Armstrong VW, Mohr FW, **Oellerich M**. Azathioprine pharmacogenetics: The relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. *Eur J Clin Chem Clin Biochem* 1996; 34:199-205.
144. Braun F, Lorf T, Schütz E, Christians U, Grupp C, Sattler B, Canelo R, Sewing K.-Fr, Armstrong VW, **Oellerich M**, Ringe B. Clinical relevance of monitoring tacrolimus: Comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. *Transplant Proc* 1996; 28:3175-3176.
145. Schütz E, Gummert J, Mohr FW, Armstrong VW, **Oellerich M**. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? *Ther Drug Monit* 1996; 18:228-233.
146. von Ahsen N, Helmhold M, Schütz E, Eisenhauer T, Armstrong VW, **Oellerich M**. Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: implications for therapeutic drug monitoring of cyclosporin A. *Ther Drug Monit* 1997; 19:140-145.
147. Leipold G, Schütz E, Haas JP, **Oellerich M**. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. *Arthritis & Rheumatism* 1997; 40:1896-1898.
148. Braun F, Schütz E, Christians U, Lorf T, Schiffmann JH, Armstrong VW, Schröter W, Sewing KF, **Oellerich M**, Ringe B. Pitfalls in monitoring tacrolimus (FK 5406). *Ther Drug Monit* 1997; 19:628-631.
149. Binder L, Schiel X, Binder C, Menke CFA, Schüttrumpf S, Armstrong VW, Unterhalt M, Erichsen N, Hiddemann W, **Oellerich M**. Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies. *Clin Chem* 1998; 44:408-414.

150. Schütz E, Armstrong VW, Shipkova M, Weber L, Niedmann PD, Lammersdorf T, Wiesel M, Mandelbaum A, Zimmerhackl LB, Mehls O, Tönshoff B, **Oellerich M** and Members of the German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. *Transplant Proc* 1998; 30:1182-84.
151. Schütz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tönshoff B, Pethig K, Wahlers T, Braun F, Ringe B, **Oellerich M**. Therapeutic drug monitoring of mycophenolic acid: comparison of hplc and immunoassay reveals new MPA metabolites. *Transplant Proc* 1998; 30:1185-1187.
152. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, Zimmerhackl LB, Schütz E, Mehls O, **Oellerich M**, Armstrong VW, Tönshoff B. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. *J Am Soc Nephrol* 1998; 9: 1511-1520.
153. Armstrong VW, Schütz E, Zhang Q, Groothusien S, Scholz C, Shipkova M, Aboleneen H, **Oellerich M**. Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography-tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II). *Clin Chem* 1998; 44: 2516-2523.
154. Braun F, Canelo R, Schütz E, Shipkova M, Lorf T, Hanack U, Niedmann D, Armstrong VW, **Oellerich M**, Ringe B. How to handle mycophenolate mofetil in combination with tacrolimus? *Transplant Proc* 1998; 30: 4094-4095.
155. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Wieland E, **Oellerich M**. Overestimation of mycophenolic acid by Emit correlates with MPA metabolite. *Transplant Proc* 1999; 31:1135-1137.
156. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schütz E, Brenner-Weiß G, Voihsel M, Braun F, **Oellerich M**. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. *British J Pharmacol* 1999; 126:1075-1082.

157. Shipkova M, Armstrong VW, Schneider T, Niedmann PD, Schütz E, Wieland E, **Oellerich M**. Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma. *Clin Chem* 1999; 45: 127-129.
158. Schütz E, Shipkova M, Armstrong VW, Wieland E, **Oellerich M**. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. *Clin Chem* 1999; 45: 419-422.
159. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, Staskewitz A, Schütz E, Mehls O, **Oellerich M**, Armstrong VW, Tönshoff B and members of the German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. *Ther Drug Monit* 1999; 21: 498-506.
160. Wieland E, Shipkova M, Schellhaas U, Schütz E, Niedmann PD, Armstrong VW, **Oellerich M**. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? *Clin Biochem* 2000; 33: 107-113.
161. Kiehl MG, Shipkova M, Basara N, Blau IW, Schütz E, Armstrong VW, **Oellerich M**, Fauser AA. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. *Clin Biochem* 2000; 33: 203-208.
162. Holt DW, Johnston A, Kahan BD, Morris RG, **Oellerich M**, Shaw LM. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. *Clin Chem* 2000; 6: 872-874.
163. Pickenpack A, Straub RH, Distler O, Hammond A, **Oellerich M**, Schölmerich J, Lang B, Schütz E. Safety and efficacy of an intravenous loading dose of azathioprine for treatment of non-TPMT-deficient patients with rheumatic diseases. *Rheumatology* 2000; 39:1435-1436.
164. Ringe B, Braun F, Wietzke P, **Oellerich M**, Ramadori G. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression. *Transplant Proc* 2000; 32: 2543.
165. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, **Oellerich M**, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. *Clin Chem* 2000; 46: 365-372.

166. Braun F, Armstrong VW, Lorf T, Canelo R, Arndt C, **Oellerich M**, Ringe B. Comparison of trough level and C(2) cyclosporine blood concentration monitoring in outpatient kidney transplant recipients. *Transplant Proc* 2001; 33: 3108-3109.
167. Braun F, Kassuhn M, Laabs S, Streit F, Armstrong VW, **Oellerich M**, Ringe B. Intestinal biotransformation of cyclosporine A in an extracorporeal pig intestine perfusion model. *Transplant Proc* 2001; 33: 3145-3155.
168. Braun F, Schütz E, Peters B, Talaulicar R, Grupp C, Undre N, Schafer A, Armstrong VW, **Oellerich M**, Ringe B. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. *Transplant Proc* 2001; 33: 2127-2128.
169. Wieland E, Shipkova M, Schütz E, Braun F, Niedmann PD, Armstrong VW, Ringe B, Svinarov DA, **Oellerich M**. Preliminary report on the effect of xenoperfusion with human blood on cyclosporin A metabolism and cytochrome-P-4503A4-mRNA expression in a pig liver perfusion model. *Clin Biochem* 2001; 34: 53-57.
170. Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, **Oellerich M**, Wieland E. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. *British J Pharmacol* 2001; 132:1027-1034.
171. Armstrong VW, Shipkova M, Schütz E, Weber L, Tönshoff B, **Oellerich M**. Monitoring of mycophenolic acid in pediatric renal transplant recipients. *Transplant Proc* 2001; 33: 1040-1043.
172. Shipkova M, Wieland E, Schütz E, Wiese C, Niedmann PD, **Oellerich M**, Armstrong VW. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. *Transplant Proc* 2001; 33: 1080-1081.
173. Ringe B, Braun F, Schütz E, Füzesi L, Lorf T, Canelo R, **Oellerich M**, Ramadori G. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. *Transplantation* 2001; 71: 508 - 515.
174. von Ahsen N, Richter M, Grupp C, Ringe B, **Oellerich M**, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP 3A4 promoter polymorphism

- (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. *Clin Chem* 2001; 47: 1048-1052.
175. Shipkova M, Armstrong VW, Kiehl MG, Niedmann PD, Schütz E, **Oellerich M**, Wieland E. Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil. *Clin Chem* 2001; 47: 1485 – 1488.
176. Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H, Wieland E, **Oellerich M**. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. *Ther Drug Monit* 2001; 23: 717-721.
177. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, Zimmerhackl LB, **Oellerich M**, Tönshoff B. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. *Clin Chem* 2002; 48: 517-525.
178. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O, Zimmerhackl LB, **Oellerich M**, Tönshoff B. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. *J Am Soc Nephrol* 2002; 13: 759-768.
179. Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, Tönshoff B, **Oellerich M**. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. *Ther Drug Monit* 2002; 24: 390-399.
180. Maes B, **Oellerich M**, Ceuppens JL, Armstrong VW, Evenepoel P, Kuypers D, Messiaen T, Shipkova M, Wieland E, Vanrenterghem Y. A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. *Nephrol Dial Transplant* 2002; 17: 923-926.
181. Braun F, Peters B, Schütz E, Lorf T, Undre N, **Oellerich M**, Ringe B. Therapeutic drug monitoring of tacrolimus early after liver transplantation. *Transplant Proc* 2002; 34: 1538-1539.

182. Wigger M, Armstrong VW, Shipkova M, Wacke R, Nizze H, Streit F, von Ahsen N, Muscheites J, Glasenapp S, Stolpe HJ, **Oellerich M**. Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. *Ther Drug Monit* 2002; 24:438-443.
183. Shipkova M, Armstrong VW, Wieland E, **Oellerich M**. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. *Clin Chem* 2003; 49: 260-268.
184. Johnston A, Chusney G, Schütz E, **Oellerich M**, Lee TD, Holt DW. Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C₂). *Ther Drug Monit* 2003; 25: 167-173.
185. Maes BD, Dalle I, Geboes K, **Oellerich M**, Armstrong VW, Evenepoel P, Geypens B, Kuypers D, Shipkova M, Geboes K, Vanrenterghem YFCh. Erosive enterocolitis in mycophenolate mofetil - treated renal-transplant recipients with persistent afebrile diarrhea. *Transplantation* 2003; 75: 665-672.
186. Kuypers DRJ, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, **Oellerich M**, Armstrong V, Shipkova M, Daems J. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. *Ther Drug Monit* 2003; 25: 609-622.
187. Indjova D, Atanasova S, Shipkova M, Armstrong VW, **Oellerich M**, Svinarov D. Phenotypic and genotypic analysis of thiopurine S-methyltransferase polymorphism in the Bulgarian population. *Ther Drug Monit* 2003; 25:631-636.
188. Indjova D, Shipkova M, Atanasova S, Niedmann PD, Armstrong VW, Svinarov D, **Oellerich M**. Determination of thiopurine methyltransferase phenotype in isolated human erythrocytes using a new simple nonradioactive HPLC method. *Ther Drug Monit* 2003; 25: 637-644.
189. Weber LT, Shipkova M, Armstrong VW, Mehls O, **Oellerich M**, Tönshoff B, for the German Study Group Pediatric Renal Transplantation. C₂ monitoring and absorption profiling of cyclosporine for optimization of immunosuppressive therapy in pediatric renal transplant recipients. *Transplant Proc* 2003; 35:2128-2130.

190. Barten MJ, Streit F, Boeger M, Dhein S, Tarnok A, Shipkova M, Armstrong VW, Mohr FW, **Oellerich M**, Gummert JF. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. *Transplantation* 2004; 77: 1154-1162.
191. Shipkova M, Spielbauer B, Volland A, Gröne HJ, Armstrong VW, **Oellerich M**, Wieland E. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. *Transplantation* 2004; 78: 1145-1152.
192. Weber LT, Armstrong VW, Shipkova M, Feneberg R, Wiesel M, Mehls O, Zimmerhackl LB, **Oellerich M**, Tönshoff B and members of the German Study Group on Pediatric Renal Transplantation. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. *Ther Drug Monit* 2004; 26: 415-424.
193. Heller T, **Oellerich M**, Armstrong VW, von Ahsen N. Rapid detection of ITPA 94C>A and IVS2 + 21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2 + 21A>C polymorphism on splicing efficiency. *Clin Chem* 2004; 50: 2182-84.
194. Kenkel JM, Lipschitz AH, Shepherd G, Armstrong VW, Streit F, **Oellerich M**, Luby M, Rohrich RJ, Brown SA. Pharmacokinetics and safety of lidocaine and monoethylglycinexylidide in liposuction: a microdialysis study. *Plast Reconstr Surg* 2004; 114: 516-524.
195. Atanasova SY, von Ahsen N, Toncheva DI, Dimitrov TG, **Oellerich M**, Armstrong VW. Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). *Clin Biochem* 2005; 38: 223-228.
196. Barten MJ, Shipkova M, Bartsch P, Dhein S, Streit F, Tarnok A, Armstrong VW, Mohr FW, **Oellerich M**, Gummert JF. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo. *Ther Drug Monit* 2005; 27: 123-131.
197. Armstrong VW, Tenderich G, Shipkova M, Parsa A, Koerfer R, Schröder H, **Oellerich M**. Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. *Ther Drug Monit* 2005; 27: 315-321.

198. El Desoky ES, AbdelSalam YM, Salama RH, El Akkad MA, Atanasova S, von Ahsen N, Armstrong VW, **Oellerich M**. NAT2*5/*5 genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians. *Ther Drug Monit* 2005; 27: 297-304.
199. Kamdem LK, Streit F, Zanger UM, Brockmöller J, **Oellerich M**, Armstrong VW, Wojnowski L. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. *Clin Chem* 2005; 51: 1374-1381.
200. von Ahsen N, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, **Oellerich M**, Kruis W, Reinshagen M. Association of inosine triphosphatase 94C>A and thiopurine s-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. *Clin Chem* 2005; 51: 2282-2288.
201. Shipkova M, Lorenz K, **Oellerich M**, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. *Clin Chem* 2006; 2: 240-247.
202. Wilson D, Johnston F, Holt D, Moreton M, Engelmayer J, Gaulier JM, Luthe H, Marquet P, Moscato D, **Oellerich M**, Mosso R, Streit F, Brunet M, Fillee C, Schmid R, Wallemacq, Barnes G. Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus. *Clin Biochem* 2006; 39: 378-386.
203. Weber LT, Hoecker B, Armstrong VW, **Oellerich M**, Tönshoff B. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. *Ther Drug Monit* 2006; 28: 623-631.
204. Brandhorst G, Streit F, Goetze S, **Oellerich M**, Armstrong VW. Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites. *Clin Chem* 2006; 52: 1962-1964.
205. Naesens M, Kuypers DRJ, Streit F, Armstrong VW, **Oellerich M**, Verbeke K, Varenterghem Y. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. *Clin Pharmacol Ther* 2006; 80: 509-21.

206. Birnbaum F, Reis A, Böhringer D, Sokolowska Y, Meyer K, Voiculescu A, **Oellerich M**, Sundmacher R, Reinhard T. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. *Transplantation* 2006; 81: 767-772.
207. Heller T, van Gelder T, Budde K, de Fijter JW, Kuypers D, Arns W, Schmidt J, Rostaing L, Powis SH, Claesson K, MacPhee IAM, Pohanka E, Engelmayer J, Brandhorst G, **Oellerich M**, Armstrong VW. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. *Am J Transplant*, 2007; 7: 1822-1831.
208. van Hest RM, Doorduijn JK, de Winter BCM, Cornelissen JJ, Vulto AG, **Oellerich M**, Löwenberg B, Mathot RAA, Armstrong VW, van Gelder T. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. *Ther Drug Monit* 2007; 29: 353-360.
209. Reinshagen M, Schütz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Kruis W, **Oellerich M**, von Ahsen N. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. *Clin Chem* 2007; 53: 1306-1314.
210. Wolff NA, Burckhardt BC, Burckhardt G, **Oellerich M**, Armstrong VW. Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. *Nephrol Dial Transpl* 2007; 22: 2497-2503.
211. Brandhorst G, Tenderich G, Zittermann A, Oezpeker C, Koerfer R, **Oellerich M**, Armstrong VW. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. *Ther Drug Monit* 2008; 30: 113-116.
212. Brandhorst G, Marquet P, Shaw LM, Liebisch G, Schmitz G, Coffing MJ, Domke I, Streit F, Luthe H, **Oellerich M**. Multicenter evaluation of a new inosine monophosphate

- dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. *Ther Drug Monit* 2008; 30: 428 – 433.
213. Weber LT, Hoecker B, Armstrong VW, **Oellerich M**, Tönshoff B. Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. *Ther Drug Monit* 2008; 30: 570-575.
214. van Agteren M, Armstrong VW, van Schaik RHN, de Fijter Hans, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, **Oellerich M**, van Gelder T. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. *Ther Drug Monit* 2008; 30: 439-444.
215. van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, **Oellerich M**, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RD. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. *Transplantation* 2008; 86: 1043-1051.
216. Beckebaum S, Armstrong VW, Cicinnatti VR, Streit F, Klein CG, Gerken G, Paul A, **Oellerich M**. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil. *Ther Drug Monit* 2009; 31: 205-210.
217. Heller T, Asif AR, Petrova DT, Doncheva Y, Wieland E, **Oellerich M**, Shipkova M, Armstrong VW. Differential proteomic analysis of lymphocytes treated with mycophenolic acid reveals caspase-3 induced cleavage of Rho GDP-dissociation inhibitor 2. *Ther Drug Monit* 2009; 31: 211-217.
218. van Gelder T, Domke I, Engelmayer J, de Fijter H, Kuypers D, Budde K., Koeger R, Luthe H, **Oellerich M**. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. *Ther Drug Monit* 2009; 31: 218-223.
219. Petrova DT, Heller T, Hitt R, Wieland E, **Oellerich M**, Armstrong VW, Shipkova M. Regulation of IL2 and NUCB1 in mononuclear cells treated with acyl glucuronide of

- mycophenolic acid reveals effects independent on inosine monophosphate dehydrogenase inhibition. *Ther Drug Monit* 2009; 31: 31-41.
220. Brandhorst G, Luthe H, Domke I, Knoke C, Rhode KH, Sauter H, **Oellerich M**. Therapeutic Drug Monitoring and drugs of abuse testing on the cobas[®] 6000 analyzer series: analytical performance under routine-like conditions. *Clin Chem Lab Med* 2009; 47: 854-859.
221. Jones AE, Wilson HK, Meath P, Meng X, Holt DW, Johnston A, **Oellerich M**, Armstrong VW, Stachulski AV. Convenient syntheses of the in vivo carbohydrate metabolites of mycophenolic acid: reactivity of the acyl glucuronide. *Tetrahedron Lett* 2009; 50: 4973 – 4977.
222. Brandhorst G, Brehmer F, Petrova DT, Gross O, Miosge N, Armstrong VW, **Oellerich M**. Mycophenolic acid predose concentrations and renal function in a mouse model for progressive renal fibrosis. *Ther Drug Monit* 2010; 32: 73 – 78.
223. Soldin SJ, Hardy RW, Wians FH, Balko JA, Mendu DR, Chaffin CH, Streit F, Barbarakis M, Martel J, Canfield W, Levy HR, **Oellerich M**. Performance evaluation of the new ADVIA Centaur system cyclosporine assay (single-step-extraction). *Clin Chim Acta* 2010; 411: 806-811.
224. Petrova DT, Brandhorst G, Brehmer F, Gross O, **Oellerich M**, Armstrong VW. Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function. *Ther Drug Monit* 2010; 32: 405-412.
225. Prémaud A, Weber LT, Tönshoff B, Armstrong VW, **Oellerich M**, Urien S, Marquet P, Rousseau A. Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. *Pharmacol Res* 2011; 63: 216-224.
226. van Gelder T, Silva HT, de Fijter H, Budde K, Kuypers D, Mamelok RD, Armstrong VW, **Oellerich M**. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation. *Ther Drug Monit* 2011; 33: 155-164.
227. Streit F, Binder L, Hafke A, Brandhorst G, Braulke F, Haase D, Armbrust T, Cameron S, Ramadori G, **Oellerich M**, Walson P. Use of total and unbound imatinib and

- metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. *Ther Drug Monit* 2011; 33: 632 - 643.
228. Rother A, Glander P, Vitt E, Czock D, von Ahsen N, Armstrong VW, **Oellerich M**, Budde K, Feneberg R, Tönshoff B, Weber LT. Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. *Eur J Clin Pharmacol* 2012; 68: 913 – 922.
229. Schulz-Jürgensen S, Burdelski M, **Oellerich M**, Brandhorst G. Intracellular ATP production in CD4+ T cells as a predictor for infection and allograft rejection in trough-level guided pediatric liver transplant recipients under calcineurin-inhibitor therapy. *Ther Drug Monit* 2012; 34: 4-10.
230. Misdaq M, Andag R, **Oellerich M**, Asif AR, von Ahsen N. Establishment of thiopurine S-methyltransferase gene knockdown in Jurkat T-lymphocytes: An in vitro model of TPMT polymorphism. *Ther Drug Monit* 2012; 34: 584-592.
231. Binder L, Schwörer H, Hoppe S, Streit F, Neumann S, Beckmann A, Wachter R, **Oellerich M**, Walson PD. Pharmacokinetics of meropenem in critically ill patients with severe infections. *Ther Drug Monit* 2013; 35: 63-70.
232. **Oellerich M**, Schütz E, Kanzow P, Schmitz J, Beck J, Kollmar O, Streit F, Walson PD. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. *Ther Drug Monit* 2014; 36: 136-140.
233. Shipkova M, Petrova DT, Rosler AE, Orth M., Engelmayer J, Wieland E, Brandhorst G, **Oellerich M**. Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring. *Ther Drug Monit* 2014; 36: 433-441.
234. Graff J, Scheuermann EH, Brandhorst G, **Oellerich M**, Gossmann J. Pharmacokinetic analysis of mycophenolate mofetil and enteric-coated mycophenolate sodium in calcineurin inhibitor-free renal transplant recipients. *Ther Drug Monit* 2016; 38: 388-392.

Proteomics

235. Shipkova M, Beck H, Voland A, Armstrong VW, Gröne HJ, **Oellerich M**, Wieland E. Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. *Proteomics* 2004; 4: 2728-2738.
236. Asif AR, **Oellerich M**, Armstrong VW, Riemenschneider B, Monod M, Reichard U. Proteome of conidial surface associated proteins of aspergillus fumigatus reflecting potential vaccine candidates and allergens. *J Proteome Res* 2006; 5: 954-962.
237. Köhler SC, von Ahsen N, Schlumbohm C, Asif AR, Goedel-Armbrust U, **Oellerich M**, Wojnowski, Armstrong VW. Mamoset CYP3A21, a model for human CYP3A4: Protein expression and functional characterization of the promoter. *Xenobiotica* 2006; 36: 1210-1226.
238. Asif AR, Armstrong VW, Voland A, Wieland E, **Oellerich M**, Shipkova M. Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. *Biochimie* 2007; 89: 393-402.
239. Dihazi H, Müller GA, Lindner S, Meyer M, Asif AR, **Oellerich M**, Strutz F. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. *Clin Chem* 2007; 53: 1636-1645.
240. Petrova DT, Asif AR, Armstrong VW, Dimova I, Toshev S, Yaramov N, **Oellerich M**, Toncheva D. Expression of chloride intracellular channel protein 1 (CLIC1) and tumor protein D52 (TPD52) as potential biomarkers for colorectal cancer. *Clin Biochem* 2008; 41: 1224-1236.
241. Asif AR, **Oellerich M**, Armstrong VW, Hecker M, Cattaruzza M. T-786C polymorphism of the *NOS-3* gene and the endothelial cell response to fluid shear stress – a proteome analysis. *J Proteome Res* 2009; 8: 3161-3168.
242. Schultze FC, Petrova DT, **Oellerich M**, Armstrong VW, Asif AR. Differential proteome and phosphoproteome signatures in human T-lymphoblast cells induced by sirolimus. *Cell Prolif* 2010; 43: 396-404.

243. Asif AR, **Oellerich M**, Armstrong VW, Gross U, Reichard U. Analysis of the cellular *Aspergillus fumigatus* proteome that reacts with sera from rabbits developing an acquired immunity after experimental aspergillosis. *Electrophoresis* 2010; 31:1947-1958.
244. Singh B, **Oellerich M**, Kumar R, Kumar M, Bhadoria DP, Reichard U, Gupta VK, Sharma GL, Asif AR. Immuno-reactive molecules identified from the secreted proteome of *aspergillus fumigatus*. *J Proteome Res* 2010, 9: 5517-5529.
245. Singh B, Sharma GL, **Oellerich M**, Kumar R, Singh S, Bhadoria DP, Katyal A, Reichard U, Asif AR. Novel cytosolic allergens of *Aspergillus fumigatus* identified from germinating conidia. *J Proteome Res* 2010; 9: 5530-41.
246. Petrova DT, Brehmer F, Schultze FC, Asif AR, Gross O, **Oellerich M**, Brandhorst G. Differential kidney proteome profiling in a murine model of renal fibrosis under treatment with mycophenolate mofetil. *Pathobiology* 2011; 78: 162-170.
247. Zafar S, von Ahsen N, **Oellerich M**, Zerr I, Schulz-Schaeffer WJ, Armstrong VW, Asif AR. Proteomics approach to identify the interacting partners of cellular prion protein and characterization of Rab7a interaction in neuronal cells. *J Proteome Res* 2011; 7: 3123-35.
248. Qasim, M, Rahman H, **Oellerich M**, Asif AR. Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycophenolic acid treatment. *Proteome Sci* 2011; 9: 57.
249. Rahman H, Qasim M, Schultze F, **Oellerich M**, Asif AR. Fetal calf serum heat inactivation and lipopolysaccharide contamination influence the human T lymphoblast proteome and phosphoproteome. *Proteome Sci* 2011; 9: 71.
250. Zahid S, **Oellerich M**, Asif AR, Ahmed N. Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer's disease patients. *J Neurochem* 2012; 121: 954 - 963.
251. Nasim FF-H, Ejaz S, Ashraf M, Asif AR, **Oellerich M**, Ahmad G, Malik GA, Attiq uR. Potential Biomarkers in the sera of breast cancer patients from Bahawalput, Pakistan. *Biomarkers in Cancer* 2012; 4: 19-34.

252. Biswas S, Sharma S, Saroha A, Bhakuni DS, Malhotra R, Zahur M, **Oellerich M**, Das HR, Asif AR. Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach. *PLoS ONE* 2013; 8: e56246.
253. Zahid S, Khan R, **Oellerich M**, Ahmed N, Asif AR. Differential S-nitrosylation of proteins in Alzheimer's disease. *Neuroscience* 2014; 256: 126-136.
254. Zahid S, **Oellerich M**, Asif AR, Ahmed N. Differential expression of proteins in brain regions of Alzheimer's disease patients. *Neurochem Res* 2014; 39: 208-215.
255. Qasim M, Rahman H, Raees A, **Oellerich M**. Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions. *Exp Cell Res* 2014; 322: 277-289.
256. Rahman H, Qasim M, **Oellerich M**, Asif AR. Identification of the novel interacting partners of the mammalian target of rapamycin complex 1 in human CCRF-CEM and HEK293 cells. *Int J Mol Sci* 2014; 15: 4823-4836.
257. Rahman H, Qasim M, **Oellerich M**, Asif AR. Crosstalk between Edc4 and mammalian target of rapamycin complex 1 (mTORC1) signaling in mRNA decapping. *Int J Mol Sci* 2014; 15: 23179-23195.
258. Petrova DT, Schultze FC, Brandhorst G, Luchs KD, Lenz C, Urlaub H, Rubel D, Gross O, Walson PD, **Oellerich M**. Effects of mycophenolate mofetil on kidney function and phosphorylation status of renal proteins in Alport COL4A3-deficient mice. *Proteome Sci* 2014; 12: 56.
259. Misdaq M, Ziegler S, von Ahsen N, **Oellerich M**, Asif AR. Thiopurines induce oxidative stress in T-lymphocytes: A proteomic approach. *Mediat Inflamm* 2015; Article ID 434825; doi 10.1155/2015/434825.
260. Petrova DT, Brandhorst G, Koch C, Schultze FC, Eberle C, Walson PD, **Oellerich M**. Mycophenolic acid reverses TGF beta-induced cell motility, collagen matrix contraction and cell morphology *in vitro*. *Cell Biochem Funct* 2015; 33: 503-508.

Molecular diagnostics

261. von Ahsen N, Schütz E, Armstrong VW, **Oellerich M**. Rapid detection of prothrombotic mutations of prothrombin (G20210A), factor V (G1691A) and methylenetetrahydrofolate reductase (C677T) by real time fluorescence PCR with the LightCycler. Clin Chem 1999; 45: 694-696.
262. von Ahsen N, **Oellerich M**, Armstrong VW, Schütz E. Application of a thermodynamic nearest-neighbor model to estimate nucleic acid stability and optimize probe design: prediction of melting points of different mutations of apolipoprotein B 3500 and factor V Leiden with a hybridization probe genotyping assay on the LightCycler. Clin Chem 1999; 45: 2094-2101.
263. von Ahsen N, **Oellerich M**, Schütz E. Use of two reporter dyes without interference in a single-tube rapid-cycle PCR: alpha1-antitrypsin genotyping by multiplex real-time fluorescence PCR with the LightCycler. Clin Chem 2000; 46:156-161.
264. Schütz E, von Ahsen N, **Oellerich M**. Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, "two-color/shared" anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design. Clin Chem 2000; 46:1728-1737.
265. von Ahsen N, Lewczuk P, Schütz E, **Oellerich M**, Ehrenreich H. Prothrombin activity and concentration in healthy subjects with and without the prothrombin G20210A mutation. Thrombosis Research 2000; 99:549-556.
266. von Ahsen N, **Oellerich M**, Schütz E. DNA base bulge vs unmatched end formation in probe-based diagnostic insertion/deletion genotyping: genotyping the UGT1A1 (TA)_n polymorphism by real-time fluorescence PCR. Clin Chem 2000; 46:1939-1945.
267. von Ahsen N, **Oellerich M**, Schütz E. A method for homogeneous color-compensated genotyping of factor V (G1691A) and methylenetetrahydrofolate reductase (C677T) mutations using real-time multiplex fluorescence PCR. Clin Biochem 2000; 33:535-539.
268. von Ahsen N, **Oellerich M**. The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism

- on mRNA amount and expression in a stable reporter gene assay system. *Blood* 2004; 103: 586-592.
269. von Ahsen N, Armstrong VW, **Oellerich M**. Rapid, long-range molecular haplotyping of thiopurine S-methyltransferase (TPMT) *3A, *3B and *3C. *Clin Chem* 2004; 50: 1528-1534.
270. Heller T, Kirchheiner J, Armstrong VW, Luthe H, Tzvetkov M, Brockmüller J, **Oellerich M**. AmpliChip CYP450 GeneChip®: a new gene chip that allows rapid and accurate CYP2D6 genotyping. *Ther Drug Monit* 2006; 28: 673-677.
271. Atanasova S, Shipkova M, Svinarov D, Mladenova A, Genova M, Wieland E, **Oellerich M**, von Ahsen N. Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. *Ther Drug Monit* 2007; 29: 6-10.
272. Petrova DT, Nedeva P, Maslyankov S, Toshev S, N, Atanasova S, Toncheva D, **Oellerich M**, von Ahsen N. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. *J Cancer Res Clin Oncol* 2008; 134: 317-22.
273. Petrova DT, Yaramov N, Toshev S, Nedeva P, Maslyankov S, von Ahsen N, **Oellerich M**, Toncheva D. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls. *Onkologie* 2007; 30: 559-63.
274. von Ahsen N, **Oellerich M**, Armstrong VW. Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function. *Ther Drug Monit* 2008; 30: 16-22.
275. von Ahsen N, Tzvetkov M, Karunajeewa HA, Gomorrai S, Ura A, Brockmüller J, Davis TE, Mueller I, Ilett KF, **Oellerich M**. CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. *Int J Mol Edpidemiol Genet* 2010; 1: 310 – 319.
276. Schultze FC, Andag R, Alwahsh SM, Toncheva D, Maslyankov S, Yaramov N, von Ahsen N, Brandhorst G, Walson PD, **Oellerich M**, Petrova DT. FoxP3 demethylation is increased in human colorectal cancer and rat cholangiocarcinoma tissue. *Clin Biochem* 2014; 47: 201-205.

277. Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Moerer O, Slotta JE, Walson P, Kollmar O, **Oellerich M**, Schütz E. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. *Clin Chem* 2013; 59: 1732-1741.
278. Brandhorst G, Petrova DT, Weigand S, Eberle C, von Ahsen N, Schmitz J, Schultze FC, Raddatz D, Karaus M, **Oellerich M**, Walson PD. Lack of correlation between Treg quantification assays in inflammatory bowel disease patients. *World J Gastroenterol* 2015; 21: 3325-3329.
279. Beck J, **Oellerich M**, Schulz U, Schauerte V, Reinhard L, Fuchs U, Knabbe C, Zittermann A, Olbricht C, Gummert JF, Shipkova M, Birschmann I, Wieland E, Schütz E. Donor-derived cell-free DNA is a novel universal biomarker for allograft rejection in solid organ transplantation. *Transplant Proc* 2015; 47: 2400-2403.
280. Billing H, Höcker B, Fichtner A, van Damme-Lombaerts R, Friman S, Jaray J, Vondrak K, Sarvary E, Dello Strologo L, **Oellerich M**, von Ahsen N, Tönshoff B. Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: A pharmacogenetic substudy of the TWIST trial. *Ther Drug Monit* 2017; 39: 21-28.
281. Schütz E, Fischer A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nshan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, **Oellerich M**. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. *PLOS Med* 2017; 14: e1002286; doi: 10.1371/journal.pmed.1002286.
282. Schirmer MA, Beck J, Leu M, **Oellerich M**, Rave-Fränk M, Walson PD, Schütz E, Canis M. Cell-free plasma DNA for disease stratification and prognosis in head and neck cancer. *Clin Chem* 2018; 64: 959-970.
283. **Oellerich M**, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, Kabakchiev M, Hasche G, Gröne HJ, Friede T, Wieland E, Schwenger V, Schütz E, Beck J. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. *Am J Transplant* 2019; 19: 3087-3099.

284. Tran JN, Günther OP, Sherwood KR, Fenninger F, Allan LL, Lan J, Sapir-Pichhadze R, Duquesnoy R, Claas F, Marsh SG, McMaster R, Keown PA & Genome Canada Transplant Consortium* (German Working Group: Opelz G, **Oellerich M**). High-throughput sequencing defines donor and recipient HLA B-cell epitope frequencies for prospective matching in transplantation. *Communications Biology* 2021; doi.org/10.1038/s42003-021-01989-3.
285. Osmanodja B, Akifova A, Budde K, Choi M, **Oellerich M**, Schütz E, Beck J. Absolute or relative quantification of donor-derived cell-free DNA in kidney transplant recipients: case series. *Transplant Direct* 2021; 7: e778
286. Knüttgen F, Beck J, Dittrich M, **Oellerich M**, Zittermann A, Schulz U, Fuchs U, Knabbe C, Schütz E, Gummert J, Birschmann I. Graft-derived cell-free DNA as a noninvasive biomarker of cardiac allograft rejection: a cohort study on clinical validity and confounding factors. *Transplantation* 2022; 106: 615-622
287. Baumann A K, Beck J, Hartleben B, Schütz E, **Oellerich M**, Wedemeyer H, Jaeckel E, Taubert R. Elevated donor-specific cell-free DNA during subclinical graft injury after liver transplantation. *Liver Transplantation* 2022; 28: 1911-1919
288. Schrezenmeier E, Hector Rincon-Arevalo H, Jens A, Stefanski A-L, Hammett C, Osmanodja B, Koch N, Zukunft B, Beck J, **Oellerich M**, Pross V, Stahl C, Choi M, Bachmann F, Liefeldt L, Glander P, Schütz E, Bornemann-Kolatzki K, Lopez del Moral C, Schrezenmeier H, Ludwig C, Jahrsdorfer B, Eckardt K-U, Lachmann N, Kotsch K, Dörner T, Halleck F, Sattler A, Budde K. Temporary antimetabolite hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. *JCI Insight* 2022;7: e157836. doi: 10.1172/jci.insight.157836.
289. Osmanodja B, Akifova A, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E and Budde K. Donor-Derived Cell-Free DNA for Kidney Allograft Surveillance after Conversion to Belatacept: Prospective Pilot Study. *J. Clin. Med.* 2023, 12, 2437.
290. Akifova A, Budde K, Choi M, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E and Osmanodja B. Donor-Derived Cell-Free DNA in Biopsy-Proven Antibody-Mediated Rejection Versus Recurrent IgA Nephropathy After Kidney Transplantation. *Kidney Int Rep* 2023, <https://doi.org/10.1016/j.ekir.2023.07.011>.

291. Osmanodja B, Budde K, **Oellerich M**. Zellfreie Transplantat-DNA zur Diagnose und Monitoring bei antikörpervermittelter Abstoßung nach Nierentransplantation. *Transfusionsmedizin* 2023, 13: 196-200.
292. Osmanodja B, Akifova A, Budde K, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Velden J, Lehmann C, Krüger BM, Bachmann A, Kowald J. Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series. *Transpl Int* 2024; 37:13213
293. Akifova A, Budde K, Choi M, Amann K, Buettner-Herold M, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Bachmann F, Halleck F, Schrezenmeier E, Seelow E, Zukunft B, Lachmann N, Stauch D, Osmanodja B. Association of blood donor-derived cell-free DNA levels with Banff scores and histopathological lesions in kidney allograft biopsies: results from an observational study. *Transplant direct* 2025; submitted
294. Akifova A, Budde K, Amann K, Buettner-Herold M, Choi M, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Bachmann F, Halleck F, von Hoerschelmann E, Koch N, Schrezenmeier E, Seelow E, Waiser J, Zukunft B, Eckardt K-U, Kettritz R, López Del Moral C, Lachmann N, Stauch D, Niemann M, Schmidt D, Halloran P F, Osmanodja B. Absolute donor-derived cell-free DNA monitoring reduces time to diagnosis of antibody-mediated rejection in kidney transplant recipients with de novo donor-specific antibodies: a randomized clinical trial; *Nephrol Dial Transplant* 2024; in press
295. Hansmann H, Fante M A, Harrer D C, Heidemanns S, **Oellerich M**, Beck J, Schütz E, Perl M, Zartner B, Wolff D, Edinger M, Herr W, Banas B, Zecher D, Hansmann L. CD19 CAR-T-cells mediate sustained tolerance of a kidney allograft despite discontinued conventional immunosuppression. *Am J Transplant* 2025; submitted

BOOK CHAPTERS

296. Haeckel R, **Oellerich M**. Enzymimmuntests zum Nachweis von Arzneimitteln im Serum und Harn. In: Engelhardt A, Lommel H, Hrsg. Akute Syndrome. Weinheim: Verlag Chemie, 1978: 281-286.
297. **Oellerich M**, Haeckel R. Rationalisierung von Enzymimmuntests. In: Haeckel R, Hrsg. Rationalisierung des medizinischen Laboratoriums, 2 Aufl. Darmstadt: GIT-Verlag, 1979: 188-195.
298. **Oellerich M**. Die vollmechanisierte Bestimmung von Theophyllin mit dem homogenen Enzymimmuntest. In: Vogt W, Hrsg. Praktische Anwendung des Enzymimmunoassays in der Klinischen Chemie und Serologie. Stuttgart: G.Thieme Verlag, 1979: 85-90.
299. **Oellerich M**. Anwendung der EMIT-Technik beim Drogenscreening. In: Vogt W, Hrsg. Praktische Anwendung des Enzymimmunoassays in der Klinischen Chemie und Serologie. Stuttgart: G.Thieme Verlag, 1979: 66-75.
300. **Oellerich M**. Die Bestimmung von Methotrexat mit einem vollmechanisierten, homogenen Enzymimmuntest. In: Sommer R, Hrsg. Kontrolle der Plasmaspiegel von Pharmaka. Stuttgart: G. Thieme Verlag, 1980: 61-66.
301. **Oellerich M**. Methodik der Theophyllin-Bestimmung. In: Wettengel R, Hrsg. Asthma-Therapie mit Theophyllin. Optimierung durch Blutspiegel-Bestimmung. München-Deisenhofen: Dusterl-Verlag Dr. K. Feistle, 1980: 66-82.
302. **Oellerich M**. Drug Monitoring mit Enzymimmuntests. In: Vogt W, Hrsg. Radioaktivitätsfreie, quantitative Immunoassays in der klinischen Chemie. Stuttgart: G. Thieme Verlag, 1981: 81-101.
303. **Oellerich M**. Monitoring therapeutic drugs in clinical chemical laboratories. In: Kaiser E, Gabel F, Müller MM, Bayer M, eds. XI. International Congress of Clinical Chemistry. Berlin, New-York: W. de Gruyter & Co., 1982: 897-910.
304. **Oellerich M**, Böhm MM, Tietjen HG, Sybrecht GW. Klinische Erfahrungen mit der Bestimmung der Theophyllin-Konzentration im Serum bei Patienten mit obstruktiven

- Ventilationsstörungen. In: Rietbrock N, Woodcock BG, Staib AH, Hrsg. Theophylline and other methylxanthines. Braunschweig, Wiesbaden: Vieweg Verlag, 1982: 255-266.
305. **Oellerich M**, Külpmann WR, Beneking M, Haindl H, Müller-Vahl H. Future of drug monitoring: new developments for drug measurement. In: Masson, ed. Biologie prospective. 5e Colloque International de Pont-à-Mousson. 1983: 1169-1173.
306. **Oellerich M**. Principles of enzyme-immunoassays. In: Bergmeyer HU, ed. Methods of enzymatic analysis, 3rd ed. Weinheim: Verlag Chemie, 1983: 233-260.
307. Sybrecht GW, **Oellerich M**. Antiallergische - antiobstruktive Therapie durch Mastzellenprotektion: Theophyllin. In: Schmidt OP, Hrsg. Mastzellenproduktion, Antiallergische/ antiobstruktive Therapie. München-Deisenhofen: Dustri-Verlag Dr. Karl Feistle, 1983: 77-86.
308. **Oellerich M**, Sybrecht GW. Drug Monitoring und Dosisvorhersage. In: Oellerich M, Sybrecht GW, Wettengel R, Hrsg. Theophyllin, Optimierung der Therapie in Klinik und Praxis. Neu-Isenburg: I.M.P. Verlag, 1983: 85-98.
309. Sybrecht GW, **Oellerich M**. Therapie mit Theophyllin: Charakteristik verschiedener Theophyllin-Präparate, Indikation und individuelle Dosierung. In: Oellerich M, Sybrecht GW, Wettengel R, Hrsg. Theophyllin, Optimierung der Therapie in Klinik und Praxis. Neu-Isenburg: I.M.P. Verlag, 1983: 127-139.
310. **Oellerich M**, Schmäschke J, Schumann G, Sybrecht GW. Bioverfügbarkeit von Theophyllin, Proxiphyllin und Diprophyllin in einer oral applizierten Lösung und einem Retard-Präparat. In: Nolte D, Krejci G, Hrsg. Methylxanthine bei obstruktiven Atemwegserkrankungen. München-Deisenhofen: Dustri-Verlag Dr. Karl Feistle, 1984: 49-69.
311. **Oellerich M**, Thomas L. Pharmaka (Drug Monitoring). In: Thomas L. Hrsg. Labor und Diagnose, 2. Aufl. Marburg: Die Medizinische Verlagsgesellschaft, 1984: 838-850.
312. Müller-Vahl H, **Oellerich M**. Zum klinischen Wert der Bestimmung der Serumkonzentration des freien, nicht eiweißgebundenen Phenytoin. Epilepsie 84. Reinbeck: Einhorn-Press Verlag, 1985: 335-343.

313. **Oellerich M.** Theophylline. In: Bergmeyer HU, ed., Oellerich M, ed. consultant. Methods of enzymatic analysis, Vol. XII, Drugs and Pesticides, 3rd ed., Weinheim: VCH Verlagsgesellschaft, 1986: 5-23.
314. Evans WE, **Oellerich M.** Drugs monitored during therapy. Introduction. In: Bergmeyer HU, ed., Oellerich M, ed. consultant. Methods of enzymatic analysis, Vol. XII, Drugs and Pesticides, 3rd ed., Weinheim: VCH Verlagsgesellschaft, 1986: 2-4.
315. **Oellerich M.** Influence of protein binding commentary. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics, principles of therapeutic drug monitoring. Spokane: Applied Therapeutics, Inc., 1986: 220-228.
316. **Oellerich M.** Clearancewerte und Metabolitenkinetik in der Leberdiagnostik. In: Seidel D, Lang H, Hrsg. Funktion und Funktionsdiagnostik der Leber. Merck-Symposium der Deutschen Gesellschaft für Klinische Chemie 1985. Berlin, Heidelberg: Springer-Verlag, 1987: 53-55.
317. **Oellerich M.** Allgemeine Grundlagen der Therapiekontrolle durch Bestimmung der Serumkonzentrationen von Pharmaka. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart: Schattauer, 1987: 1089-1095.
318. **Oellerich M.** Pharmaka und deren klinisch-chemische Bestimmungsmethoden. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie. Stuttgart: Schattauer, 1987: 1096-1114.
319. **Oellerich M,** Sybrecht GW, Raude E, Schulz M, Ringe B, Schmidt FW, Wilkens JH. Drug Monitoring im Notfall-Labor. In: Henkel E, Hrsg., Kleinkonferenz der Dt. Ges. für Klin. Chemie 1985, Darmstadt: GIT Verlag, 1987: 78-87.
320. Schumann G, **Oellerich M,** Olthafer KJ, Leirich C, Wonigeit K. Entwicklung eines spezifischen HPLC-Routineverfahrens zur Bestimmung von Ciclosporin im Blut. In: Königsteiner Chromatographie-Tage 1987. Eschborn: Waters, Division of Millipore, 1987.
321. **Oellerich M.** Pharmaka (Drug monitoring). In: Thomas L. Hrsg. Labor und Diagnose, 3. Aufl. Marburg: Die Medizinische Verlagsgesellschaft, 1988: 1192-1211.

322. **Oellerich M.** Bestimmung von Antiepileptika mittels radioaktivitätsfreier homogener Immunoassays. In: Schliak H, Hopf HC, Hrsg. Diagnostik in der Neurologie. Stuttgart: Georg Thieme Verlag, 1988: 263-275.
323. **Oellerich M,** Schwabe H, Stein U, Schwarting H, Sybrecht GW. Theophyllin im Speichel. In: Haeckel R, Hrsg. Speicheldiagnostik. Darmstadt: GIT Verlag, 1988: 57-63.
324. **Oellerich M.** Diagnostik des Drogenabusus mittels klinisch-chemischer Methoden. In: Hellbrügge T, Pachler JM, Hrsg. Drogen im Kindes- und Jugendalter. Lübeck: Hansisches Verlagskontor, 1988: 31-43.
325. **Oellerich M,** Schumann G. Is there a need for standardization in drug monitoring? In: Ashby JP, ed. Towards improving laboratory economics and working practice. Lund: Proceedings of the 7th ECCLS Annual Conference Salzburg 1987, The European Committee for Clinical Laboratory Standards, 1988: 169-201.
326. **Oellerich M,** Schneider B. Single-point and Bayesian approach for individualizing theophylline dosage. In: Keller H, Trendelenburg Ch, eds, Curtius HCh, Roth M, series eds. Clinical biochemistry, 2. Data presentation, interpretation. Berlin: W. de Gruyter & Co., 1989: 403-423.
327. **Oellerich M,** Böttger HCh, Sybrecht GW, Raude E. Anwendung der Bayes-Statistik zur Vorhersage des individuellen Serumkonzentrationsverlaufs von Pharmaka. In: Gibitz HJ, Geldmacher von Mallinckrodt M, Hrsg. Klinisch-toxikologische Analytik bei akuten Vergiftungen und Drogenmißbrauch. Weinheim: DFG Deutsche Forschungsgemeinschaft, VCH Verlagsgesellschaft, 1989: 169-175.
328. **Oellerich M.** Allgemeine Grundlagen der Therapiekontrolle durch Bestimmung der Serumkonzentrationen von Pharmaka. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie, 2. überarb. Aufl. Stuttgart: Schattauer, 1989: 1089-1095.
329. **Oellerich M.** Pharmaka und deren klinisch-chemische Bestimmungsmethoden. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie, 2. überarb. Aufl. Stuttgart: Schattauer, 1989: 1096-1114.

330. Schumann G, **Oellerich M**, Kohlhaw K, Wonigeit K, Leirich C. Monitoring cyclosporine (CSA) in transplantation: FPIA compared with RIA and HPLC. In: Tanaka K, Pippenger CE, Mimaki T, Walson PD, Ohgitani S, eds. *Advances in therapeutic drug monitoring. Proceedings of the 1st International Congress of Therapeutic Drug Monitoring*. Tokyo: Enterprise, 1990: 279-281.
331. Haeckel R, **Oellerich M**, Binder L. Hydrazonopropionic acid derivatives. In: Bailey CJ, Flatt PR, eds. *New antidiabetic drugs*. London: Smith-Gordon, 1990: 207-216.
332. Burdelski M, **Oellerich M**, Pippenger CE, Meng X, Rodeck B, Latta A, Binder L, Heller C. Free radical scavenging enzyme activities in erythrocytes of paediatric patients with Crohn's disease. In: Williams CN, ed. *Trends in inflammatory bowel disease therapy*. Dordrecht: Kluwer Academic Publishers, 1991: 393-454.
333. **Oellerich M**, Burdelski M, Ringe B, Ozaki N, Binder L, Pichlmayr R. Assessment of donor organ function. In: Rodes J, Arroyo V, eds. *Therapy in liver diseases*. Barcelona: Ediciones Doyma S.A., 1992:227-236.
334. **Oellerich M**, Burdelski M, Lautz HU, Hartmann H, Ringe B, Pichlmayr R. Donor rating and assessment of pretransplant prognosis by use of the MEGX test. In: Paoletti R, ed. *Drugs and the liver*. Fondazione Giovanni Lorenzini 1992.
335. **Oellerich M**. Pharmaka (Drug Monitoring). In: Thomas L, Hrsg. *Labor und Diagnose*, 4. überarb. Aufl. Marburg: Die Medizinische Verlagsgesellschaft, 1992: 1444-1465.
336. **Oellerich M**, Burdelski M, Goeschen K, Lautz HU, Wedeking H. Drug metabolism as an index of liver function. In: Sunshine I, ed. *Recent developments in therapeutic drug monitoring and clinical toxicology*. New York: Marcel Dekker, Inc., 1992: 765-771.
337. Petersen D, Schumann G, **Oellerich M**, Klauke R, Wittner N. HPLC reference method for theophylline: Calibration by use of standard addition. In: Sunshine I, ed. *Recent developments in therapeutic drug monitoring and clinical toxicology*. New York: Marcel Dekker, Inc., 1992: 277-284.
338. Burdelski M, **Oellerich M**, Rodeck B, Latta A, Düwel J. The role of dynamic liver function tests in liver transplantation. In: *Paediatric Cholestasis. Novel Approaches to Treatment*. Ed. M Lentze, J Reichen. Kluwer Academic Publishers, Dordrecht, Boston, London, 1992: 215-224.

339. **Oellerich M**, Burdelski M, Beyrau R, Ringe B, Lamesch P, Gubernatis G, Pichlmayr R. Assessment of liver function in donors by use of the MEGX test. In: G.Brunner, M.Mito, eds. Artificial Liver Support, 2nd ed. Springer-Verlag Berlin Heidelberg 1992: 132-139.
340. **Oellerich M**, Kaltefleiter M, Luy M, Armstrong VW, Schütz E, Binder L, Ringe B. Use of drugs of assess liver function. In: Biologie prospective. Comptes rendus du 8e Colloque de Pont-à-Mousson. Ed. MM Galteau, G Siest, J Henry. John Libbey Eurotext, Paris. 1993: 411-416.
341. **Oellerich M**. Current status of the use of liver function tests in transplantation. In: III Simposio Nazionale. Monitoraggio farmaci e droghe d'abuso. ATTI. Antonio Delfino Editore, Roma 1993: 55-67.
342. **Oellerich M**. Allgemeine Grundlagen der Therapiekontrolle durch Bestimmung der Serumkonzentrationen von Pharmaka. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie, 3. überarb. Aufl. Stuttgart: Schattauer, 1995: 1353-1359.
343. **Oellerich M**. Pharmaka und deren klinisch-chemische Bestimmungsmethoden. In: Greiling H, Gressner AM, Hrsg. Lehrbuch der Klinischen Chemie und Pathobiochemie, 3. überarb. Aufl. Stuttgart: Schattauer, 1995: 1360-1376.
344. Armstrong VW, Zielmann S, **Oellerich M**, Therapeutic drug monitoring in critical care medicine. In: Dellinger RP, ed. Current Topics in Intensive Care, No. 3, London: Saunders, 1996: 1-22.
345. Armstrong VW, **Oellerich M**, Practical aspects of TDM. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry, 3rd ed., St.Louis: Mosby, 1996, 1098-1102.
346. **Oellerich M**, Schütz E, Armstrong VW, Wieland E, Ringe B,. Liver transplantation: Assessment of liver function in both transplant candidates and recipients. In: Kleesiek K, Heubner A, eds., Transplantation of organs and cells, Berlin: Blackwell, 1997, 22-34.
347. Schütz E, Armstrong VW, **Oellerich M**. Drug Monitoring nach Organtransplantation. In: Bruhn, Fölsch Hrsg., Labormedizin, Schattauer Verlagsgesellschaft, 1999: 124-131.

348. **Oellerich M.** Pharmaka (Drug Monitoring). In: Thomas L, Hrsg., Labor und Diagnose, 5. überarb. Aufl. Frankfurt/Main: TH-Books Verlagsgesellschaft, 1998: 1170-1183.
349. **Oellerich M.** Therapeutic drug monitoring. In: Thomas L, ed., Clinical laboratory diagnostics. Use and assesment of clinical laboratory results, 1. edition. Frankfurt/Main: TH-Books Verlagsgesellschaft, 1998:1145-1157.
350. **Oellerich M.** Pharmaka (Drug Monitoring). In: Thomas L., Hrsg., Labor und Diagnose, 5. erweiterte Aufl., Frankfurt/Main: TH-Books Verlagsgesellschaft, 2000:1170-1183.
351. **Oellerich M.** Drug-Monitoring: Absorptionsprofile – individuelle Pharmakokinetik. In: Land W., Hrsg., Ciclosporin in der Transplantationsmedizin. 1. Aufl., Stuttgart/New York: Thieme, 2001:62-72.
352. **Oellerich M.** Biomarkers of hepatic disease. In: Trull AK, ed., Biomarkers of Disease, An evidence-based approach. 1. edition., Cambrigde: University Press Cambridge, 2002; 167-174.
353. **Oellerich M,** Armstrong VW. Therapeutic Drug Monitoring (TDM). Part 2: Practical aspects of TDM. In: Kaplan LA, Pesce AJ, Kazmierczak SC., eds., Clinical Chemistry. Theory, Analysis, Correlation. 4. edition., St. Louis: Mosby, 2003; 1086-1091.
354. Armstrong VW, Schwab M, **Oellerich M.** Metabolismus von Xenobiotika und Drug Monitoring. In: Renz H., Hrsg., Integrative Klinische Chemie und Laboratoriumsmedizin. 1. Aufl., Berlin/ New York: Walter de Gruyter, 2003; 615-631.
355. **Oellerich M.** Therapeutic drug monitoring. In: Thomas L, ed., Clinical laboratory diagnostics. Use and assesment of clinical laboratory results, 1. Chinese edition. Frankfurt/Main: TH-Books Verlagsgesellschaft, 2004:1140-1151.
356. Tönshoff B, Weber LT, Armstrong VW, **Oellerich M.** Mycophenolate mofetil in pediatric patients. Pharmacokinetics and pharmacodynamics of mycophenolic acid. A CME monograph. Roche Pharmaceuticals 2004: 35-48.
357. **Oellerich M.** Pharmaka (Drug Monitoring). In: Thomas L, ed., Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. 6. Aufl., Frankfurt/Main: TH-Books Verlagsgesellschaft, 2005:1552-1568.

358. Armstrong VW, **Oellerich M**. Critical evaluation of methods for therapeutic drug monitoring. In: Burton ME, Shaw L, Schentag JJ, Evans WE eds. Applied Pharmacokinetics and Pharmacodynamics. Principles of Therapeutic Drug Monitoring, 4th edition. Philadelphia: Lippincott, Williams & Wilkins, 2006: 30-39.
359. **Oellerich M**, Streit F, Schütz E. Ciclosporin: Formulierungsabhängige Pharmakokinetik. In: Petersen KU, Abendroth D. Austauschbarkeit von Pharmaka kritischer Dosierung: Bestandsaufnahme am Beispiel Ciclosporin. Lengerich: Pabst Science Publishers, 2008: 42-53.
360. Armstrong VW, Schütz E, **Oellerich M**. Drug Monitoring nach Organtransplantation. In: Bruhn HD, Fölsch UR, Schäfer H, Hrsg. Labormedizin, 2. überarbeitete Aufl., Schattauer, 2008: 145 – 155.
361. **Oellerich M**. Pharmaka (Drug Monitoring). In: Thomas L, ed., Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. 7. Aufl., Frankfurt/Main: TH-Books Verlagsgesellschaft, 2008: 1552 - 1568.
362. **Oellerich M**, Ritschel WA, Armstrong VW. Therapeutic Drug Monitoring. In: Kaplan LA, Pesce AJ, eds., Clinical Chemistry. Theory, Analysis, Correlation. 5. edition, St. Louis: Mosby Elsevier, 2010: 263 – 280.
363. Brandhorst G, Armstrong VW, Schütz E, **Oellerich M**. Drug Monitoring nach Organtransplantation. In: Bruhn HD, Junker R, Schäfer H, Schreiber S, Hrsg. Labormedizin, 3. überarbeitete Aufl., Schattauer, 2011: 139 – 150.
364. **Oellerich M**, Brandhorst G, Shipkova M, Wieland E. Biomarkers: The link between therapeutic drug monitoring and pharmacodynamics of immunosuppressants. In: Dasgupta A, ed., Therapeutic drug monitoring: newer drugs and biomarkers, 1. edition, San Diego. Elsevier, 2012: 349 - 372.
365. **Oellerich M**. Pharmaka (Drug Monitoring). In: Thomas L, ed., Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. 8. Aufl., Frankfurt/Main: TH-Books Verlagsgesellschaft, 2012: 1899 - 1917.
366. Singh B, Sharma GL, Singh S, Reichard U, **Oellerich M**, Bhadoria DP, Asif AR. Aspergillosis: a major challenge for public health. In: Kappas M, Groß U, Kelleher D,

- eds. *Global Health. A challenge for interdisciplinary research*. Göttingen: Universitätsverlag Göttingen, 2012: 191-208.
367. **Oellerich M**, Beck J, Kanzow P, Schmitz J, Kollmar O, Walson PD, Schütz E. Graft-derived cell-free DNA as a marker of graft integrity after transplantation. In: Oellerich M, Dasgupta A, eds., *Personalized immunosuppression in transplantation: Role of biomarker monitoring and therapeutic drug monitoring*, 1. edition, San Diego. Elsevier, 2016; 153-176.
368. **Oellerich M**, Schütz E, Beck J, Kollmar O, Kanzow P, Blum A, Walson PD. Graft-derived cell-free DNA as a biomarker in liver transplantation. In: Patel VB, Preedy VR, eds., *Biomarkers in Disease: Methods, Discoveries and Applications. Biomarkers in Liver Disease*. 1. edition. Springer, 2016; doi: 10.1007/978-94-007-7742-2_10-1.
369. Beck J, **Oellerich M**, Schütz E. A universal droplet digital PCR approach for monitoring of graft health after transplantation using a preselected SNP set. In: Karlin-Neumann G, Bizouarn F, eds., *Digital PCR. Methods in Molecular Biology* (vol. 1768). Humana Press, New York, NY, 2018. doi: 10.1007/978-1-4939-7778-9_19.
370. **Oellerich M**, Budde K, Bornemann-Kolatzki K, Sherwood K, Osmanodja B, Melter M, Beck J, Schütz E, Keown P, Walson PD. Donor-derived cell-free DNA as a marker of graft injury after solid organ transplantation. In: Dasgupta A ed., *Therapeutic drug monitoring: newer drugs and biomarkers*. 2. edition, San Diego, Elsevier, 2024; 475-498.

REVIEWS

371. Haeckel R, **Oellerich M**. Enzymimmuntests für die Routinediagnostik. Lab med 1977; 1:121-131.
372. **Oellerich M**, Haeckel R. Diagnostischer Wert klinisch-chemischer Untersuchungen. Kriterien und deren praktische Anwendung. Med Welt 1978; 29:866-872.
373. **Oellerich M**. Überwachung der Serumkonzentrationen von Arzneimitteln mit Hilfe von Enzymimmuntests. Nieders Ärzteblatt 1978; 24:852-854.
374. **Oellerich M**, Haeckel R. Einsatz von Enzymimmuntests beim Drogenscreening. Lab med 1979; 3:65-70.
375. Haeckel R, **Oellerich M**. Die Bestimmung der Transferrin-Eisenbindungskapazität. Lab med 1979; 3:163-166.
376. **Oellerich M**. Enzyme immunoassays in clinical chemistry - present status and trends. J Clin Chem Clin Biochem 1980; 18:197-208.
377. **Oellerich M**. Praktikabilität und Zuverlässigkeit des enzym-immunologischen Opiatnachweises. Med Labor 1980; 33:199-206.
378. Diehl V, Kotz R, Salzer M, Winkler K, Baumgärtner G, Sekera J, Ramach W, Illinger J, Janka GE, Pralle H, Mc Vie JG, Willoughby MLN, Engelhardt P, **Oellerich M**. Report on various clinical studies on high dose methotrexate in Europe (non-EORTC). Onkologie 1981; 4:308-319.
379. **Oellerich M**, Sybrecht GW. Indikation und Methodik der Bestimmung des Theophyllinspiegels im Serum. Therapiewoche 1981; 31:5110-5116.
- Indications and methods for determining theophylline levels in serum. Brit J Clin Pract., Suppl. 10:22-27.
380. Sybrecht GW, **Oellerich M**. Stellenwert des Theophyllins in der Asthmatherapie unter Berücksichtigung der Blutspiegel. Atemw.-Lungenkrkh. 1981; 7:269-276.

381. **Oellerich M.** Neuere Entwicklungen der Mechanisierung von Enzymimmuntests. MTA-Zeitschrift d. dvta 1981; 27:316-320.
382. **Oellerich M.** Diagnostik und Drogenabusus mit klinisch-chemischen Methoden. Deutsches Ärzteblatt 1982; 79:41-49.
383. **Oellerich M,** Sybrecht GW, Klein H. Therapieüberwachung durch Bestimmung von Pharmaka-Konzentrationen im Serum. Methodik und klinische Bedeutung. Internist 1982; 23:174-181.
384. **Oellerich M.** Das Konsilium im Rahmen der klinischen Toxikologie und des Drug Monitoring. Dt Ges f Klin Chem e.v.- Mitteilungen 1983; 14:206-214.
385. **Oellerich M.** Enzymimmuntests zur in-vitro Schilddrüsendiagnostik. Akt Endokr Stoffw 1984; 5:6-12.
386. **Oellerich M.** Enzyme-immunoassay - a review. J Clin Chem Clin Biochem 1984; 22:895-904.
387. Maes RAA, **Oellerich M,** Enders PW. Theophylline profile. Report V of the Senate Commission for Clinical-Toxicological Analysis. DFG Deutsche Forschungsgemeinschaft. Weinheim: VCH Verlagsgesellschaft, 1985.
388. **Oellerich M,** Beneking M, Schumann G, Sybrecht GW. Überwachung der Serumkonzentration unter Theophyllin- und Digoxintherapie. Therapiewoche 1986; 36:1114-1124.
389. Wilkens JH, Wilkens H, Meins M, Kurtin L, **Oellerich M,** Sybrecht GW. Treatment of nocturnal asthma: the role of sustained-release theophylline and oral β -2-mimetics. Chronobiology International 1987; 4:387-396.
390. Maes RAA, **Oellerich M.** Tobramycin profile. Report IX of the Senate Commission for Clinical-Toxicological Analysis. DFG Deutsche Forschungsgemeinschaft. Weinheim: VCH Verlagsgesellschaft, 1988.
391. **Oellerich M,** Schumann G, Raude E. Sources of errors in different protein binding assay systems - pharmacology and toxicology. Scand J Clin Lab Invest, 49 Suppl. 1989: 193:62-71.

392. Pichlmayr R, Lautz HU, **Oellerich M**, Gubernatis G. Functional studies in assessment of donor and recipient selection. *Eur J Gastroenterol Hepatol* 1989; 1:87-91.
393. Uges DRA, von Clarmann M, Geldmacher von Mallinckrodt M, van Heijst Ad NP, Ibe K, **Oellerich M**, Schütz H, Stamm D, Wunsch F. Orientierende Angaben zu therapeutischen und toxischen Konzentrationen von Arzneimitteln und Giften in Blut, Serum oder Urin. Mitteilung XV der Senatskommission für klinisch-toxikologische Analytik. DFG Deutsche Forschungsgemeinschaft. Weinheim: VCH Verlagsgesellschaft, 1990.
394. **Oellerich M**. Drug metabolism as an indicator of liver function. *Clinical Chemistry News, Special Issue, Frontiers in therapeutic drug monitoring and clinical toxicology*, Miceli J and Wong SH eds., American Association for Clinical Chemistry, 1992, p 16-19.
395. **Oellerich M**. Therapeutic drug monitoring and pharmacokinetic dose prediction methods. *Wien Klin Wochenschr* 1992; 104:12-15.
396. **Oellerich M**. Leberfunktionstests bei Lebertransplantation. Prognose heute besser beurteilbar. *Krankenhaus Arzt* 1993; 66:163-168.
397. **Oellerich M**, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K, Schütz E, Schran H, Annesley T. Lake Louise Consensus Conference on Cyclosporin Monitoring in Organ Transplantation: Report of the Consensus Panel. *Ther Drug Monit* 1995; 17:642-654.
398. Potter JM, **Oellerich M**. The use of lidocaine as a test of liver function in liver transplantation. *Liver Transplantation and Surgery* 1996; 2: 211-224.
399. **Oellerich M**, Schütz E, Armstrong VW. Monitoring of cyclosporin and azathioprine in organ transplantation. *Drug Metabolism and Drug Interactions* 1997; 14:17-31.
400. **Oellerich M**, Armstrong VW, Schütz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. *Clin Biochem* 1998; 31: 309-316.
401. Shaw LM, Nicholls A, Hale M, Armstrong VW, **Oellerich M**, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, Morris RG.

- Therapeutic monitoring of mycophenolic acid. A consensus panel report. *Clin Biochem* 1998; 31: 317-322.
402. **Oellerich M**, Shipkova M, Schütz E, Wieland E, Weber L, Tönshoff B, Armstrong VW and members of the German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. *Ther Drug Monit* 2000; 22: 20-26.
403. Armstrong VW, **Oellerich M**. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus and azathioprine. *Clin Biochem* 2001; 34: 9-16.
404. **Oellerich M**, Armstrong VW. The MEGX test: A tool for the real-time assessment of hepatic function. *Ther Drug Monit* 2001; 23: 81-92.
405. Shaw LM, Holt DW, **Oellerich M**, Meiser B, van Gelder T. Current Issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. *Ther Drug Monit* 2001; 23: 305-315.
406. **Oellerich M**, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor Neoral therapy? *Ther Drug Monit* 2002; 24: 40-46.
407. Shipkova M, Armstrong VW, **Oellerich M**, Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. *Ther Drug Monit* 2003; 25: 1-16.
408. Dresing K, Pouwels C, Bonsack S, **Oellerich M**, Schwörer H, Uy A, Stürmer KM. HCV-, HBV- und HIV-Infektionen – Gefahren für Arzt und Pflegepersonal. *Chirurg* 2003; 74: 1026-1033.
409. Armstrong VW, Shipkova M, von Ahsen N, **Oellerich M**. Analytic aspects of monitoring therapy with thiopurine medications. *Ther Drug Monit* 2004; 26: 220-226.
410. **Oellerich M**, Armstrong VW, Streit F, Weber L, Tönshoff B. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. *Clin Biochem* 2004; 37: 424-428.
411. Tönshoff B, Weber LT, Höcker B, Köpf S, Zimmerhackl LB, Armstrong VW, **Oellerich M**. Der Stellenwert des Immunsuppressivums Mycophenolatmofetil bei pädiatrischen Nierentransplantatempfängern. *Tx Med* 2004; 16: 26-37.

412. Johnston A, Belitsky P, Frei U, Horvath J, Hoyer P, Helderman JH, **Oellerich M**, Pollard S, Riad H, Rigotti P, Keown P, Nashan B. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. *Eur J Clin Pharmacol* 2004; 60: 389-395.
413. Shipkova M, Armstrong VW, **Oellerich M**, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. *Expert Opin. Drug Metab. Toxicol.* 2005; 1: 505-526.
414. **Oellerich M**, Barten MJ, Armstrong VW. Biomarkers. The link between therapeutic drug monitoring und pharmacodynamics. *Ther Drug Monit* 2006; 1: 35-38.
415. van Gelder T, Le Meur Y, Shaw LM, **Oellerich M**, DeNorfrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Tönshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. *Ther Drug Monit* 2006; 28: 145-154.
416. **Oellerich M**, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. *Ther Drug Monit* 2006; 28: 720-725.
417. Davies NM, Grinyó J, Heading R, Maes B, Meier-Kriesche HU, **Oellerich M**. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. *Nephrol Dial Transpl*, 2007; 22: 2440-2448.
418. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers D, Le Meur Y, Marquet P, **Oellerich M**, Thervet E, Toenshoff B, Undre N, Weber LT, Westley IS, Mourad M. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European Consensus Conference. *Ther Drug Monit* 2009; 31: 139-152.
419. von Ahsen N, Binder C, Brockmöller J, **Oellerich M**. CYP2D6 und Tamoxifen: pharmakogenetische Neuentdeckung eines etablierten Medikaments? *J Lab Med* 2009; 33: 293-302.

420. Wieland E, Olbricht CJ, Süsal C, Gurragehaa P, Böhler T, Israeli M, Sommerer C, Budde K, Hartmann B, Shipkova M, **Oellerich M**. Biomarkers as a tool for management of immunosuppression in transplant patients. *Ther Drug Monit* 2010; 32: 560-572.
421. **Oellerich M**. The future of pathology and laboratory medicine. *BJCL* 2011; 19:9-14.
422. Israeli M, Klein T, Brandhorst G, **Oellerich M**. Confronting the challenge: individualized immune monitoring after organ transplantation using the cellular immune function assay. *Clin Chim Acta* 2012; 413: 1374 - 1378.
423. Singh B, Singh S, Asif AR, **Oellerich M**, Sharma GL. Allergic aspergillosis and the antigens of *Aspergillus fumigatus*. *Curr Protein Pept Sci* 2014; 15: 403-423.
424. **Oellerich M**, Walson PD, Beck J, Schmitz J, Kollmar O, Schütz E. Graft-derived cell-free DNA as a marker of transplant graft injury. *Ther Drug Monit* 2016; 38 (Suppl. 1): S75-S79.
425. Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, López-Hoyos M, Barten MJ, Bergan S, Picard N, Millán López O, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, **Oellerich M**. Barcelona Consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation. *Ther Drug Monit* 2016; 38 (Suppl 1): S1-S20.
426. Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, Brunet M, Budde K, Barten MJ, De Simone P, Wieland E, López OM, Masuda S, Seger C, Picard N, **Oellerich M**, Langman LJ, Wallemacq P, Morris RG, Thompson C, Marquet P. Therapeutic drug monitoring of everolimus: A consensus report. *Ther Drug Monit* 2016; 38: 143-169.
427. Seger C, Shipkova M, Christians U, Billaud EM, Wang P, Holt DW, Brunet M, Kunicki PK, Pawinski T, Langman LJ, Marquet P, **Oellerich M**, Wieland E, Wallemacq P. Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. *Ther Drug Monit* 2016; 38: 170-189.

428. Price CP, John AS, Christenson R, Scharnhorst V, **Oellerich M**, Jones P, Morris HA. Leveraging the real value of laboratory medicine with the value proposition. *Clin Chim Acta* 2016; 462: 183-186.
429. **Oellerich M**, Kanzow P, Walson PD. Therapeutic drug monitoring – Key to personalized pharmacotherapy. *Clin Biochem* 2017; 50: 375-379.
430. **Oellerich M**, Schütz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, Walson PD. Using circulating cell-free DNA to monitor personalized cancer therapy. *Crit Rev Clin Lab Sci* 2017; 54: 205-218.
431. **Oellerich M**, Schütz E, Beck J, Walson PD. Circulating cell-free DNA – diagnostic and prognostic applications in personalized cancer therapy. *Ther Drug Monit* 2019; 41: 115-120.
432. Eiben B, Glaubitz R, Schütz E, Beck J, Eiben C, Teubert A, Wagner H, Winkler T, Kupatt W, **Oellerich M**. Die Untersuchung zellfreier DNA durch Liquid Biopsy in der Medizin (The investigation of cell-free DNA by liquid biopsy in medicine). *Deutsche Zeitschrift für Onkologie* 2019; 51: 60-64.
433. **Oellerich M**, Christenson RH, Beck J, Walson PD. Plasma *EGFR* mutation testing in non-small cell lung cancer: A value proposition. *Clin Chim Acta* 2019; 495: 481-486.
434. O’Kane M, Porter D, McCann M, Juelicher P, Christenson R, **Oellerich M**, Price CP, St John A. A value proposition for natriuretic peptide measurement in the assessment of patients with suspected acute heart failure. *Clin Chim Acta* 2020; 500: 98-103
435. **Oellerich M**, Christenson RH, Beck J, Schütz E, Sherwood K, Price CP, Keown PA, Walson PD. Donor-Derived Cell-Free DNA Testing in Solid Organ Transplantation: A Value Proposition. *JALM* 2020; 5: 993-1004.
436. Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S, Millan O, Mizuno T, Moes

- DJ, **Oellerich M**, Picard N, Salzmann L, Tönshoff B, van Schaik RH, Vethe NT, Vinks A, Wallemacq P, Asberg A, Langman LJ. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. *Ther Drug Monit* 2021; 43: 150-200.
437. **Oellerich M**, Sherwood K, Keown P, Schütz E, Beck J, Stegbauer J, Rump LC, Walson PD. Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. *Nat Rev Nephrol* 2021; 17: 591-603.
438. Danesi R, Lo YMD, **Oellerich M**, Beck J, Galbiati S, Del Re M, Lianidou E, Neumaier M, van Schaik RHN. What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology?- Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. *Clin Chim Acta* 2021; 520: 168-171
439. St John A, O'Kane M, Christenson R, Jülicher P, **Oellerich M**, Price CP. Implementation of medical tests in a Value-Based healthcare environment: A framework for delivering value. *Clin Chim Acta* 2021; 521: 90-96.
440. **Oellerich M**, Budde K, Osmanodja B, Bornemann-Kolatzki K, Beck J, Schütz E, Walson PD. Donor-derived cell-free DNA as a diagnostic tool in transplantation. *Front. Genet.* 2022; 13:1031894.
441. **Oellerich M**, Budde K, Osmanodja B, Bornemann-Kolatzki K, Beck J, Schütz E, Walson PD. Donor-derived cell-free DNA for personalized immunosuppression in renal transplantation. *Ther Drug Monit* 2023; 45: 20-25.
442. Akifova A, Budde K, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Osmanodja B. Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications. *Transpl Int* 2024; 37:13239.
443. Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, Vinks S, Wieland E, Bornemann-Kolatzki K, Brunet M, de Winter B, Dieterlen MT, Elens L, Ito T, Johnson-Davis K, Kunicki PK, Lawson R, Lloberas N, Marquet P, Millan O, Mizuno T, Moes DJ, Noceti O, **Oellerich M**, Pattanaik S, Pawinski T, Seger C, van Schaik R, Venkataramanan R, Walson P, Woillard JB Langman LJ. Everolimus Personalized

13.01.25
REVIEWS

Therapy: Second Consensus Report by the International Association of Therapeutic
Drug Monitoring and Clinical Toxicology. Ther Drug Monit 2025; 47: 4-31

MULTICENTRE STUDIES

444. Bernutz C, Horn K. Ergebnisse der gemeinsamen Erprobung eines Enzymimmunoassays für Thyrotropin (TSH). *J Clin Chem Clin Biochem* 1986; 24:659-666.
445. Knedel M, Assmann G, Courbe A, van Impe L, Kattermann R, Keller H, **Oellerich M**. Investigation of the performance of the ES 600 Enzym-Test^R system. A multicenter study. *J Clin Chem Clin Biochem* 1988; 26:149-162.
446. Klein G, Castiñeiras MJ, Collinsworth W, Courbe A, Delavenne M, Hänseler E, Hannak D, Kaspar P, Kattermann R, Knoke A, Mastropaolo W, Moia F, Nelson P, **Oellerich M**, Suigo E, Swanson R, Torralba A, Valdes R, Jr., Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA theophylline assay. *Wien Klin Wochenschr* 1992; 104:31-37
447. Klein G, Collinsworth W, Courbe A, Fuentes-Arderiu X, Graham J, Hänseler E, Hannak D, Kattermann R, Knoke A, Lehmann P, Mastropaolo W, Moia F, Nelson P, **Oellerich M**, Suigo E, Torralba A, Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA phenytoin assay. *Wien Klin Wochenschr* 1992; 104:38-42.
448. Klein G, Collinsworth W, Courbe A, Diez O, Domke I, Hänseler E, Haux P, Kattermann R, Knoke A, Lehmann P, Moia F, Nelson P, **Oellerich M**, Suigo E, Torralba A, Valdes R, Jr., Wilders-Truschnig M, Wu AHB. Results of the multicenter evaluation of the CEDIA phenobarbital assay. *Wien Klin Wochenschr* 1992; 104:43-47.
449. Horn K, Haux P, Kattermann R, **Oellerich M**, Knoke A, Sommer R, Weißmann A, Vockenhuber M, Clark D, Ng RH, Glick MR, Collinsworth W, Schröder S, Dubois H. Results of the multicenter evaluation of the CEDIA cortisol assay. *Wien Klin Wochenschr* 1992; 104:80-85.
450. Horowitz GL, Zaman Z, Blanckaert NJC, Chan DW, DuBois JA, Golaz O, Mensi N, Keller F, Stolz H, Klingler K, Marocchi A, Prencipe P, McLawhon RW, Nilsen OL, **Oellerich M**, Luthe H, Orsonneau JL, Richeux G, Recio F, Roldan E, Rymo L, Wicktorsson AC, Welch SL, Wieland H, Busse Grawitz A, Mitsumaki H, McGovern M, Ng K, Stockmann W. Modular Analytics: a new approach to automation in the clinical laboratory. *J Autom Method Manag* 2005; 1: 8-25 .

451. Brandhorst G, Streit F, Kratzsch J, Schiettecatte J, Roth HJ, Luppä PB, Körner A, Kiess W, Binder L, **Oellerich M**, von Ahsen N. Multicenter evaluation of a new automated electrochemiluminescence immunoassay for the quantification of testosterone compared to liquid chromatography tandem mass spectrometry. *Clin Biochem* 2011; 44: 264-267.
452. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, **Aldo-DHF Investigators**. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. *JAMA* 2013; 309: 781-791.

BOOKS EDITED

453. **Oellerich M**, Sybrecht GW, Wettengel R. Theophyllin, Optimierung der Therapie in Klinik und Praxis. Neu-Isenburg: I.M.P. Verlag, 1983.
454. Evans WE, **Oellerich M**. Therapeutic drug monitoring clinical guide, (dtsch., franz., ital., span., holländ. Übersetzung 1984) Abbott Laboratories, 1984.
455. Bergmeyer HU, ed. **Oellerich M**, ed. consultant. Methods of enzymatic analysis, Vol. XII, Drugs and Pesticides, 3rd ed., Weinheim: VCH Verlagsgesellschaft, 1986.
456. Taylor WJ, Diers Caviness MH, eds., **Oellerich M**, ed. consultant. A textbook for the clinical application of therapeutic drug monitoring. Irving: Abbott Laboratories, 1986.
457. Diers Caviness M, Mac Kichan J, Bottorff MB, Taylor WJ, ed., **Oellerich M**, ed. consultant. Therapeutic drug monitoring: a guide to clinical application. Irving: Abbott Laboratories, 1987.
458. Sunshine I, ed., **Oellerich M**, ed. board. Recent developments in therapeutic drug monitoring and clinical toxicology. New York: Marcel Dekker Inc., 1992.
459. Evans WE, **Oellerich M**, Holt DW. Therapeutic drug monitoring clinical guide: (dtsch., ital., franz. Übersetzung 1994), 2nd ed., Abbott Laboratories, 1994.
460. Evans WE, Schentag JJ, Jusko WJ, eds., **Oellerich M**, ed. consultant. Applied pharmacokinetics, 3rd ed., Vancouver: Applied Therapeutics, 1996.
461. Evans WE, **Oellerich M**. Therapeutic drug monitoring clinical guide, (dtsch., ital. Übersetzung 1994) Abbott Laboratories, 1994.
462. Evans WE, **Oellerich M**. Surveillance Thérapeutique par le dosage des médicaments. Guide pratique, 3ème éd. Abbott Laboratories, 1994.
463. Burtis CA, Ashwood ER, Bruns DE. Eds.; associate editors: Ann Gronowski, Greg Miller, **Oellerich M**, Francois Rousseau, Mitch Scott, Karl Voelkerding. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed., St. Louis: Elsevier Saunders, 2012.

464. **Oellerich M**, Dasgupta A. Personalized immunosuppression in transplantation: Role of biomarker monitoring and therapeutic drug monitoring. 1. edition, San Diego. Elsevier, 2016.

EDITORIALS, LETTERS TO THE EDITOR, QUESTIONS AND ANSWERS

465. **Oellerich M.** Theophyllin allein oder kombiniert mit N-substituierten Derivaten? *Selecta* 1980; 37:3246.
466. **Oellerich M.** Workshop conference of the German Society for Clinical Chemistry, Immunological Diagnostics, Guest Editorial. *J Clin Chem Clin Biochem* 1984; 22:845.
467. **Oellerich M,** Sybrecht GW. Pharmacokinetics and theophylline. *Brit J Clin Pract* 1984; 38, Suppl. 35:3-4.
468. **Oellerich M.** Leserbrief zur Frage des therapeutischen Bereiches von Lithium. *Lab med* 1985; 9:338.
469. Haeckel R, Kaiser R, **Oellerich M,** Siliprandi N. Workshop conference on carnitine. Preface. *Carnitine: Metabolism function and clinical application. J Clin Chem Clin Biochem* 1990; 28:291-295.
470. Schütz E, Gummert J, Mohr F, **Oellerich M.** Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. *Lancet* 1993; 341:436.
471. Armstrong VW, Wieland E, Diedrich F, Renner A, Rath W, Kreuzer H, Kuhn W, **Oellerich M.** Serum antibodies to oxidised low-density lipoprotein in pre-eclampsia and coronary heart disease. *Lancet* 1994; 343:1570.
472. **Oellerich M.** Editorial. *Ther Drug Monit* 1996; 18:321.
473. **Oellerich M.** Klinisch-chemische Forschung im Spannungsfeld zwischen Medizin und Naturwissenschaften (Emeritierung von Prof.Dr.Dr.J.Büttner). *DG Klinische Chemie Mitteilungen* 1996; 27:55-59
474. Shaw LM, **Oellerich M.** The role of therapeutic drug monitoring in disease management: introduction. *Clin Chem* 1998; 44:369.

475. Schütz E, Shipkova M, Armstrong VW, **Oellerich M**. Monoethylglycinexylidide (MEGX) liver function test is not compromised by 3-hydroxy MEGX in humans. *Hepatology* 1998; 28:1439-1440.
476. Ivanova A, von Ahsen N, Adjarov D, Krastev Z, **Oellerich M**, Wieland E. C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria. *Hepatology* 1999; 30: 1531-1532.
477. Schütz E, Shipkova M, Wieland E, Niedmann P, Armstrong VW, **Oellerich M**. Evaluation of an immunoassay for mycophenolic acid. *Ther Drug Monit* 2000; 22:141-142.
478. **Oellerich M**. Laboratory evaluation and monitoring of transplant recipients. *Ther Drug Monit* 2000; 22:640.
- Oellerich M**. Laboratoriumsmedizinische Diagnostik und Verlaufskontrolle bei Transplantatempfängern. *DG Klinische Chemie Mitteilungen* 2000; 31:167-169.
479. Hummel KM, von Ahsen N, Kühn R-B, Kaboth U, Grunewald RW, **Oellerich M** Müller GA. Pseudohypercreatininemia due to positive interference in enzymatic creatinine measurements caused by monoclonal IgM in patients with Waldenström's macroglobulinemia. *Nephron* 2000; 86: 188-189.
480. **Oellerich M**, Shaw L. Proceedings of the Analytica Conference 2000 symposium on laboratory evaluation and monitoring of transplant recipients Munich, Germany, April 11, 2000. *Clin Biochem* 2001; 34:1.
481. **Oellerich M**, Armstrong VW. Prodrug metabolites: implications for therapeutic drug monitoring. *Clin Chem* 2001; 5: 805 - 806.
482. von Ahsen N, Wieland E, Adjarov D, Krastev Z, **Oellerich M**, Ivanova A. The HFE gene S65C polymorphism is rare among Bulgarian porphyria cutanea tarda patients. *J Hepatol* 2001; 34: 484-488.
483. von Ahsen N, **Oellerich M**, Schütz E. Limitations of genotyping based on amplicon melting temperature. *Clin Chem* 2001; 7: 1331-1332

484. **Oellerich M.** Editorial zur Fusion der Deutschen Gesellschaft für Laboratoriumsmedizin und der Deutschen Gesellschaft für Klinische Chemie. *J Lab Med* 2003; 27: 6-7.
485. **Oellerich M.** Editorial. *J Lab Med* 2004; 28: 2.
486. **Oellerich M, Kohse KP.** Editorial *Klinische Chemie Mitteilungen* 2004; 35: 81-82.
487. von Ahsen N, **Oellerich M.** Prothrombin 19911A>G as a functional noncoding variant: the evidence remains. *Blood* 2005; 105: 2995-6.
488. Meier-Kriesche HU, Davies NM, Grinyó J, Heading R, Mamelok R, Wijngaard P, **Oellerich M, Maes B.** Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil. *Am J Transplant* 2005; 5: 1164.
489. von Ahsen N, **Oellerich M.** Chip-Based Genotyping: Translation of pharmacogenetic research to clinical practice. *Clin Chem* 2007; 53: 1186-1187.
490. Brandhorst G, **Oellerich M** (moderators), Brunet M, Kowalski R, Vinks A, Wallemacq P (experts). Q & A: Individually tailored immunosuppression: is there a role for biomarkers? *Clin Chem* 2011; 57: 376-381.
491. Brandhorst G, **Oellerich M, Maine G, Taylor P, Veen G, Wallemacq P.** Liquid chromatography-tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring? *Clin Chem* 2012; 58: 821-825.
492. Wieland E, Shipkova M, **Oellerich M.** Biomarkers in transplantation medicine: Guide to the next level in immunosuppressive therapy. *Clin Chim Acta* 2012; 413: 1309.
493. Kanzow P, Kollmar O, Schütz E, **Oellerich M, Schmitz J, Beck J, Walson PD, Slotta JE.** Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. *Transplantation* 2014; 98: e43-e45.

494. Scott MG, Rifai N (moderators), Smith B, **Oellerich M**, Panteghini M, Apple F, Sikaris K, Young I (experts). Q & A: The changing face of laboratory medicine: a more service and less academically oriented profession? *Clin Chem* 2015; 61: 322-329.
495. **Oellerich M**, Koren G. In memoriam: Offie Soldin, PhD, MBA. *Ther Drug Monit* 2015; 37: 555-556.
496. Christenson RH, Grenache DG, **Oellerich M**. Preamble. Special Collection on the Value of Laboratory Medicine. *JALM* 2020; 5: 841-843.
497. **Oellerich M**: Zellfreie Tumor-DNA in der molekularen Diagnostik bei Kopf-Hals-Karzinomen. *HNO* 2021; 69: 324; doi.org/10.1007/s00106-021-01009-0.
498. Agbor-Enoh S (moderator), **Oellerich M**, Wu A, Halloran P F, De Vlaminck I, Keller M (experts). Q&A: Novel approaches for transplant monitoring; is the horizon here? *Clin Chem* 2021; 67: 1443-1449

GUEST EDITOR

499. **Oellerich M**, Wieland E, Shipkova M (eds.). Special issue: Peripheral biomarkers as a complementary tool to TDM for individualizing immunosuppression in transplantation medicine. *Clin Chim Acta* 2012; 413: 1309-1418.
500. Christenson R, Grenache D, **Oellerich M** (eds.). Special collection: Value of laboratory testing and the value proposition, *JALM* 2020; doi.org/10.1093/jalm/jfaa120

GENE BANK ENTRIES

501. Schütz E, Andag R, Wieland E, **Oellerich M**. Porcine Cytochrome-P450 with high protein homology to human CYP3A4 (Nifedipine oxidase J04449). GenBank, Acc.no. AF 109068; 23-Nov-1998.
502. Atansova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. AY966403: Marmoset glutathione peroxidase 1 mRNA, complete cds.
503. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. AY966404: Marmoset glutathione peroxidase 4 mRNA, complete cds.
504. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. DQ164097: Callithrix jacchus gamma-glutamylcysteine synthetase regulatory subunit mRNA, complete cds.
505. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. DQ241811: Callithrix jacchus catalase mRNA, complete cds.
506. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. DQ486898: Callithrix jacchus glutathione synthetase mRNA, complete cds.
507. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. EF059744: Callithrix jacchus eukaryotic translation elongation factor EF2 mRNA, complete cds.
508. Atanasova S, von Ahsen N, Schlumbohm C, Wieland E, **Oellerich M**, Armstrong VW. EF203010: Callithrix jacchus glutathione reductase (GSR) mRNA, complete cds.

PROTEOME ENTRIES

509. Allergome Platform Entries

(<http://www.allergome.org>)

Immuno-reactive molecules identified from the secreted proteome of *Aspergillus fumigatus*. Singh B, **Oellerich M**, Kumar R, Kumar M, Bhadoria DB, Reichard U, Gupta VK, Sharma GL, Asif AR. *J Proteome Res* 2010; 9: 5517-5529.

Immuno-reactive molecules identified from the secreted proteome of *Aspergillus fumigatus*. Singh B, **Oellerich M**, Kumar R, Kumar M, Bhadoria DB, Reichard U, Gupta VK, Sharma GL, Asif AR. *J Proteome Res* 2010; 9: 5530-5541.

Asp f AT V

Aspergillus, *Aspergillus fumigatus*, Fungi Molds, *Neosartorya fumigata*, *Sartorya fumigata*, Trichocomaceae 2010-09-13 8983

Asp f Catalase

Aspergillus, *Aspergillus fumigatus*, Fungi Molds, *Neosartorya fumigata*, *Sartorya fumigata*, Trichocomaceae 2011-08-09 8987

Asp f Chitosanase

Aspergillus, *Aspergillus fumigatus*, Fungi Molds, *Neosartorya fumigata*, *Sartorya fumigata*, Trichocomaceae 2010-09-13 8985

Asp F CP

Aspergillus, *Aspergillus fumigatus*, Fungi Molds, *Neosartorya fumigata*, *Sartorya fumigata*, Trichocomaceae 2010-09-13 8994

Asp f DPPV

Aspergillus, *Aspergillus fumigatus*, Fungi Molds, *Neosartorya fumigata*, *Sartorya fumigata*, Trichocomaceae 2010-08-13 8984

Asp f FDH

Aspergillus, *Aspergillus fumigatus*, Fungi Molds, *Neosartorya fumigata*, *Sartorya fumigata*, Trichocomaceae 2010-09-13 8992

Asp f gamma Actin

Aspergillus, *Aspergillus fumigatus*, Fungi Molds, *Neosartorya fumigata*, *Sartorya fumigata*, Trichocomaceae 2011-04-29 9533

Asp f Glucosidase

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8995

Asp f GPI

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-05-15 2543

Asp f GT

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-07-02 8986

Asp f IAO

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8996

Asp f IPMI

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-05-20 9531

Asp f LPL1

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-07-02 8989

Asp f LPL3

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-07-02 8988

Asp f Mannosidase

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8990

Asp f MDH

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-04-29 8993

Asp f PL

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8991

Asp f PUP

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2010-09-13 8982

Asp f RPS3

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-04-29 9532

Asp f SXR

Aspergillus, Aspergillus fumigatus, Fungi Molds, Neosartorya fumigata, Sartorya fumigata, Trichocomaceae 2011-04-29 9530

COMMITTEE RECOMMENDATIONS

510. Guder WG, Groß J, Jaroß J, Kattermann R, Katz N, **Oellerich M**. Kommission für die Ausbildung der Deutschen Gesellschaft für Klinische Chemie e.V.: Empfehlungen zur ärztlichen Ausbildung im Fach Klinische Chemie. Dt Ges f Klin Chem e.V. - Mitteilungen 1993; 24: 200-207.
511. Levy G, Thervet E, Lake J, Uchida K on behalf of the CONCERT group. Patient management by Neoral C₂ monitoring: an international consensus statement. Transplantation 2002; 73: S12-S18.
512. Pollard S, Nashan B, Johnston A, Hoyer P, Belitsky P, Keown P, Helderman H. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin Ther 2003, 25: 1654-1669.
513. Kuypers DR; Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Tönshoff B, Holt DW, Chapman J, Gelder T, Transplantation Society (TTS) Consensus Group on TDM of MPA. Clin J Am Soc Nephrol 2010; 5: 341-58.

NEWSLETTER

514. **Oellerich, M.** Challenges of Transplantation in Children. IATDMCT Newsletter. Ther Drug Monit 2002; 24: 322.
515. **Oellerich, M.** Individualisierte Arzneimitteltherapie
Zertifizierte Fortbildung in Zusammenarbeit mit der Bayerischen Landesärztekammer.
Der Internist 2006, 1 (Beilage): 1-8.
516. **Oellerich M,** von Ahsen N. Nachruf Victor William Armstrong. Klinische Chemie Mitteilungen. Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e.V. 2010; 41: 133 – 135.
517. **Oellerich M.** Obituary. Prof. Dr. Victor William Armstrong 1948 – 2010. Ther Drug Monit 2010; 32:379.
518. **Oellerich M.** Obituary. Prof. Dr. rer. nat. Victor William Armstrong. J Lab Med 2010; 34: 237-238.
519. **Oellerich M.** Internationale Fachgesellschaften beteiligen sich an einer einzigartigen Initiative für eine neue Sichtweise auf die Laboratoriumsmedizin. Klinische Chemie Mitteilungen 2011; 42: 6-7.
520. **Oellerich M.** XXVI. WASPaLM Weltkongress in Las Vegas. Klinische Chemie Mitteilungen 2012; 43: 21-22.
521. **Oellerich M.** Neue Entwicklungen bei WASPaLM. Klinische Chemie Mitteilungen 2013; 44: 49.
522. **Oellerich M.** Liquid Biopsy in der Transplantationsmedizin. DIATRA 2019; 29: 46-47.
523. **Oellerich M,** Beck J, Bauer C, Schütz E. Zellfreie DNA als Biomarker in der Transplantationsmedizin. transplant campus, 07.01.2020; <https://www.transplant-campus.de/nierentransplantation-lebertransplantation-herztransplantation-highlights/allgemein/wissen-kompakt/zellfreie-dna-und-liquid-biopsy-nach-transplantation/>

ABSTRACTS

524. Kley HK, **Oellerich M**, Wiegelmann W, Herrmann J, Rudorff KH, Nieschlag E, Krüskemper HL. Pituitary and peripheral glandular functions in male drug addicts at the end of the methadone maintenance program. *Acta Endocrinol* 1977; Suppl. 212:162.
525. **Oellerich M**, Haeckel R, Schumann G. Hydrazonverbindungen - eine neue Gruppe von blutglucosesenkenden Substanzen. *Aktuelle Endokrinologie und Stoffwechsel* 1980; 1:214-215.
526. Külpmann WR, **Oellerich M**. Determination of therapeutic serum concentrations of antiepileptic drugs by a newly developed gas chromatographic procedure and enzyme immunoassay: a comparative study. *J Clin Chem Clin Biochem* 1980; 18:720.
527. **Oellerich M**, Böhm MM, Sybrecht GW. Klinische Bedeutung der Kontrolle der Theophyllinserumkonzentration bei Patienten mit Asthma bronchiale. *Verhandlungen der Deutschen Gesellschaft für Innere Medizin* 1982; 88:426-427.
528. Külpmann WR, **Oellerich M**, Gey S, Beneking M, Heyer R. Determination of phenytoin in serum by non-isotopic immunoassays (EMIT, FPIA, NIA, SLFIA) and gaschromatography. *J Clin Chem Clin Biochem* 1982; 20:665-666.
529. Steenken Ch, **Oellerich M**, Werner PC, Klein H, Lichtlen PR. Klinische Wertigkeit der Bestimmung von Disopyramid-Serumspiegeln bei antiarrhythmischer Therapie. *Zeitschrift für Kardiologie* 1984; Suppl 1, 73:78.
530. Wrenger M, **Oellerich M**, Sybrecht GW. Determination of enprofylline by HPLC using column switching. *J Clin Chem Clin Biochem* 1985; 23:615.
531. Schulz M, **Oellerich M**, Raude E, Freise J, Schmidt FW. Untersuchungen zur Kinetik des Lidocainmetaboliten und Patienten mit Leberzirrhose. *Z Gastroenterol* 1987; 25:1-2.
532. Burdelski M, **Oellerich M**, Raude E, Ringe B, Kämmerling L, Worm M, Scheruhn M, Raith H, Bortfeld St, Westphal C. Erste Erfahrungen mit quantitativen Leberfunktionstesten zur Erfassung von Leberschäden bei Organspendern. *WZ Gastroenterol* 1987; 25:79-80.

533. Lamesch P, Blumhardt G, Ringe B, Burdelski M, **Oellerich M**, Schmidt E, Pichlmayr R. Wertigkeit von Funktionstests zur Beurteilung von Lebertransplantaten. *Z Gastroenterol* 1987; 25:80.
534. Beneking M, **Oellerich M**, Haeckel R, Binder L. Untersuchungen zur Hemmung der Carnitin-Acylcarnitin-Translocase an Mitochondrien der Meerschweinchenleber. *Z Gastroenterol* 1987; 25:63-64.
535. Wrenger M, **Oellerich M**, Riedmann M. Development of HPLC methods using column switching techniques and automatic mobile phase adjustment for the determination of disopyramide and antiepileptic drugs. *J Clin Chem Clin Biochem* 1987; 25:636-637.
536. Burdelski M, **Oellerich M**, Ringe B, Raith H, Scheruhn M, Lamesch P, Rodeck B, Pichlmayr R. Prognostische Bedeutung quantitativer Leberfunktionsteste (MEGX-, ICG-, GEK- und Coffein-Test) bei Lebertransplantierten. *Z Gastroenterol* 1988; 26:12-13.
537. **Oellerich M**, Burdelski M, Lautz HU, Raude E, Ringe B, Lamesch P, Gubernatis G, Beneking M, Rodeck B, Pichlmayr R. Efficiency of the MEGX formation test in liver transplantation. *Hepatology* 1988; 8:1220.
538. **Oellerich M**, Burdelski M, Lautz HU, Lamesch P, Herrmann H, Raude E, Ringe B, Gubernatis G, Beneking M, Schulz M, Schmidt FW, Pichlmayr R. Prognostische Wertigkeit des MEGX-Tests bei Transplantations-Kandidaten und lebertransplantierten Patienten. *Z Gastroenterol* 1989; 27:50-51.
539. Lautz HU, **Oellerich M**, Schulz M, Knoke A, Raude E, Burdelski M, Bürger M, Schmidt FW. Zur klinischen Bedeutung der Monoethylglycinxylylidid (MEGX) Bestimmung bei hepatischen und biliären Leberzirrhosen. *Z Gastroenterol* 1989; 27:42.
540. **Oellerich M**, Burdelski M, Lautz HU, Rodeck B, Duevel J. Prognostic value of the MEGX liver function test in transplant candidates. *Clin Chem.* 1989; 35:1135.
541. **Oellerich M**, Burdelski M, Lautz HU, Rodeck B, Schmidt FW. Assessment of short-term prognosis in transplant candidates with cirrhosis. *J Hepatol* 1989; 9, Suppl 1:67.

542. **Oellerich M**, Burdelski M, Lautz HU. Prognostic sensitivity and specificity of the monoethylglycinexylidide liver function test in transplant candidates. *J Clin Chem Clin Biochem* 1989; 27:757.
543. **Oellerich M**, Burdelski M, Beyrau R, Ringe B, Lamesch P, Wonigeit K, Lautz HU, Gubernatis G, Taki Y, Pichlmayr R. Lidocaine metabolite formation as a measure of early post-transplant liver function. *Hepatology* 1989; 10:625.
544. Duewel J, Burdelski M, **Oellerich M**, Rodeck B. Evaluation of liver function tests as prognostic indicators in chronic pediatric liver disease. *Hepatology* 1989; 10:660.
545. Kohlhaw K, Hoeft R, Muraca M, Ringe B, Bunzendahl H, Schumann G, Sonntag O, **Oellerich M**, Pichlmayr R. Serum esterified bilirubin (EB) and serum total bile acids (BA) in episodes of cholestasis after orthotopic liver transplantation (OLT). *Hepatology* 1989; 10:662.
546. Lamesch P, Rabe C, Ringe B, **Oellerich M**, Burdelski M, Gubernatis G, Pichlmayr R. Efficiency of MEGX and ICG-test for the prediction of postoperative complications after hepatic resections. *Hepatology* 1989; 10:663.
547. **Oellerich M**. Sources of error in protein binding assay systems, pharmacology and toxicology. *Biochem Clin.* 1989; 13:25-26.
548. **Oellerich M**, Sonntag O, Burdelski M. Decentralized performance of clinical chemical analysis: methodological aspects. *Biochem Clin* 1990; 14, Suppl 1:35.
549. Burdelski M, **Oellerich M**, Düwel J, Rodeck B, Herrmann H. Prognostische Wertigkeit von Leberfunktionstesten und klinischen Befunden bei pädiatrischen Transplantationskandidaten. *Z Gastroenterol* 1990; 28:73.
550. Kohlhaw K, Muraca M, Hoeft R, Sonntag O, Villei T, Ringe B, Bunzendahl H, Schumann G, **Oellerich M**, Pichlmayr R. Differentialdiagnostische Bedeutung von Bilirubin-Fractionen und Gallensäuren bei Leberfunktionsstörungen nach orthotoper Lebertransplantation (OLT). *Z Gastroenterol* 1990; 28:72-73.
551. **Oellerich M**. Lidocaine metabolite formation as measure of pretransplant liver function. *Hepatitis Digest* 1990; 1:20-21.

552. Rieß U, Binder L, Gulba DC, **Oellerich M**, Lichtlen P. Herzmuskelspezifisches Troponin T: Ein neuer Reperfusionmarker? *Z Kardiologie* 1990; 79, Suppl 1:116.
553. **Oellerich M**, Burdelski M, Lautz HU, Rodeck B, Herrmann H. Lidocaine metabolite formation as a prognostic indicator in transplant candidates with cirrhosis. *Clin Chem* 1990; 36:1170.
554. Burdelski M, **Oellerich M**, Rodeck B. Prognostic indicators in liver cirrhosis. *Pediatric Research* 1990; 27:535.
555. **Oellerich M**. Drug metabolism as an index of liver function. *Quimica Clinica* 1990; 9:314.
556. Schumann G, **Oellerich M**, Petersen D. HPLC reference method for theophylline: calibration by use of standard addition. *Quimica Clinica* 1990; 9:352.
557. Burdelski M, **Oellerich M**, Düwel J, Rodeck B, Brodehl J. Predictors of one-year survival in pediatric liver cirrhosis. *Hepatology* 1990; 12:858.
558. **Oellerich M**, Goeschen K, Wedeking H, Elling D, Burdelski M. Lidocaine metabolite formation as a measure of liver function in pregnancy. *Hepatology* 1990; 12:1011.
559. Binder L, **Oellerich M**, Haeckel R. Untersuchungen zur Hypoglykämischen Wirkung von 2-(3-Phenylpropoxyimino)-butyrat. *DG Klinische Chemie Mitteilungen* 1990; 21:239.
560. **Oellerich M**. Drug metabolism as an indicator of liver function. *Clin Chem* 1991; 37:1099.
561. Petersen D, Schumann G, **Oellerich M**, Demertzis S. Monitoring 5-fluorocytosine serum concentrations in immunocompromized patients with severe fungal infections. *Clin Chem* 1991; 37:1004.
562. Schumann G, Kunze K, **Oellerich M**, Petersen D, Hoyer P, Filler G, Offner G. Determination of cyclosporine in capillary blood by an affinity column mediated immunoassay (ACMIA) on the ACAR. *Clin Chem* 1991; 37:998.

563. **Oellerich M**, Burdelski M, Lautz HU, Pichlmayr R. Assessment of one-year pretransplant survival by flow-dependent dynamic liver function tests and Pugh score. *Hepatology* 1991; 14:286A.
564. **Oellerich M**, Hartmann H, Burdelski M, Lautz HU, Binder L. Prognostische Wertigkeit der Kombination von Pugh-Score und MEGX-Test bei Lebertransplantations-Kandidaten. *Z Gastroenterol* 1992; 30:74.
565. Kynast B, Binder L, Marx D, Zoll B, **Oellerich M**, Schmoll HJ, Schauer A. p185-Überexpression beim Mammakarzinom. Nachweis mit ICA und ELISA. *Verh.Dtsch.Ges.Path.* 1992; 76:278.
566. Wieland E, Armstrong VW, **Oellerich M**. Probleme der Bestimmung oxidiertes Lipoproteine in vitro und in vivo. *Dt.Ges.f.Klin.Chemie e.V. - Mitteilungen* 1992; 23:127-128.
567. Binder L, **Oellerich M**. Influence of 2-(3-phenylpropoxyimino)-butyrate on glucose transport in 3T3-L1 adipocytes. *Eur J Clin Chem Clin Biochem* 1993; 31:A16.
568. Schütz E, Gummert J, Jendras I, Mohr F, **Oellerich M**. Erythrocyte thiopurine methyltransferase as a predictor of potential azathioprine intolerance in heart transplantation. *Eur J Clin Chem Clin Biochem* 1993; 31:A46.
569. Wieland E, David A, Armstrong VW, **Oellerich M**. Enzymatic determination of aldehydic lipid peroxidation products using bacterial bioluminescence: Application to oxidized low density lipoproteins. *Eur J Clin Chem Clin Biochem* 1993; 31:A54.
570. Schütz E, Polzien F, Ringe B, Armstrong VW, **Oellerich M**. Differences in cytochrome P-450-mediated lidocaine metabolite formation between normal subjects and liver donors. *Hepatology* 1993; 18:343A.
571. Wieland E, Schütz E, Küthe F, Heller C, Armstrong VW, **Oellerich M**. Supplementation of organ preservation solutions with idebenone (QSA-10) protects liver microsomes against oxygen-radical-mediated damage. *Hepatology* 1993; 18:64A.
572. Wieland E, Schütz, E, Armstrong VW, **Oellerich M**. Oxygen radical mediated damage of hepatic microsomal lipids and proteins: protective effects of benzoquinones and α -tocopherol compared. *Z Gastroenterol* 1994; 32:64.

573. Binder L, Marx D, Kynast B, Meden H, Schauer A, **Oellerich M**. Determination of c-erb-2 oncoproteins in primary tumor and serum from breast cancer patients: prognosis and relapse. *J Cancer Res Clin Oncol* 1994; Suppl 120:R3.
574. Petersen D, Freund M, Poliwoda H, Schöffski P, Paaz U, Knoche MF, Schumann G, **Oellerich M**. Monitoring serum concentrations of 5-fluorocytosine and dosage individualization in cancer patients. *J Cancer Res Clin Oncol* 1994; Suppl 120:R61.
575. Schütz E, Kaltefleiter M, Luy-Kaltefleiter M, Ringe B, Armstrong VW, Burdelski M, **Oellerich M**. Prediction of early graft survival and complications by serial determination of MEGX and hyaluronic acid after OLT. *Hepatology* 1994; 20:126A.
576. Wieland E, Schütz E, Hensel A, Niedmann PD, Armstrong VW, **Oellerich M**. Antioxidant defense and lipid peroxidation during extended cold storage of pig livers in UW and HTK organ preservation solutions. *Hepatology* 1994; 20:414A.
577. Binder L, Wiemann S, **Oellerich M**. Effects of hydrazonopropionic acid derivates on glucose transport in 3T3-LI adipocytes. *Diabetologia* 1994; 37:A125.
578. Binder C, Binder L, **Oellerich M**, Hiddemann W. Proliferative activity and expression pattern of glucose transporter mRNA'S in human tumors and cell lines. *Onkologie* 1994; Suppl.2 17:10.
579. Wieland E, Schütz E, Hensel A, Niedmann PD, Nebendahl K, Armstrong VW, **Oellerich M**. Antioxidantienstatus und Lipidperoxidation während ausgedehnter kalter Ischämie in UW- und HTK-Organprotektionslösung am Modell der explantierten Schweineleber. *Z Gastroenterol* 1995; 33:57.
580. Schütz E, Wieland E, Hensel A, Dietrich K, Nebendahl K, Armstrong VW, Ringe B, **Oellerich M**. Idebenon unterdrückt den leukozytenvermittelten Hyaluronsäureanstieg im Ischämie/ Reperusionsmodell der isoliert perfundierten Schweineleber. *Z Gastroenterol* 1995; 33:59-60.
581. Schütz E, Gummert J, Armstrong VW, Mohr FW, **Oellerich M**. Azathioprine pharmacogenetics: The relationship of TPMT and 6-TGN in heart and kidney transplant recipients. *Ther Drug Monit* 1995; 17:429.

582. Schütz E, Dietrich D, Weyland W, Ringe B, **Oellerich M**. Does high-flow ascites compromise the MEGX-test? *Ther Drug Monit* 1995; 17:428.
583. von Ahsen N, Armstrong VW, Helmhold M, Schütz E, Eisenhauer T, **Oellerich M**. Cyclosporin trough levels correlate with serum lipoproteins and apolipoproteins in renal transplant recipients. *Ther Drug Monit* 1995; 17:430.
584. Heller C, Schütz E, Armstrong VW, **Oellerich M**. Improved EMIT assay for semiautomated cyclosporine determination. *Ther Drug Monit* 1995; 17:416.
585. Braun F, Schütz E, Grupp C, Canelo R, Armstrong VW, **Oellerich M**, Ringe B. Interaction of tacrolimus (FK-506) and fluconazole. *Ther Drug Monit* 1995; 17:397.
586. Schütz E, Wieland E, Heine L, Hensel A, Schmiedl A, Armstrong VW, Richter J, Günther E, **Oellerich M**. Heat-shock protein 70 gene expression in a pig liver cold ischemia/reperfusion model: influence of storage time and gadolinium chloride. *Hepatology* 1995; 22:218A.
587. Schettler V, Wieland E, Methe H, Schuff-Werner P, **Oellerich M**, Müller GA. Granulocyte glutathione peroxidase and glutathione reductase activities are significant changes during dialysis treatment: hemofiltration and hemodialysis compared. *JASN* 1995; 6:561.
588. Schettler, V, Wieland E, Schuff-Werner P, Kreuzer H, **Oellerich M**, Müller GA. Modified erythrocyte free radical scavenging enzymes activities (FRSEA) in patients suffering from coronary heart disease (CHD) undergoing LDL-apheresis (HELP). *Nieren- und Hochdruckkrankheiten* 1995; 24:526.
589. Schettler, V, Wieland E, Schuff-Werner P, Kreuzer H, **Oellerich M**, Müller GA. Modified erythrocyte free radical scavenging enzymes activities (FRSEA) in patients suffering from coronary heart disease (CHD) undergoing LDL-apheresis (HELP). *Nephrol. Dial. Transplant* 1996; 11: 1476.
590. Schettler V, Wieland E, Methe H, Schuff-Werner P, **Oellerich M**, Müller GA. Oxidative stress in granulocytes of patients undergoing hemodialysis and hemofiltration. *Nieren- u.Hochdruckkrankheiten* 1996; 25:400.

591. Schettler V, Wieland E, Iven H, Schuff-Werner P, **Oellerich M**, Müller M. Free radical scavenging enzyme activities (FRSEA) in granulocytes from renal transplant recipients (RTR) under cyclosporine therapy. *JASN* 1996; 7: 1922.
592. Schütz E, Wieland E, Hensel A, Heine L, Günther E, **Oellerich M**. Expression von HSP70, c-fos, TNF-alpha und iNOS mRNA in einem Schweineleberperfusionsmodell: Einfluß der kalten Ischämie in HTK-Organprotektionslösung. *Z Gastroenterol* 1996; 33:74.
593. **Oellerich M**, Armstrong VW. Assessment of liver function by the use of MEGX- and ICG-tests. *Clinical Intensive Care* 1996; Suppl, 7:29-30.
594. Wieland E, Schütz E, Armstrong VW, **Oellerich M**. QSA-10 (idebenone) protects the sinusoidal endothelium from oxygen radical mediated damage in a pig liver ischemia / reperfusion model. *Hepatology* 1996; 24:430A.
595. Schütz E, Wieland E, Armstrong VW, **Oellerich M**. Early ischemia/reperfusion damage after cold storage in a pig liver model is not related to TNF- α and iNOS mRNA expression. *Hepatology* 1996; 24:432A.
596. Delinikolas A, Binder L, Luthe H, Heller C, **Oellerich M**. Evaluation of the Stratus cardiac troponin I immunoassay. *Laboratoriumsmedizin* 1996; 20: 676.
597. **Oellerich M**. Stellenwert des MEGX-Tests in der Leberfunktionsdiagnostik. *DG Klinische Chemie Mitteilungen* 1996; 27:68-69.
598. Schütz E, Wieland E, Heine L, Günther E, **Oellerich M**. Die hepatozytäre Energiedefizienz in der frühen Reperfusionsphase nach kalter Leberischämie ist an der Auslösung der Hitzeschock Protein 70 Expression beteiligt. *Z Gastroenterol* 1997; 1: 79.
599. Wieland E, Schütz E, Andreeva M, Zwerger B, **Oellerich M**. Effekt der Reperfusion auf die Cytochrom P-450 3A Aktivität und mRNA Expression in der Schweineleber nach kalter Ischämie in HTK-Organprotektionslösung. *Z Gastroenterol* 1997; 1: 79.
600. Binder L, Schiel X, Fernandes A, Menke C, Schüttrumpf S, Armsstrong VW, Unterhalt M, Hiddemann W, **Oellerich M**. Clinical outcome and economic impact of therapeutic drug monitoring: an outcome and economic study of aminoglycoside TDM in

- immunoscompromised patients with hematologic malignancies. *Clinical Chemistry* 1997; 6:83-84.
601. Schettler V, Wieland E, Methe H, Schuff-Werner P, **Oellerich M**, Müller GA. Oxidative stress in granulocytes during extracorporeal treatment: free radical scavenging enzymes and glutathione in hemodialysis and LDL apheresis compared. *Nieren- und Hochdruckkrankheiten* 1997; 26:485.
602. Burdelski M, Helmke K, Schütz E, Knoke A, **Oellerich M**. MEGX formation depends on liver blood flow rather than on liver CYP 3A4 content in pediatric patients with chronic end stage liver disease. *Hepatology* 1997; 26:281A.
603. Schütz E, Wieland E, Wagner A, Armstrong VW, Hecker M, **Oellerich M**. Suppression of IL-6 and TNF- α receptor mRNA expression during liver reperfusion after cold preservation with idebenone. *Hepatology* 1997; 26:353A.
604. Wieland E, Schütz E, Andreeva A, Zwerger B, Armstrong VW, **Oellerich M**. Oxygen radicals (OR) mediate the effect of white blood cells (WBC) on cytochrome P-450-3A4 (CYP3A4)-activity and -mRNA expression in a pig liver cold storage/perfusion model. *Hepatology* 1997; 26:629A.
605. Braun F, Lorf T, Schütz E, Hanack U, Bockhoff I, Canelo R, Klinge B, Schulze FP, Armstrong VW, **Oellerich M**, Ringe B. Clinical experience of mycophenolic acid (MPA) monitoring following liver (LTX) and kidney transplantation (KTX). *Ther Drug Monit* 1997; 19:552.
606. Armstrong VW, Schütz E, Meinecke I, Andreeva M, Niedmann PD, Weber L, Lamersdorf T, Wiesel M, Mandelbaum A, Mehls O, Zimmerhackl LB, Tönshoff B, **Oellerich M**. Noncompartmental pharmacokinetic analysis of mycophenolic acid concentrations in pediatric renal transplant recipients. *Ther Drug Monit* 1997; 19:554.
607. Armstrong VW, Schütz E, Groothuisen S, Scholz C, Andreeva M, Niedmann PD, **Oellerich M**. Pentamer formation assay for determination of tacrolimus and its active metabolites in whole blood. *Ther Drug Monit* 1997; 19:554.
608. Schütz E, Armstrong VW, Andreeva M, Niedmann PD, Weber L, Tönshoff B, **Oellerich M**. Prediction of mycophenolic acid plasma AUC by a three point model in pediatric kidney recipients. *Ther Drug Monit* 1997; 19:555.

609. Andreeva M, Niedmann D, Schütz E, Armstrong VW, **Oellerich M**. An HPLC procedure for simultaneous determination of mycophenolic acid and its glucuronide in human plasma. *Ther Drug Monit* 1997; 19:565.
610. Schütz E, Andreeva M, Niedmann PD, Armstrong VW, Weber L, Braun F, Tönshoff B, Ringe B, **Oellerich M**. Mycophenolic acid determination after solid organ transplantation: RP-HPLC and EMIT™ compared. *Ther Drug Monit* 1997; 19:566.
611. Engelmayer U, Engelmayer J, Binder L, Kölch M, **Oellerich M**. Evaluation of the digoxin assay for the Immulite® chemiluminescent immunoassay system. *Ther Drug Monit* 1997, 19:575.
612. Engelmayer J, Engelmayer U, Binder L, Ringe B, **Oellerich M**. False positive digoxin levels in sera from liver-transplanted patients. *Ther Drug Monit* 1997; 19:575.
613. Schütz E, Wieland E, Andag R, Armstrong VW, **Oellerich M**. Partial sequence of a pig gene with high homology to human CYP3A4. *Ther Drug Monit* 1997; 19:593.
614. El Desoky ES; Ahmed AM, Nafeh MA, El-Aty Ahmed HA, Schütz E, Armstrong VW, **Oellerich M**. Monoethylglycinexylidide (MEGX) formation in patients with liver cirrhosis and schistosomal hepatic fibrosis. *Ther Drug Monit* 1997; 19:601.
615. Burdelski M, Knoke A, Schütz E, **Oellerich M**. MEGX formation and expression of liver CYP3A4 mRNA compared in pediatric patients with chronic end stage liver disease. *Ther Drug Monit* 1997, 19:601.
616. Schütz E, Andreeva M, Niedmann PD, Armstrong VW, **Oellerich M**. Determination of monoethylglycinexylidide (MEGX) by FPIA in serum samples with high bilirubin: modified precipitation procedure and HPLC compared. *Ther Drug Monit* 1997; 19:602.
617. Tönshoff B, Weber L, Armstrong VW, Lamersdorf T, Andreeva M, Niedmann PD, Schütz E, Wiesel M, Mandelbaum A, Zimmerhackl LB, Mehls O, **Oellerich M**. Pharmacokinetic analysis of mycophenolic acid (MPA), free MPA and MPA-glucuronide (MPAG) in pediatric renal transplant recipients - a multicenter study. *J Am Soc Nephrol* 1997; 8:706A.

618. Wieland E, Schütz E, Andreeva M, Zwerger B, Armstrong VW, **Oellerich M**. Einfluß von Sauerstoffradikalen auf die CYP3A-Aktivität und Genexpression während der Reperfusion am Modell der isoliert perfundierten Schweineleber. *Z Gastroenterol* 1998; 36:79.
619. Armstrong VW, Schütz E, Zhang Q, Groothuisen S, Scholz C, Andreeva M, Aboleneen H, **Oellerich M**. Pentamer formation assay for determination of tacrolimus compared with hplc tandem mass spectrometry and microparticle enzyme immunoassay. *Clin Chem* 1998; 44:A100.
620. Engelmayer U, Binder L, Armstrong VW, Nguyen T, **Oellerich M**. Comparison of the Abbott AxSYM® Digoxin II assay with the Stratus and the ACS:180 assays. *Clin Chem* 1998; 44:A104.
621. Schütz E, Svinarov D, Andreeva M, Niedmann PD, **Oellerich M**. CEDIA, EMIT and mFPIA (AxSYM) for cyclosporin A(CsA) determination compared to HPLC. *Clin Chem* 1998; 44:A105.
622. Luthe H, Binder L, Meyer T, Greber T, Buchwald A, Kreuzer H, **Oellerich M**. Emergency room triage of patients with acute chest pain by determination of cardiac troponin I. *Clin Chem* 1998; 44:A132.
623. Braun F, Lorf T, **Oellerich M**, Ramadori G, Ringe B. Liver transplantation without steroids. *Hepatology* 1998; 28: 263A.
624. Shipkova M, Wieland E, Schütz E, Armstrong VW, Niedmann PD, Braun F, Svinarov DA, **Oellerich M**. New metabolites of mycophenolic acid identified in human plasma specimens are formed by human liver microsomes. *Hepatology* 1998; 28:383A.
625. Wieland E, Shipkova M, Niedmann PD, Braun F, Schütz E, Armstrong VW, **Oellerich M**, Svinarov DA. Species related difference in cyclosporin a (CSA) metabolism: pig and human liver microsomes compared. *Hepatology* 1998; 28:606A.
626. Schütz E, Shipkova M, Armstrong VW, Wieland E, **Oellerich M**. Identification of an active metabolite of mycophenolic acid in plasma of liver transplantation recipients. *Hepatology* 1998; 28:739A.

627. Weber LT, Schütz E, Lamersdorf T, Andreeva M, Niedmann PD, **Oellerich M**, Zimmerhackl LB, Mehls O, Armstrong VW, Tönshoff N and the German Study Group on Mycophenolat Mofetil (MMF) Therapy. Therapeutic drug monitoring of mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in pediatric renal transplant recipients. *Pediatr Nephrol* 1998; 12:C204.
628. Weber LT, Lamersdorf T, Andreeva M, Niedmann PD, **Oellerich M**, Zimmerhackl LB, Mehls O, Armstrong VW, Tönshoff B and the German Study Group on Mycophenolat Mofetil (MMF) Therapy. Pharmacokinetics (PK) of mycophenolic acid (MPA) and free MPA in pediatric renal transplant recipients - a multicentre study. *Pediatr Nephrol* 1998; 12:C205.
629. Binder C, Schulz M, Hagemann T, Hiddemann W, **Oellerich M**. Induction of inducible NO-synthase in relation to caspase-activation during TNF α -induced apoptosis. *Ann Hematol* 1998; 77(Suppl II):S36.
630. **Oellerich M**. Lidocaine metabolism as an index of liver function. *BJCL* 1998; 2:32.
631. Burdelski M, Schütz E, Badur N, Knoke A, **Oellerich M**. Correlation of monoethylglycineethylidide (MEGX) in vivo test results with hepatic CPY3A4 content in pediatric transplant candidates. *BJCL* 1998; 2:36.
632. Schütz E, **Oellerich M**. Pharmacogenetics:thiopurine methyltransferase (TPMT) in the immunosuppressive treatment with azathiopurine. *BJCL* 1998; 2:101.
633. Shipkova M, Wieland E, Schütz E, Braun F, **Oellerich M**, Svinarov DA. Cyclosporin A (CsA) metabolism in human and pig liver microsomes compared. *BJCL* 1998; 2:104.
634. Koleva V, Niedmann PD, **Oellerich M**. A modified high-performance liquid chromatographic method for determination of methotrexate in human plasma. *BJCL* 1998; 2:107.
635. Wieland E, Vogl I, Pollok R, Schuff-Werner P, **Oellerich M**. Lipidperoxidation im Plasma und mRNA Expression antioxidativer Enzyme in Leukozyten während der Behandlung mit der Herz-Lungen-Maschine (HLM). *J Lab Med* 1998; 11:655.

636. Schütz E, Stürzenhofecker B, **Oellerich M**. A non-isotopic electrophoretic mobility shift assay (EMSA) for NF κ B and CREB using the LI-COR DNA sequencer. *J Lab Med* 1998; 11: 674-675.
637. Schütz E, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, **Oellerich M**. Bedeutung neu entdeckter Metabolite für das Drug Monitoring von Mycophenolsäure. *J Lab Med* 1998; 11:683.
638. Schütz E, Wieland E, Stürzenhofecker B, **Oellerich M**. Identifikation eines porcinen hepatischen CYP3A mit hoher Homologie zum humanen CYP3A4: Abhängigkeit der Expression vom Transkriptionsfaktor NF κ B. *Z Gastroenterol* 1999; 37:59-111.
639. Wieland E, Schütz E, Bonitz M, v. Ahsen N, **Oellerich M**. Effekt der Reperfusion nach kalter Ischämie auf die Aktivität und Genexpression der Superoxiddismutase im Model der isolierten Schweineleber. *Z Gastroenterol* 1999; 37:59-111.
640. Schütz E, Armstrong VW, Weber L, Shipkova M, Tönshoff B, **Oellerich M**. Abbreviated AUC for monitoring of mycophenolic acid in pediatric kidney recipients. *Clin Chem Lab Med* 1999; 37: S317.
641. Binder L, Schiel X, Binder C, Schüttrumpf S, Armstrong VW, Hiddemann W, **Oellerich M**. Substantial cost savings by individualized aminoglycoside therapy in febrile neutropenic patients with underlying malignant hematologic disorders. *Clin Chem Lab Med* 1999; 37: S304.
642. Armstrong VW, Shipkova M, Schütz E, Weber L, Niedmann PD, Zimmerhackl LB, Mehls O, Tönshoff B, **Oellerich M**, et al. Area under the plasma concentration-time curve for total but not for free mycophenolic acid increases in the stable phase post renal transplantation. *Clin Chem Lab Med* 1999; 37: S 42.
643. Binder L, Luthe H, Schettler V, Hanack U, Lorf T, Dittig J, Warnecke G, Müller GA, **Oellerich M**. Cardiac Troponin T – a powerful marker to predict early cardiac death in patients with end-stage renal disease? *Clin Chem Lab Med* 1999; 37: S 88.
644. von Ahsen N, Schütz E, Armstrong VW, **Oellerich M**. Genetic thrombophilia screening: rapid detection of the prothrombin (G20210A) mutation by real time fluorescence PCR with the LightCycler. *Clin Chem* 1999; 45: A43.

645. Luthe H, Binder L, Martetschläger I, **Oellerich M**. WBC Differentials, flagging performance and reticulocyte quantification on the Abbott Cell-DYN 4000 in comparison to the coulter STKS and the reticulocyte analyzer sysmex R-1000. Clin Chem 1999; 45: A62.
646. Wieland E, Shipkova M, Schütz E, Wiese C, Bonitz U, Niedmann PD, Armstrong VW, **Oellerich M**. The acyl glucuronide metabolite of the immunosuppressant mycophenolic acid induces release of proinflammatory cytokines and TNF-alpha mRNA expression. Clin Chem 1999; 45: A127.
647. Shipkova M, Niedmann PD, Schneider T, Schütz E, Armstrong VW, Wieland E, **Oellerich M**. Determination of the newly detected pharmacologically active acyl glucuronide metabolite of mycophenolic acid by HPLC. Clin Chem 1999; 45: A128.
648. Armstrong VW, Shipkova M, Schütz E, Weber L, Zimmerhackl LB, Tönshoff B, **Oellerich M**. Pharmacokinetic – pharmacodynamic relationships of free and total mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 1999; 21: 434.
649. Wieland E, Shipkova M, Schellhaas U, Schütz E, Niedmann PD, Armstrong VW, **Oellerich M**. Effect of mycophenolic acid and its metabolites on TNF- α , IL-1 β and IL-6 liberation from human mononuclear leukocytes. Ther Drug Monit 1999; 21: 435.
650. Ringe B, Braun F, Schütz E, Ramadori G, **Oellerich M**. Therapeutic window of tacrolimus in liver transplantation. Ther Drug Monit 1999; 21: 438.
651. Braun F, Schütz E, Peters B, Lorf T, Armstrong VW, **Oellerich M**, Ringe B. Pharmacokinetics of tacrolimus during the early phase after liver transplantation. Ther Drug Monit 1999; 21: 438.
652. Shipkova M, Wieland E, Braun F, Gröne HJ, Schütz E, Armstrong VW, Ringe B, **Oellerich M**. Extrahepatic glucuronidation of mycophenolic acid in human gut and kidney. Ther Drug Monit 1999; 21:441.
653. Braun F, Shipkova M, Christians U, Laabs S, Elias K, Bothur P, Schütz E, Armstrong VW, **Oellerich M**, Ringe B. Influence of tacrolimus on mycophenolate mofetil metabolism in an ex vivo isolated small bowel perfusion model. Ther Drug Monit 1999; 21: 445.

654. Ringe B, Braun F, Lorf T, Canelo R, Schütz E, **Oellerich M**. Clinical experience with tacrolimus in kidney and liver transplant recipients. *Ther Drug Monit* 1999; 21: 446.
655. Wieland E, Shipkova M, Schütz E, Niedmann PD, Svinarov DA, **Oellerich M**. Effect of ischemia/reperfusion on mycophenolic acid metabolism in a pig liver model. *Ther Drug Monit* 1999; 21: 448.
656. Armstrong VW, Roth S, Brady AT, Jeong HJ, Schütz E, Kasper KC, **Oellerich M**. Evaluation of an Emit[®] tacrolimus antibody: comparison with pentamer formation assay and tacrolimus II MEIA. *Ther Drug Monit* 1999; 21: 448.
657. Binder L, Schiel X, Binder C, Behre G, Menke C, Armstrong VW, Hiddemann W, **Oellerich M**. Clinical and economic benefit by optimized aminoglycoside therapy in neutropenic patients with fever of unknown origin. *Ther Drug Monit* 1999; 21: 454.
658. Engelmayer J, Engelmayer U, Armstrong VW, **Oellerich M**. Comparison of the Roche elecsys[®] digoxin assay with the chiron ACS: 180 plus. *Ther Drug Monit* 1999; 21: 458.
659. Schütz E, Pickenpack A, Lang B, **Oellerich M**. Pharmacokinetics of 6-thioguanine nucleotides under i.v. therapy with azathioprine. *Ther Drug Monit* 1999; 21: 476.
660. Schütz E, Shipkova M, Armstrong VW, **Oellerich M**. Time-stratified correlation analysis of Emit and HPLC for TDM of MPA. *Ther Drug Monit* 1999; 21: 479.
661. Schütz E, Armstrong VW, Weber L, Shipkova M, Tönshoff B, **Oellerich M**. MPA-AUC models in relation to outcome in pediatric KTx. *Ther Drug Monit* 1999; 21: 479.
662. Schütz E, von Ahsen N, **Oellerich M**, Wieland E. Early reperfusion injury of cold preserved pig liver is associated with an inflammatory response and apoptosis and can be ameliorated by A₂ receptor stimulation. *Hepatology* 1999; 4: 224A.
663. Weber LT, Schütz E, Lamersdorf T, Shipkova M, Niedmann PD, **Oellerich M**. Pharmacokinetics of mycophenolic acid (MPA) and free MPA in paediatric renal transplant recipients – a multicentre study. *Nephrol Dial Transplant* 1999; 14: 33-34.
664. Weber LT, Schütz E, Lamersdorf T, Shipkova M, Niedmann PD, **Oellerich M**. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited

- sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. *Nephrol Dial Transplant* 1999; 14: 34-35.
665. Streit F, Schütz E, Armstrong VW, **Oellerich M**. Quantification of tacrolimus and five metabolites by API tandem mass spectrometry. *Clin Chem* 2000; 6: A195.
666. Schütz E, Diaz VC, Ilett KF, LeGatt DF, Prohanka E, Wagner O, Wong PY, **Oellerich M**. Multicenter evaluation of the new CEDIA CsA PLUS assay for whole blood cyclosporine. *Clin Chem* 2000; 6: A195.
667. von Ahsen N, **Oellerich M**, Hartung S, Schütz E. Thermodynamically optimizing PCR setup: a method for homogenous color compensated genotyping of the factor V (G1691A) and methylenetetrahydrofolate reductase (C677T) mutations by real time multiplex fluorescence PCR with the LightCycler. *Clin Chem* 2000; 6: A202.
668. Schütz E, von Ahsen N, **Oellerich M**. Total genotyping of thiopurine methyltransferase with the LightCycler: examples for anchor sharing, three colour multiplexing and thermodynamic model based probe design. *Clin Chem* 2000; 6: A202-203.
669. von Ahsen N, Schütz E, **Oellerich M**. Thermodynamische Optimierung der Detektion von Punktmutationen mittels Hybridisierungssonden. *DG Klinische Chemie Mitteilungen* 2000; 31: 56-57.
670. Armstrong VW, **Oellerich M**. Immunosuppressive drug monitoring. *J Lab med* 2000; 24:445.
671. Armstrong VW, **Oellerich M**. Therapeutic drug monitoring for the intensive care unit. *Journal für Anästhesie und Intensivbehandlung* 2001; I.Quartal 7-8.
672. Schütz E, Braun B, Ringe B, **Oellerich M**, Wieland E. Expression der Stressgene c-fos und Egr-1 in einem Ischämie-Reperfusion-Modell der Schweineleber und Effekt der Stimulierung von Adenosin-A₂-Rezeptoren mit CGS 21680. *Z Gastroenterol* 2000; 39:108.
673. Johnston A, Lee TD, Chusney GD, Cowper AL, Schütz E, **Oellerich M**, Holt DW. New approaches to Neoral ® monitoring: methodological implications. *Ther Drug Monit* 2001; 23: 465.

674. Luthe H, Engelmayer J, Engelmayer U, Streit F, Rickers A, Ulbricht B, **Oellerich M**. Comparison between LC/MS/MS and three immunoassays for cyclosporine. *Ther Drug Monit* 2001; 23: 467.
675. Schütz E, Streit F, Dias VC, Lewer M, Illett KF, LeGatt DF, Pohanka E, Wagner O, Wong PY, **Oellerich M**. CsA immunoassays in comparison to LC-MS/MS, is there a difference between trough (C0) and C2 levels? *Ther Drug Monit* 2001; 23: 471.
676. Streit F, **Oellerich M**, Schütz E. A LC-MS/MS method for the rapid quantification of CsA and metabolites. *Ther Drug Monit* 2001; 23: 471.
677. Shipkova M, Armstrong VW, Haley J, Tönshoff B, Weber L, Niedmann PD, Wiese C, **Oellerich M**, Wieland E. The mycophenolic acid acyl glucuronide forms covalent adducts with albumin in plasma of kidney transplant recipients. *Ther Drug Monit* 2001; 23: 472.
678. Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H, Wieland E, **Oellerich M**. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function. *Ther Drug Monit* 2001; 23: 472.
679. Shipkova M, Rapondijeva A, Armstrong VW, Lazarov V, Delijska B, Wieland E, Nedialkov A, Nikolov D, Tishkov I, **Oellerich M**. Pharmacokinetics of mycophenolic acid (MPA) and its phenolic glucuronide (MPAG) in patients with immune nephropathies. *Ther Drug Monit* 2001; 23: 472.
680. Streit F, Armstrong VW, **Oellerich M**. A simple rapid lc-ms/ms method for simultaneous quantification of sirolimus, tacrolimus, everolimus and CsA. *Ther Drug Monit* 2001; 23: 473.
681. Schettler V, Cordes C, Müller GA, **Oellerich M**, Wieland E. Effect of cyclosporin A and tacrolimus on free radical enzyme gene expression in leukocytes of kidney transplant recipients. *Ther Drug Monit* 2001; 23: 475.
682. Wieland E, Shipkova M, Armstrong VW, **Oellerich M**. Effect of mycophenolic acid and its glucuronide metabolites on MCP-I and ICAM-1 gene expression in human mononuclear leukocytes. *Ther Drug Monit* 2001; 23: 475.

683. Engelmayer J, Luthe H, Engelmayer U, Kyriatsoulis A, Schenk J, **Oellerich M**. Comparison of the Roche Elecsys[®] Digitoxin assay with two commercial immunoassays. *Ther Drug Monit* 2001; 23: 481.
684. Igonin AA, Armstrong VW, Shipkova M, Kukes VG, **Oellerich M**. The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia. *Ther Drug Monit* 2001; 23: 497.
685. von Ahsen N, Ehrlich B, Riggert J, **Oellerich M**. Positive cryoglobulin interference with automated optical or impedance platelet counts but not with the CD-61 immunoplatelet count. *Clin Chem and Lab Med* 2001; 39:A80.
686. **Oellerich M**. Therapeutic drug monitoring of cyclosporin and tacrolimus in transplant patients/progress and pitfalls. *Diagnostyka Laboratoryjna* 2001; 37: 218-219.
687. Atanasova S, von Ahsen N, Dimitrov T, **Oellerich M**, Toncheva D. NAT polymorphisms in Bulgarian patients with Balkan Endemic Nephropathy (BEN). *European Journal of Human Genetics* 2002; 10: 179
688. Binder L, Hoppe S, Grüning H, Beckmann A, Puls M, Niedmann PD, Binder C, **Oellerich M**, Schwörer H. Variability of meropenem plasma levels in febrile intensive care patients. *Clin Chem* 2002; 48: A67.
689. Hon K, Bertholf R, Cobbaert M, Engelmayer J, Johannsen L, LeGatt DF, Luthe H, **Oellerich M**, Domke I. Multicenter evaluation of acetaminophen on Roche/ Hitachi analyzers. *Clin Chem* 2002; 48: A141.
690. Indjova-Hristova D, Shipkova M, Niedmann PD, Svinarov DA, **Oellerich M**. A simple high-performance liquid chromatographic method for determination of thiopurine methyltransferase (TPMT) activity in erythrocytes. *J Lab Med* 2002; 26: 521.
691. von Ahsen N, Schütz E, Hartung S, Andag R, **Oellerich M**. Thiopurine methyltransferase (TPMT) *3A, *3B and *3C haplotyping by combined long range PCR, intramolecular ligation and real time ASA-PCR. *J Lab Med* 2002; 26: 522.
692. von Ahsen N, Grupp C, **Oellerich M**, Armstrong VW. The C3435T and G2677 polymorphisms of the MDR1 gene as well as the G69 866A polymorphism of the

- CYP3A5 gene do not influence cyclosporine C2 concentrations in renal transplant recipients. *J Lab Med* 2002; 26: 522.
693. Hoppe S, Schwörer H, Beckmann A, Grüning H, Niedmann PD, Binder C, Schiel X, **Oellerich M**, Binder L. Pharmakokinetik von Meropenem bei neutropenischen Patienten mit Fieber. *J Lab Med* 2002; 26: 519-520.
694. **Oellerich M**, Armstrong VW, Shipkova M, von Ahsen N. Thiopurine methyltransferase: do we need to genotype, phenotype or both to optimise azathioprine therapy? *Clin Chem Lab Med* 2002, 40: S 77.
695. Luthe H, Bertholf R, Cobbaert CM, Domke I, Engelmayer J, Hon K, Legatt DF, **Oellerich M**. Multicenter evaluation of an enzymatic acetaminophen assay on Roche/Hitachi analyzers. *Clin Chem Lab Med* 2002; 40: S 187.
696. von Ahsen N, **Oellerich M**. In vitro evidence against a functional role of the intronic prothrombin G19911A polymorphism. *Clin Chem Lab Med* 2002; 40: S 196.
697. **Oellerich M**, von Ahsen N, Shipkova M, Armstrong VW. Genotypic and phenotypic evaluations in connection with azathioprine toxicity. *The Toxicologist* 2003; 23 Suppl.1: 3.
698. Streit F, Armstrong VW, Dresing K, Leip CL, Burchardi H, **Oellerich M**. Real-time assessment of hepatic function is related to clinical outcome in critically ill patients after polytrauma. *Clin Chem* 2003; 49, Suppl: A52.
699. Binder LE, Beckmann A, Pouwels C, Hoppe S, Gruening H, Niedmann D, Binder C, Nacke A, **Oellerich M**, Schwoerer H. Variable biliary ceftriaxone levels under antibiotic prophylaxis prior to ERC. *Clin Chem* 2003; 49, Suppl: A58.
700. Lilje DJ, Flexer J, Bertholf RL, Coffing M, Domke I, Engelmayer J, Johannsen L, Luthe H, Minon J, **Oellerich M**, Wuertemberger M. Multicenter evaluation of Roche Gentamicin OnLine TDM on Hitachi systems. *Clin Chem* 2003; 49, Suppl: A121.
701. Binder LE, Pouwels C, Puls M, Beckmann A, Hoppe S, Niedmann D, Binder C, Nacke A, **Oellerich M**, Schwoerer H. Determination of free and total ceftriaxone concentrations in plasma and bile. *Clin Chem* 2003; 49, Suppl: A123 – A124.

702. Bertholf RL, Johannsen L, Coffing M, Domke I, Engelmayer J, Flexer J, Lilje D, Luthe H, Minon J, **Oellerich M**. Theophylline measured by kinetic interaction of microparticles in solution (KIMS) homogenous immunoassay: Results of a multi-site evaluation. *Clin Chem* 2003; 49, Suppl: A124 – A125.
703. **Oellerich M**, Armstrong VW. Analytical and clinical aspects of monitoring sirolimus, everolimus and C₂ cyclosporin concentrations. *Clin Chem Lab Med* 2003; 41, Special Suppl: S46.
704. Armstrong VW, **Oellerich M**. Pharmacogenetics: impact on immunosuppressive drug dosing. *Clin Chem Lab Med* 2003; 41, Special Suppl: S46.
705. Luthe H, Bertholf RL, Coffing MJ, Domke I, Engelmayer J, Flexer J, Johannsen L, Lilje D, Minon J, **Oellerich M**. Multicenter evaluation of new online TDM assays for determination of gentamicin and theophylline on Roche/Hitachi systems. *Clin Chem Lab Med* 2003; 41, Special Suppl: S541.
706. Röddiger R, Luthe H, Rhode K, **Oellerich M**, Bertholf R, Verstraete A, De Bel A, Jones J, Coffing MJ, Sauter H. Multicenter evaluation of the new Roche phenytoin online[®] TDM assay developed for use on RD/Hitachi analyzer systems. *Clin Chem Lab Med* 2003; 41, Special Suppl: S544.
707. Shipkova M, Beck H, Volland A, Armstrong VW, Gröne HJ, **Oellerich M**, Wieland E. Identification of protein targets for mycophenolic acid acyl glucuronide (AcMPAG) in rat liver and colon tissue using 2D page and MALDI-TOF-MS. *Clin Chem Lab Med* 2003; 41, Special Suppl: S545.
708. Shipkova M, Spielbauer B, Volland A, Gröne HJ, Armstrong VW, **Oellerich M**, Wieland E. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. *Clin Chem Lab Med* 2003; 41, Special Suppl: S546.
709. Binder L, Puls M, Niedmann PD, Pouwels C, Nacke A, **Oellerich M**, Binder C. A simple and rapid HPLC method for the determination of meropenem – preanalytical and analytical aspects. *Ther Drug Monit* 2003; 25: 496.

710. Engelmayer J, Bertholf RL, Coffing MJ, Domke I, Flexer J, Johannsen L, Lilje D, Luthe H, Minon JM, **Oellerich M**. Online TDM gentamicin and theophylline assays – results of the multicenter evaluation. *Ther Drug Monit* 2003; 25: 497.
711. Luthe H, Rhode K, **Oellerich M**, Bertholf R, Verstraete A, DE Bel A, Jones J, Coffing MJ, Sauter H, Roeddiger R. Multicenter evaluation of the new Roche phenytoin online® TDM assay on RD/Hitachi systems. *Ther Drug Monit* 2003; 25: 499.
712. Shipkova M, Maes B, Armstrong VW, Wieland E, **Oellerich M**. Pre-dose plasma concentrations of the reactive acyl glucuronide of mycophenolic acid (AcMPAG) in kidney transplant recipients under therapy with mycophenolate mofetil (MMF), tacrolimus and steroids. *Ther Drug Monit* 2003; 25: 505.
713. Streit F, Shipkova M, Armstrong VW, **Oellerich M**. Quantification of plasma total MPA and free MPA using liquid chromatography tandem mass spectrometry. *Ther Drug Monit* 2003; 25: 506.
714. Streit F, Armstrong VW, **Oellerich M**. Mass interferences in quantification of cyclosporine using tandem mass spectrometry without chromatography. *Ther Drug Monit* 2003; 25: 506.
715. Engelmayer U, Pouwels C, Engelmayer J, Streit F, **Oellerich M**. Comparison of the Dade Behring Dimension® XPAND ACMIA cyclosporine assay with Emit and LC/MS-MS. *Ther Drug Monit* 2003; 25: 510.
716. Indjova D, Atanasova S, Shipkova M, Armstrong VW, **Oellerich M**, Svinarov D. Phenotypic and genotypic analysis of thiopurine s-methyltransferase polymorphism in the Bulgarian population. *Ther Drug Monit* 2003; 25: 524.
717. Shipkova M, Volland A, Gröne HJ, Armstrong VW, **Oellerich M**, Wieland E. Relationship between plasma concentrations of mycophenolic acid (MPA) and its acyl glucuronide (AcMPAG) and intestinal damage in Wistar rats treated with mycophenolate mofetil (MMF). *Ther Drug Monit* 2003; 25: 537.
718. Tönshoff B, Weber LT, Armstrong VW, Zimmerhackl LB, **Oellerich M**. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. *Am J Transplant* 2004; 4, Suppl 8: 208.

719. Roeddiger R, Luthe H, Rhode KH, **Oellerich M**, Bertholf RL, Johannsen L, Verstraete A, De Vleeschauwer A, De Bel A, Kroll M, Coffing MJ, Sauter H. Multicenter evaluation of the new Roche Carbamazepine OnLine® TDM assay developed for use on Roche Diagnostics/Hitachi analyzer systems. *Clin Chem* 2004; 50, Suppl 6: A128.
720. Bertholf R, Johannsen L, Verstraete A, De Bel A, Jones J, Sargent D, Luthe H, **Oellerich M**, Rhode KH, Roeddiger R, Sauter H, Coffing MJ. Phenytoin measured by kinetic interaction of microparticles in solution (KIMS) homogeneous immunoassay: multisite evaluation of the Roche OnLine® TDM method. *Clin Chem* 2004; 50, Suppl 6: A133.
721. Pouwels C, Streit F, von Ahsen N, Fiedler M, Armstrong VW, **Oellerich M**. Positive interference due to a plasma component causes overestimation of whole blood cyclosporine concentrations measured with the Dimension ACMIa cyclosporine assay. *Clin Chem* 2004; 50, Suppl 6: A134.
722. Luthe H, Averdunk R, Busse Grawitz A, Claudius C, Domke I, Engelmayer J, Nauck M, **Oellerich M**. Roche ONLINE TDM Digitoxin – results of the multicenter evaluation. *Clin Chem* 2004; 50, Suppl 6: A135.
723. Binder LE, Schüttrumpf S, Binder C, Hagemann T, Trümper L, Armstrong VW, **Oellerich M**. Discrimination of elevated CRP concentrations by PCT in patients with suspected infection and underlying malignant disease. *Clin Chem* 2004; 50, Suppl 6: A157.
724. **Oellerich M**, Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. *The Clinical Biochemist Reviews, Supplement* 2004; S 19.
725. El Desoky E, AbdelSalam YM, Salama RH, ElAkkad MA, Atanasova S, von Ahsen N, Armstrong VW, **Oellerich M**. NAT2 genotypes and their relation to schistosomiasis associated bladder cancer in Egyptians. *Ther Drug Monit* 2005; 27: 217.
726. Engelmayer J, Engelmayer U, Streit F, Boyd J, Arabshahi L, Armstrong VW, **Oellerich M**. Comparison of the Seradyn Innofluor® Certican® assay on TDXFLX® system with LC/MS-MS. *Ther Drug Monit* 2005; 27:217.
727. Heller T, Kirchheiner J, Armstrong VW, Luthe H, Brockmöller J, **Oellerich M**. Assessment of Amplichip CYP450 based CYP2D6-genotyping and phenotype

- prediction compared to PCR-RFLP-genotyping and phenotyping by metoprolol pharmacokinetics. *Ther Drug Monit* 2005; 27: 221.
728. Luthe H, **Oellerich M**, Coffing M, Domke I. Multicenter evaluations of the Roche online® tdm assays for use on Roche/hitachi analyzer systems. *Ther Drug Monit* 2005; 27: 233.
729. Armstrong VW, Reinshagen M, von Ahsen N, Behrens Ch, Shipkova M, von Tirpitz Ch, Malchow H, Stallmach A, Herfath H, Stein J, Bias P, Adler G, Kruis W, **Oellerich M**. A prospective evaluation of the association between adverse drug reactions to azathioprine therapy and polymorphisms in the gene encoding inosine triphosphate pyrophosphatase. *Ther Drug Monit* 2005; 27: 245.
730. Wang L, Binder L, **Oellerich M**, Jiang DC. Prediction accuracy of aminoglycosides between USC*-PACK and PKS. *Ther Drug Monit* 2005; 27: 259.
731. **Oellerich M**. The role of therapeutic drug monitoring in immunosuppressant therapy. *Clin Chim Acta* 2005; 355: S43.
732. Domke I, Engelmayer J, Langmann T, Liebisch G, Streit F, Luthe H, Dorn A, Schmitz G, **Oellerich M**. Measurement of total and free mycophenolic acid with new enzyme receptor methods on COBAS INTEGRA systems. *Clin Chem* 2005; 51, Suppl 6: A148.
733. Binder L, Niedmann P, Streit F, Binder C, Blaschke S, Onufrejow M, **Oellerich M**. A simple and rapid HPLC method for the determination of moxifloxacin. *Clin Chem* 2005; 51, Suppl 6: A155.
734. Luthe H, Rhode KH, **Oellerich M**. Performance of assays for therapeutic drug monitoring and urine drugs-of-abuse screening processed in combination with clinical chemistry workload on Roche modular analytics. *Clin Chem* 2005; 51, Suppl 6: A217.
735. Asif AR, Armstrong VW, Wieland E, **Oellerich M**, Shipkova M. Cytosolic proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney from mycophenolate mofetil treated rats. *Clin Chem Lab Med* 2005; 43: A41.
736. Domke I, Engelmayer J, Langmann T, Liebisch G, Luthe H, Schmitz G, Streit F, **Oellerich M**. Measurement of total and free mycophenolic acid with new enzyme receptor methods on COBAS INTEGRA systems. *Clin Chem Lab Med* 2005; 43: A47.

737. Futh J, Steiner M, **Oellerich M**, Schuff-Werner P, von Ahsen N. The adult-type hypolactasia variant: epidemiological data from two populations and a comparison of two genotyping approaches. *Clin Chem Lab Med* 2005; 43: A51.
738. Heller T, Doncheva Y, Asif AR, Wieland E, **Oellerich M**, Shipkova M, Armstrong VW. Mycophenolic acid and its acylglucuronide metabolite modulate expression of the Rho GDP dissociation inhibitor 2 in a T-lymphoblast cell line. *Clin Chem Lab Med* 2005; 43: A56.
739. von Ahsen N, Andag R, **Oellerich M**. RNA pol II processivity rather than differential binding as patho-mechanism of 3' UTR non-coding mutations in the prothrombin gene: a study using RNA-polymerase II chromatin immunoprecipitation. *Clin Chem Lab Med* 2005; 43: A93.
740. **Oellerich M**, Streit F, Armstrong VW. Use of LC-MS/MS in immunosuppressive drug monitoring. *Clin Biochem* 2005; 38: 775.
741. Heller T, Kirchheiner J, Armstrong VW, Luthe H, Tvetkov, Brockmüller J, **Oellerich M**. AmpliChip CYP450 GeneChip®: a new gene chip allows more detailed CYP2D6 genotyping than conventional PCR-RFLP. *Clin Chem* 2006; 52: A53.
742. Heller T, Otto M, Trenkwalder C, Armstrong VW, **Oellerich M**, Mollenhauer B. Detection of CYP2D6 mutant alleles by AmpliChip CYP450 Gene-Chip® in dementia patients with Lewy Bodies or Parkinson's disease. *Clin Chem* 2006; 52: A54.
743. Domke I, Vukovich T, Engelmayer J, Kheradmand M, Luthe H, Shipkova M, Streit F, **Oellerich M**, Wieland E. Comparability between automated immunoassays and LC-MS/MS for tacrolimus determination using routine patient samples. *Clin Chem* 2006; 52: A61.
744. Domke I, Shipkova M, Engelmayer J, Kheradmand M, Luthe H, Pou L, Streit F, Vukovich T, **Oellerich M**, Wieland E. Cyclosporin determination with different immunoassays in four laboratories using routine patient samples from different transplant types: performance of automated immunoassays and comparability to tandem mass spectrometry. *Clin Chem* 2006; 52: A61.

745. von Ahsen N, Hartung S, **Oellerich M**. Pharmacogenetic factors of thiopurine intolerance: intron 2 polymorphisms associated with reduced inosine triphosphatase (ITPA) activity. *Clin Chem Lab Med* 2006; 44: A152.
746. von Ahsen N, Andag R, **Oellerich M**. Pharmacogenetic factors of thiopurine intolerance: inosine triphosphatase (ITPA) has a constitutive promoter driven by SP1 and SP3 transcription factors. *Clin Chem Lab Med* 2006; 44: A153.
747. Brandhorst G, Harloff M, **Oellerich M**, von Ahsen N. Pseudo-neutropenia: case report of a rare interference due to neutrophil agglutination and improvement by in vitro kanamycin. *Clin Chem Lab Med* 2006; 44: A169.
748. Streit F, Dogan A, Binder L, **Oellerich M**. Simultaneous quantification of 7 anti-retroviral drugs in serum by liquid chromatography tandem mass spectrometry. *Clin Chem Lab Med* 2006; 44: A186.
749. Armstrong VW, Heller T, Brandhorst G, Streit F, van Gelder T, **Oellerich M**. Relationship between free mycophenolic acid and hematologic side effects: interim results from the FDCC study. *Am J Transplant and Transplantation* 2006; Suppl.: 344: A821.
750. Heller T, Armstrong VW, Brandhorst G, Engelmayer J, van Gelder T, **Oellerich M**. Plasma concentrations of mycophenolic acid acyl glucuronide related to diarrhoea. Interim results from the FDCC study. *Am J Transplant and Transplantation* 2006; Suppl.: 344-345: A823.
751. van Agteren M, van Schaik R, de Fijter H, Hartmann A, Schmidt J, Budde K, Kuypers D, Arns W, Le Meur Y, **Oellerich M**, Holt D, Tönshoff B, van der Werf M, Gafner N, Mamelok R, van Gelder T. Polymorphisms in the uridine diphosphate (UDP)-glucuronosyltransferases (UGT) gene explain part of the inter-individual variability in mycophenolate mofetil (MMF) pharmacokinetics. *Am J Transplant and Transplantation* 2006; Suppl.: 478: A 1215.
752. van Agteren M, van Schaik R, de Fijter H, Hartmann A, Schmitdt J, Budde K, Kuypers D, Pisarksi P, Le Meur Y, **Oellerich M**, Holt D, Toenshoff B, Mamelok R, de Ducla B, van Gelder T. The impact of MRP2 gene polymorphism on mycophenolic acid exposure in renal transplant patients. *Am J Transplant and Transplantation* 2006; Suppl.: 478: A1217.

753. Naesens M, Vanrenterghem Y, **Oellerich M**, Kuypers D. Mycophenolic acid glucuronidation and elimination is influenced by interaction with UGT metabolism and/or organic anion transport. *Am J Transplant and Transplantation* 2006; Suppl.: 1004: A2882.
754. von Ahsen N, Hartung S, **Oellerich M**. Rat and mouse prothrombin 3' UTRs show significant gain-of-function in the human test system despite normal plasma prothrombin activities. *Hämostaseologie* 2007; 27: A35.
755. **Oellerich M**, Armstrong VW. Biomarkers – The link between therapeutic drug monitoring and pharmacodynamics. *Clin Chem Lab Med* 2007; 45: Suppl.: S54.
756. van Schaik RHN, van Agteren M, van der Werf M, de Fijter H, Hartmann A, Schmidt J, Budde K, Kuypers D, Arns W, Le Meur Y, **Oellerich M**, Holt DW, Toenshoff B, Gafner N, Mamelok R R, van Gelder T. Genetic Polymorphisms in UGT1A9, but not in MDR1, explain part of the inter-individual variability in mycophenolate mofetil (MMF) pharmacokinetics. *Clin Chem Lab Med* 2007; 45: Suppl.: S160.
757. Luthe H, Domke I, Jung M, Knoke C, Rhode KH, Sauter H, **Oellerich M**. External performance evaluation of the Cobas C 501 analysis system. *Clin Chem Lab Med* 2007; 45: Suppl.: S188.
758. Luthe H, Domke I, Knoke C, Rhode KH, Sauter H, **Oellerich M**. Performance of therapeutic drug monitoring and urine drugs-of-abuse screening assays under routine-like conditions on Cobas C 501. *Clin Chem Lab Med* 2007; 45: Suppl.: S188.
759. Weber LT, Hoecker B, Armstrong VW, **Oellerich M**, Toenshoff B. Long-term (3 years) pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients. *Am J Transplant* 2007; 7 (Suppl.2): 366.
760. Feneberg R, Weber LT, von Ahsen N, Armstrong VW, Hoecker B, **Oellerich M**, Toenshoff B and the German Study Group on Pediatric RTx. Consequences of CYP3A4 and MDR-1 polymorphisms on pharmacokinetic parameters of cyclosporin A and

- mycophenolic acid in pediatric renal transplant recipients. *Am J Transplant* 2007; 7 (Suppl.2): 366-367.
761. Binder L, Streit F, Engelmayer J, Götze S, Luthe H, Budde K, Beckebaum S, Doll S, **Oellerich M**. Comparison of the ADVIA Centaur[®] Cyclosporine Assay with tandem mass spectrometry (LC-MS/MS). *Clin Chem* 2007; 53 (Suppl.): A88.
762. Luthe H, Figurski M, Korecka M, Marquet P, Liebisch G, Coffing MJ, Domke I, Schmitz G, **Oellerich M**, Shaw L. Multicenter evaluation of the Roche total mycophenolic acid assay on Cobas Integra[®] Systems. *Clin Chem* 2007; 53 (Suppl.): A93.
763. Luthe H, Domke I, Jung M, Knoke C, Rhode KH, Sauter H, **Oellerich M**. External evaluation of assays for clinical chemistry, serum proteins, drugs-of-abuse and therapeutic drug monitoring on cobas c 501 analyzer. *Clin Chem* 2007; 53 (Suppl.): A95.
764. Brandhorst G, Streit F, Goetze S, Rhode KH, Engelmayer J, Luthe H, **Oellerich M**. Quantification of mycophenolic acid by an optimized LC-MS/MS method compared to a new IMPDH inhibition assay on the cobas c 501 analyzer. *Clin Chem* 2007; 53 (Suppl.): A96.
765. Soldin SJ, Hardy RW, Wians FH, Barbarakis M, Connolly PB, Martel J, Canfield WJ, **Oellerich M**. The ADVIA Centaur[®] Cyclosporine (CsA): results of a multicenter clinical evaluation. *Clin Chem* 2007; 53 (Suppl.): A97.
766. Streit F, Dogan A, Binder L, **Oellerich M**. Measurement of serum testosterone using a Waters Quattro Premier XE Micromass[®] System with an APPI interface. *Clin Chem* 2007; 53 (Suppl.): A199.
767. Dogan A, Streit F, Binder L, **Oellerich M**. Simultaneous quantification of 9 anti-retroviral drugs in serum using a Waters Quattro Micro[®] System with an ESI interface. *Ther Drug Monit* 2007; 29: 467-468.
768. van Hest RM, Doorduijn JK, de Winter BCM, Cornelissen JJ, Vulto AG, **Oellerich M**, Löwenberg B, van Gelder T, Armstrong VW, Mathot RAA. Pharmacokinetics of mycophenolate mofetil in stem cell transplant recipients. *Ther Drug Monit* 2007; 29: 471.

769. Heller T, Geide A, Bonitz U, Wegner U, Gröne HJ, Armstrong VW, **Oellerich M**. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. *Ther Drug Monit* 2007; 29: 490-491.
770. Brandhorst G, Streit F, Goetze S, Rhode KH, Engelmayer J, Luthe H, **Oellerich M**. A new IMPDH inhibition assay für the quantification of mycophenolic acid on the Roche Cobas c 501 analyzer compared to liquid chromatography tandem mass spectrometry. *Ther Drug Monit* 2007; 29: 512.
771. Luthe H, Domke I, Engelmayer J, Koeger R, van Gelder T, **Oellerich M**. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. *Ther Drug Monit* 2007; 29: 512.
772. Streit F, Dogan A, Binder L, **Oellerich M**. Simultaneous determination of clozapine, olanzapine and quetiapine using the Waters Quattro Micro® System with a ESI interface. *Ther Drug Monit* 2007; 29: 518.
773. van Gelder T, Silva HT, de Fijter H, Budde K, Kuypers D, van Hest R, Mamelok R, Armstrong VW, **Oellerich M**. How delayed graft function impacts on exposure to mycophenolic acid in patients following renal transplantation. *Ther Drug Monit* 2007; 29: 527.
774. Luthe H, Figurski M, Korecka M, Marquet P, Liebisch G, Coffing MJ, Domke I, Schmitz G, Engelmayer J, **Oellerich M**, Shaw L. Multicenter evaluation of the Roche total mycophenolic acid assay on COBAS INTEGRA® Systems. *Ther Drug Monit* 2007; 29: 547.
775. Heller T, van Gelder T, **Oellerich M**, Armstrong VW. MRP-2 mediated biliary excretion but not renal function is a major determinant of exposure to mycophenolic acid acyl glucuronide. *Ther Drug Monit* 2007; 29: 548
776. **Oellerich M**. Immunosuppressive Drug Monitoring. *Malaysian J Pathol* 2007; 29 (Suppl. A): 63.
777. **Oellerich M**. Pathology education and research in Germany. *Malaysian J Pathol* 2007; 29 (Suppl. A): 73-74.

778. Luthe H, Knoke C, Rhode KH, **Oellerich M**. External performance evaluation of the COBAS c 501 analysis system. *Malaysian J Pathol* 2007; 29 (Suppl. A): 126.
779. Shipkova M, Heller T, Petrova DT, Hitt R, Wieland E, **Oellerich M**, Armstrong VW. A microarray investigation on the effect of the acyl glucuronide of mycophenolic acid (AcMPAG) on the expression of cell proliferation related genes in mononuclear leucocytes. *Clin Chem Lab Med* 2007; 45: A104.
780. van Gelder T, Domke I, Streit F, Koeger R, Luthe H, **Oellerich M**. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. *Clin Chem* 2008; 54: A15.
781. von Ahsen N, Hartung S, **Oellerich M**. Comparison of TPMT activity measured by HPLC in washed red blood cells, whole blood, and plasma exchanged whole blood. *Clin Chem Lab Med* 2008; 46: A159.
782. Zafar S, Asif AR, Armstrong VW, **Oellerich M**. One-STrEP-tagged human prion protein expression, purification, localization and identification of interacting proteins in mamalian cell line. *Clin Chem Lab Med* 2008; 46: A175.
783. Petrova DT, Brehmer F, Brandhorst G, Schroeder H, Armstrong VW, **Oellerich M**. Mycophenolic acid displays IMPDH-dependent and –independent effects on renal fibroblast proliferation and function. *Clin Chem Lab Med* 2008; 46: A195.
784. Brandhorst G, Armstrong VW, **Oellerich M**. Arithmetical correction of potassium in hemolytic samples: do or don't? *Clin Chem Lab Med* 2008; 46: A204.
785. **Oellerich M**. Biomarkers – a link between therapeutic drug monitoring and pharmacodynamics. *Clin Chem Lab Med* 2008; 46: A204.
786. **Oellerich M**. Biomarkers – as an adjunct to immunosuppressive drug monitoring. *Ann Transplant* 2008; 13 (Suppl.1): 17.
787. **Oellerich M**, Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. *Pathology* 2009; 41 (Suppl.): 15-16.
788. **Oellerich M**, Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. *J Mol Clin Pathol* 2009; 40: 40.

789. Streit F, von Ahsen N, Brandhorst G, **Oellerich M**. Measurement of serum testosterone: Waters Quattro Premier XE Micromass® System versus Elecsys®Testosterone II and Elecsys®Testosterone. *Clin Chem* 2009; 55 (Suppl.): A186.
790. **Oellerich M**, Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. *IJCB* 2009; 24 (Suppl.):51.
791. Brandhorst G, Brehmer F, Petrova DT, Gross O, Armstrong VW, **Oellerich M**. Mycophenolic mofetil improves kidney function but not survival in a COL4A3-deficient mouse model for progressive renal fibrosis. *Ther Drug Monit* 2009; 31: 664.
792. **Oellerich M**, Armstrong VW, von Ahsen N. Impact of pharmacogenetics on therapeutic drug monitoring. *Indian J of Clin Biochem* 2009; 24 (Suppl.): 51.
793. Brandhorst G, Schulz-Jürgensen S, Burdelski M, **Oellerich M**. ATP production in CD4+ T cells as a predictor for infection and allograft rejection in pediatric liver transplant recipients. *Clin Chem* 2010; 56 (Suppl.): A241.
794. Qasim M, Rahman H, Armstrong VW, **Oellerich M**, Asif AR. Proteome alteration in human cell line in response to mycophenolic acid. *Clin Chem Lab Med* 2010; 49: A112.
795. Petrova DT, Brehmer F, Schultze FC, Asif AR, Gross O, **Oellerich M**, Brandhorst G. Differential kidney proteome profiling in a mouse model for renal fibrosis under treatment with mycophenolate mofetil: implications for epithelial-mesenchymal transition. *Clin Chem Lab Med* 2010; 49: A129.
796. Eberle C, Brandhorst G, **Oellerich M**, Goden S. Determination of regulatory T cell (Treg) counts by fluorescence activated cell sorting in patients with inflammatory bowel disease (IBD). *Clin Chem Lab Med* 2010; 49: A139.
797. von Ahsen N, Tzvetkov M, Karunajeewa H, Gomorrai S, Ura A, Brockmüller J, Davis TME, Müller L, Ilett KF, **Oellerich M**. CYP2D6 and CYP2C19 in Papua New Guinea: high frequency of previously unknown CYP2D6 alleles and heterozygote excess. *Clin Chem Lab Med* 2010; 49: A145.

798. Schulz-Jürgensen S, Brandhorst G, **Oellerich M**, Kohl M, Burdelski M. Further assessment of IATP (Cylex ImmuKnow®) in pediatric liver transplantation (LTX) and healthy controls. *Transplant International* 2010; 23 (Suppl. 2): 61.
799. Qasim M, **Oellerich M**, Rahman H, Asif A. Mycophenolic acid modulation of epithelial tight junctions – a mechanism of gastrointestinal toxicity. *Clin Chem* 2011; 57 (Suppl.): A78.
800. **Oellerich M**, Brandhorst G. Use of endogenous biomarkers to achieve personalised immunosuppression in transplant recipients. *Clin Chem Lab Med* 2011; 49 (Special Suppl.): S144.
801. **Oellerich M**. Therapeutic drug monitoring – key to personalized pharmacotherapy. *IJCB* 2011; 26 (Suppl.): 2.
802. **Oellerich M**. Use of endogenous biomarkers to achieve personalised immunosuppression in transplant recipients. *IJCB* 2011; 26 (Suppl.): 10.
803. Shipkova M, Petrova DT, Rosler AE, Orth M, Engelmayer J, Wieland E, Brandhorst G, **Oellerich M**. Comparability and imprecision of eight frequently used commercially available immunoassays for therapeutic drug monitoring. *Ther Drug Monit* 2011; 33: 501 (P078).
804. Koch C, Petrova D, Eberle C, Schultze F, Brandhorst G, **Oellerich M**. The functional effect of mycophenolic acid on renal fibrosis. *Clin Chem Lab Med* 2012; 50: A205-A270 (P06).
805. Petrova D, Luchs K, Schultze F, Alwahsh S, Rubel D, Gross O, **Oellerich M**, Brandhorst G. Kidney function and histopathological differences induced by mycophenolate mofetil in a mouse model for progressive renal disease. *Clin Chem Lab Med* 2012; 50: A205-A270 (P07).
806. Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Moerer O, Slotta J, Walson PD, Kollmar O, **Oellerich M**, Schütz E. Rapid and cost effective measurement of circulating cell free graft DNA for the early detection of liver transplant rejection. *Clin Chem* 2013; 59 (Suppl.): A-93.

807. **Oellerich M.** Therapeutic drug monitoring – key to personalized pharmacotherapy. *Jpn J Ther Drug Monit* 2013; 30 (Suppl.): 42-43.
808. Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Moerer O, Slotta J, Walson PD, Kollmar O, **Oellerich M**, Schütz E. A simple method for quantifying graft cfDNA as an early biomarker of rejection. *Clin Chem Lab Med* 2013; 51: eA17-eA18.
809. Schütz E, Warnecke G, Fegbeutel C, Haverich A, **Oellerich M**. Abbreviated MPA-AUC in lung transplantation in comparison with the immune cell response. *Ther Drug Monit* 2013; 35: 684 (O2623).
810. **Oellerich M.** Pharmacokinetic monitoring and biomarkers as a means to improve outcome in transplantation. *IJCB* 2013; 28 (Supp.): 30.
811. **Oellerich M.** Future laboratory medicine – LC/MS vs immunoassays. *IJCB* 2013; 28 (Supp.): 43.
812. Slotta JE, Kanzow P, Beck J, **Oellerich M**, Schütz E, Kollmar O. Zirkulierende Transplantat-DNA als sensitiver Biomarker der Organintegrität nach Lebertransplantation. *Z Gastroenterol* 2014; 52 – KC074.
813. Slotta JE, Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, Gaedcke J, Mörer O, Walson P, **Oellerich M**, Schütz E, Kollmar O. Quantification of donor DNA in the circulation after liver transplantation as a potential universal rejection biomarker using digital droplet PCR. *Liver Transpl* 2014; 20 (Suppl. 1): S 107-108.
814. Slotta JE, Kanzow P, Schütz E, **Oellerich M**, Kollmar O. Graft derived cell-free DNA as an early organ integrity biomarker after liver transplantation of a HELLP syndrome donor liver. *Liver Transpl* 2014; 20 (Suppl. 1): S 241-242.
815. **Oellerich M.** Biomarkers to achieve personalized immunosuppression in transplantation. *Clin Chem Lab Med* 2014; 52 (Special Suppl.): S32.

816. **Oellerich M.** Use of endogenous biomarkers to achieve personalized immunosuppression. *Malaysian J Pathol* 2014; 36 (Suppl. A): 1.
817. **Oellerich M.** Biomarkers in transplantation – graft-derived circulating cfDNA and signatures of tolerance. *Am J Pathol* 2014; 184 (Suppl.): S30.
818. Schmitz J, Götze S, Andag R, Brockmöller J, Kollmar O, Schütz E, **Oellerich M.** Droplet digital PCR (ddPCR) for quantitative analysis of Treg-specific demethylation region (TSDR) in peripheral blood compared to Flow Cytometry (FACS). *Clin Chem* 2014; 60 (Suppl): S106.
819. Beck J, Schmitz J, Kanzow P, Kollmar O, **Oellerich M,** Schütz E. Absolute quantification of graft derived cell-free DNA (GcfDNA) early after liver transplantation (LTx) using droplet digital PCR. *Clin Chem* 2014; 60 (Suppl.): S194-S195.
820. Beck J, Schmitz J, Kollmar O, Slotta J, Kanzow P, Walson P, **Oellerich M,** Schütz E. Use of plasma GcfDNA quantification to guide personalized immunosuppression. *Transpl Int* 2014; 27 (Suppl. 3): 50.
821. Kanzow P, Kollmar O, **Oellerich M,** Schütz E, Schmitz J, Beck J, Slotta J, Walson P. Potential of graft-derived cell-free DNA quantification to improve outcomes with marginal donor organs – Case report of successful liver transplantation of a HELLP syndrome donor. *Am J Transplant* 2014; 14 (Suppl.): 713-714.
822. **Oellerich M,** Kanzow P, Beck J, Schmitz J, Kollmar O, Walson P, Schütz E. Graft-derived cell-free DNA (GcfDNA) as a sensitive measure of individual graft integrity after liver transplantation. *Am J Transplant* 2014; 14 (Suppl.): 874.
823. Beck J, **Oellerich M,** Schütz E. A new universal multiplex digital PCR method with improved precision for the quantification of donor derived graft cfDNA traces. *Clin Chem* 2015; 61 (Suppl): S179.
824. Beck J, Reinhard L, **Oellerich M,** Schulz U, Fuchs U, Knabbe C, Gummert J, Schütz E, Birschmann I. Early detection of rejection after heart transplantation by a universal digital PCR method. *Clin Chem* 2015; 61 (Suppl): S180.

825. Schütz E, Blum A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M, Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockmöller J, **Oellerich M**. Graft-derived cell-free DNA – a promising rejection marker in liver transplantation – results from a prospective multicenter trial. *Clin Chem* 2016; 62 (Suppl): S34.
826. Beck J, Schirmer M, Rave-Fraenk M, Urnovitz H, Bornemann-Kolatzki K, Mitchell WM, **Oellerich M**, Schütz E, Canis M. Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer. *J Clin Oncol* 2017; 35 (suppl; abstr 6055); doi: 10.1200/JCO.2017.35.15_suppl.6055.
827. Schütz E, Reinhard L, Knüttgen F, Beck J, Schulz U, Harden M, Fuchs U, Mettenmeyer N, Knabbe C, Zittermann A, Gummert J, Birschmann I, **Oellerich M**. Graft-derived cell-free DNA - a promising rejection marker in cardiac transplantation – results from a prospective observational trial. 69th AACC Annual Scientific Meeting Abstracts, 2017: S34.
828. **Oellerich M**. Circulating cell-free DNA in cancer and transplantation. *Clin Chem Lab Med* 2017; 55, Special Suppl: S1153.
829. **Oellerich M**, Shipkova M, Schauerte V, Asendorf T, Walson PD, Mettenmeyer N, Kabakchiev M, Ellenberger D, Friede T, Wieland E, Schwenger V, Schütz E, Beck J. Absolute quantification of graft-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation – results from a prospective observational trial. 70th AACC Annual Scientific Meeting Abstracts, 2018: S226-227.
830. Knüttgen F, Beck J, Reinhard L, Zittermann A, **Oellerich M**, Schulz U, Fuchs U, Knabbe C, Flieder T, von Bargen K, Schütz E, Gummert J, Birschmann I. Cell-free DNA as non-invasive biomarker of cardiac allograft rejection. *J Lab Med* 2018; 42: eA22.
831. **Oellerich M**. Laboratory medicine – challenges and opportunities. *Clin Chem Lab Med* 2018; 56: eA204.
832. Beck J, **Oellerich M**, Teubert A, Glaubitz R, Schütz E. Analytical validation of a clinical ddPCR assay for graft-derived cell-free DNA determination. 71st AACC Annual Scientific Meeting Abstracts, 2019: S189-190.

833. Schütz E, Asendorf T, Beck J, Shipkova M, Kabkachiev M, Walson PD, Wieland E, **Oellerich M**, Schwenger V, Schauerte V. Time dependent apparent increase in dd-cfDNA percentage in clinically stable patients between one and five years following kidney transplantation. 72nd AACC Annual Scientific Meeting Abstracts, 2020: S45
834. Osmanodja B, Akifova A, **Oellerich M**, Beck J, Bornemann-Kolatzki K, Schütz E, Budde K. Longitudinal dd-cfDNA monitoring reduces time to ABMR diagnosis in dnDSA positive kidney transplant recipients: a diagnostic randomized clinical trial. ESOT Congress Abstract Book, Late Breaking Full Orals, LOS1_3, p. 445, Transpl Int, 21st Congress of the European Society for Organ Transplantation, 2023